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 Summary 
Summary 
With around half a million deaths per year, malaria is still one of the world’s most deadly 
infectious diseases, mainly caused by two species of Plasmodium parasites, P. falciparum (Pf) 
and P. vivax (Pv). Currently, there are antimalarial drugs available; however, increasing 
resistance of Plasmodium strains hampers the fight against the disease. Therefore, new 
antimalarial drugs urgently need to be developed. During their life cycle, Plasmodium 
parasites are continuously exposed to oxidative stress from different sources. Antioxidative 
systems that highly depend on the electron donor nicotinamide adenine dinucleotide 
phosphate (NADPH) are employed to maintain the redox balance. One strategy of new 
antimalarial drugs is to create a fatal dosage of oxidative stress by disturbing cellular redox 
homeostasis. For Plasmodium parasites, the oxidative pentose phosphate pathway (PPP) is 
the main source of the critically important NADPH, generated by two enzymes: the 
bifunctional glucose 6-phosphate dehydrogenase 6-phosphogluconolactonase (GluPho) and 
the 6-phosphogluconate dehydrogenase (6PGD). PfGluPho has already been shown to be 
essential for blood stage parasites; since this enzyme shares high similarities with the 
corresponding enzyme of P. vivax, PvGluPho is considered a potential drug target as well. 
6PGD contributes to the NADPH supply in the same amounts as GluPho and is already 
considered a drug target in other organisms such as the parasite Trypanosoma brucei. The aim 
of this thesis was to (further) characterize these enzymes structurally and functionally and to 
investigate the potential of several small molecules as future antimalarial drug components. 
Similar to naturally occurring human glucose 6-phosphate dehydrogenase (G6PD) variants, 
naturally occurring mutations have been discovered in PfGluPho; however, in contrast to the 
human host, these mutations as well as the studied naturally occurring phosphorylations do 
not lead to major changes in the properties of the enzyme and are therefore unlikely to have 
an impact on the parasites’ redox homeostasis; potentially, they grant the parasites with 
others than kinetic benefits, which need to be further investigated. In addition to 
P. falciparum, recombinant production and characterization of P. vivax G6PD, the C-terminal 
and NADPH-producing part of PvGluPho, are described in this thesis. Notably, PvG6PD has 
lower activity and higher KM values for substrate and cofactor than the P. falciparum enzyme, 
indicating that it has some functional disadvantages. Moreover, recombinant hexahistidly-
tagged PvG6PD existed in a presumably hexameric oligomerization state, which might 
represent an artifact. Therefore, full-length PvGluPho ought to be investigated. However, 
since the recombinant production of PvGluPho is extremely challenging, the characterization 
of PvG6PD makes this important enzyme in the meantime accessible to drug discovery 
activities. 
Within this thesis, recombinant production and kinetic characterization of Pf6PGD are 
described. In addition, we were able to solve the X-ray structures of native Pf6PGD as well as 
in complex with its substrate 6-phosphogluconate (6PG) or its cofactor NADP+ (the oxidized 
form of NADPH) at resolutions of 2.8 Å, 1.9 Å, and 2.9 Å, respectively. Knowledge of the three-
dimensional structure of an enzyme is helpful during all stages of drug discovery. With its 
dimeric conformation, each subunit consisting of a cofactor binding domain, a substrate 
binding domain, and a C-terminal tail threading through the adjacent subunit, the overall 
structure of Pf6PGD is similar to structures of 6PGDs from other species. We could, however, 
show that a flexible loop bordering the substrate binding site rearranges upon binding 6PG, 
thereby likely regulating the binding conformation of NADP+; in the absence of 6PG the loop 
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is open, and NADP+ binds in a flexible waiting position. As soon as 6PG binds, the active site 
loop adopts a closed conformation. This indicates that cofactor and substrate can bind 
independently from each other in a sequential binding mechanism, which was supported by 
kinetic studies. Furthermore, the interaction between the Plasmodium-specific residue W104 
and the conserved residue W265 was shown to play a role in the interaction between the 
cofactor and the substrate binding domain of the enzyme. 
Moreover, the impact of the two important post-translational modifications 
S-glutathionylation and S-nitrosation on PfGluPho, PfG6PD, Pf6PGD, and PvG6PD was tested 
within this thesis. None of the enzymes were prone to S-glutathionylation under the 
conditions tested, but all of them were prone to S-nitrosation. The three enzymes catalyzing 
the G6PD reaction were only moderately inhibited upon incubation with S-nitrosoglutathione, 
while the Pf6PGD activity was reversibly inhibited by up to 65%. This might protect the enzyme 
from irreversible nitrosative damage. The reason for the downregulation of this important 
pathway upon nitrosative stress needs to be further investigated. 
The aim in drug discovery is to identify compounds that specifically and effectively impact 
their target proteins. All tested compounds had comparable IC50 values and mode of inhibition 
on PfGluPho and PvG6PD. This supports the hypothesis that the two enzymes might be 
structurally very similar and that it might be possible to develop a drug that effectively treats 
both P. falciparum and P. vivax malaria. The most promising tested compound was SBI-
0797750 with an inhibitory concentration in the very low nanomolar range. Moreover, 
inhibition of hG6PD was below 50% at 99 µM as the highest concentration tested; therefore, 
this compound is highly selective for the plasmodial enzymes. In mode of inhibition studies, 
SBI-0797750 was determined to compete with the substrate glucose 6-phosphate for the 
binding site in PfGluPho. Further characterization showed that it acts in cell culture on asexual 
blood stage parasites as well as on gametocytes in the low nanomolar range; using genetically 
encoded probes, SBI-0797750 was shown to disturb the cytosolic glutathione homeostasis and 
significantly increase the cytosolic H2O2 concentration, which is most likely caused by the 
depletion of NADPH. Importantly, it did not adversely affect red blood cells from healthy and 
G6PD deficient donors. Further characterization of SBI-0797750 with regard to its absorption, 
distribution, metabolism, excretion, and toxicity is needed. An initial set of Pf6PGD inhibitors 
was identified by screening the MMV Malaria Box; several compounds showed IC50 values in 
the very low micromolar range. Since the three-dimensional structure of the enzyme is now 
known, this is a promising starting point for structure-based optimization approaches. 
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 Zusammenfassung 
Zusammenfassung 
Mit etwa einer halben Million Todesopfer pro Jahr ist Malaria bis heute eine der 
bedeutendsten Infektionskrankheiten. Die meisten Fälle werden durch die zwei Arten der 
Plasmodium-Parasiten P. falciparum (Pf) und P. vivax (Pv) verursacht. Derzeit sind 
Medikamente gegen Malaria verfügbar, jedoch erschwert das vermehrte Auftreten von 
resistenten Plasmodien eine effektive Bekämpfung der Erkrankung. Die Entwicklung neuer 
Medikamente ist daher dringend angeraten. Im Laufe ihres Lebenszyklus sind die Parasiten 
kontinuierlich oxidativem Stress unterschiedlicher Quellen ausgesetzt. Die antioxidativen 
Systeme, die für den Erhalt der Redoxbalance verantwortlich sind, sind in hohem Maß von 
dem Elektronendonator Nicotinamidadenindinukleotidphosphat (NADPH) abhängig. Eine 
Strategie neuer Malariamedikamente ist, eine tödliche Dosis an oxidativem Stress zu 
erzeugen, indem die zelluläre Redoxhomöostase gestört wird. Für Plasmodien ist der oxidative 
Pentosephosphatweg (PPP) die Hauptquelle des essentiell wichtigen NADPH. Generiert wird 
es von zwei Enzymen, der bifunktionellen Glukose-6-Phosphat-Dehydrogenase-6-
Phosphogluconolactonase (GluPho) und der 6-Phosphogluconat-Dehydrogenase (6PGD). Für 
PfGluPho konnte bereits gezeigt werden, dass das Enzym für die Blutstadien der Parasiten 
essentiell ist. Da es zudem sehr ähnlich zu dem entsprechenden Enzym in P. vivax ist, wird 
angenommen, dass auch PvGluPho ein mögliches Zielmolekül für Medikamente ist. 6PGD trägt 
zur NADPH-Versorgung im gleichen Maße wie GluPho bei. Darüber hinaus wird es bereits als 
mögliches Zielmolekül für Medikamente in anderen Organismen wie dem Parasiten 
Trypanosoma brucei angesehen. Ziel der vorliegenden Arbeit war daher die (weitere) 
strukturelle und funktionelle Charakterisierung dieser Enzyme. Daneben wurde das Potential 
verschiedener Wirkstoffe als mögliche Bestandteile neuer Malariamedikamente untersucht. 
Ähnlich wie natürlich vorkommende Varianten der humanen Glukose-6-Phosphat-
Dehydrogenase (G6PD) wurden auch in PfGluPho natürliche Mutationen entdeckt. Im 
Gegensatz zum menschlichen Wirt bewirken diese wie auch natürlich vorkommende 
Phosphorylierungen jedoch keine bedeutenden Veränderungen der Eigenschaften des 
Enzyms und tragen daher vermutlich nicht zur Redoxhomöostase der Parasiten bei. 
Möglicherweise statten sie die Plasmodien mit anderen, derzeit noch unbekannten Vorteilen 
aus. Neben P. falciparum sind die rekombinante Herstellung und Charakterisierung der 
P. vivax G6PD, des C-terminalen und NADPH-produzierenden Teils der PvGluPho, in dieser 
Arbeit beschrieben. Interessanterweise hat PvG6PD eine niedrigere Aktivität und höhere KM-
Werte als das P. falciparum Enzym, was auf einige funktionelle Nachteile hindeutet. Daneben 
befand sich rekombinant hergestellte PvG6PD in einem vermutlich hexameren 
Oligomerisierungszustand, was jedoch artifizieller Natur sein könnte. Daher sollten 
Oligomerisierung und kinetische Eigenschaften der kompletten PvGluPho untersucht werden. 
Da sich die rekombinante Produktion von PvGluPho allerdings als extrem herausfordernd 
darstellt, ermöglicht die Charakterisierung von PvG6PD in der Zwischenzeit die Verfügbarkeit 
dieses wichtigen Enzyms für die Medikamentenentwicklung. 
In dieser Arbeit sind die rekombinante Herstellung und kinetische Charakterisierung der 
Pf6PGD beschrieben. Darüber hinaus ist es uns gelungen, die Röntgenstruktur der nativen 
Pf6PGD mit einer Auflösung von 2,8 Å zu ermitteln, die Strukturen in Komplex mit dem 
Substrat 6-Phosphogluconat (6PG) oder dem Cofaktor NADP+ (der oxidierten Form von 
NADPH) hatten eine Auflösung von 1,9 beziehungsweise 2,9 Å. Kenntnisse über die 
dreidimensionale Struktur von Enzymen sind während aller Phasen der 
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Medikamentenentwicklung von Nutzen.  Pf6PGD liegt als Dimer vor, wobei jede Untereinheit 
aus einer cofaktorbindenden Domäne, einer substratbindenden Domäne, sowie einem 
C-terminalen Endstück besteht, das durch die benachbarte Untereinheit hindurchragt. Damit 
ist die Pf6PGD-Struktur den Strukturen desselben Enzyms anderer Spezies ähnlich. Wir 
konnten zeigen, dass eine flexible Schlaufe in der Nähe der Substratbindestelle eine neue 
Position einnimmt, sobald 6PG gebunden hat. Dabei wird möglicherweise die 
Bindungsposition von NADP+ reguliert. In Abwesenheit von 6PG ist die Schlaufe offen, 
während NADP+ in einer flexiblen Warteposition bindet. Sobald 6PG gebunden hat, bewegt 
sich die Schlaufe und verschließt den Zugang zur Substratbindestelle. Dies deutet darauf hin, 
dass Cofaktor und Substrat unabhängig voneinander in einem sequentiellen Mechanismus 
binden können, was durch kinetische Untersuchungen bestätigt wurde. Darüber hinaus wurde 
gezeigt, dass die Interaktion zwischen dem für Plasmodium spezifischen W104 mit dem 
konservierten W265 die Interaktion der beiden Domänen unterstützt. 
Darüber hinaus wurde in dieser Arbeit der Einfluss der zwei wichtigen posttranslationalen 
Modifikationen S-Glutathionylierung und S-Nitrosierung auf PfGluPho, PfG6PD, Pf6PGD und 
PvG6PD getestet. Unter den getesteten Bedingungen war keines der Enzyme zugänglich für 
S-Glutathionylierung, jedoch alle für S-Nitrosierung. Während die Aktivität von PfGluPho, 
PfG6PD und PvG6PD nur in sehr geringem Maß durch die Inkubation mit S-Nitrosoglutathion 
verringert wurde, wurde die Pf6PGD Aktivität reversibel um bis zu 65 % gehemmt. 
Möglicherweise können die Enzyme so vor irreversiblen Schäden durch nitrosativen Stress 
geschützt werden. Weitere Untersuchungen sind erforderlich, um die Ursachen für die 
Hemmung dieses wichtigen Stoffwechselweges aufzuklären. 
Ziel der Medikamentenentwicklung ist die Identifizierung von Wirkstoffen, die spezifisch und 
effektiv auf Zielmoleküle wirken. Alle getesteten Verbindungen zeigten eine vergleichbare 
Wirkung auf PfGluPho und PvG6PD. Dies unterstützt die Annahme, dass die zwei Enzyme 
strukturell sehr ähnlich sind und es möglich ist, einen Wirkstoff zu entwickeln, der gegen beide 
Plasmodien-Arten eingesetzt werden kann. Der vielversprechendste Wirkstoff war SBI-
0797750 mit einer mittleren hemmenden Wirkung auf PfGluPho und PvG6PD im sehr 
niedrigen nanomolaren Bereich. Selbst bei der höchsten getesteten Konzentration von 99 µM 
war die Hemmung von hG6PD bei unter 50 %, womit der Wirkstoff hochselektiv für 
plasmodiale Enzyme ist. Hemmstudien zeigten, dass SBI-0797750 mit dem Substrat Glukose-
6-Phosphat um die Bindestelle in PfGluPho konkurriert. Des Weiteren konnte gezeigt werden, 
dass SBI-0797750 in Zellkultur das Wachstum sowohl asexueller Blutstadien als auch von 
Gametozyten im niedrigen nanomolaren Bereich hemmt. Mithilfe genetisch kodierter Sonden 
wurde darüber hinaus gezeigt, dass der Compound die zytosolische Glutathionhomöostase 
stört, während der H2O2-Spiegel ansteigt, vermutlich aufgrund des hervorgerufenen NADPH-
Mangels. Gleichzeitig konnten keine nachteiligen Veränderungen der Erythrozyten sowohl 
gesunder als auch G6PD-defizienter Spender festgestellt werden. Weitere Charakterisierung 
von SBI-0797750 im Hinblick auf Absorption, Verteilung, Metabolismus, Ausscheidung und 
Toxizität wird benötigt. Daneben konnten durch das Screening der Malariabox erste 
Inhibitoren der Pf6PGD mit einer Wirksamkeit im unteren mikromolaren Bereich identifiziert 
werden. Da die dreidimensionale Struktur des Enzyms jetzt bekannt ist, stellt dies einen 
vielversprechenden Ansatzpunkt für strukturbasierte Optimierungsversuche dar.  
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1 Introduction 
Poverty-related diseases are still a major burden for low-income countries. WHO prioritizes 
17 neglected tropical diseases, including Chagas disease, dengue, leishmaniasis, and 
schistosomiasis, threatening more than one billion people in 149 countries worldwide (WHO, 
2015b). These diseases not only significantly deteriorate the health status and life quality of 
infected people, but also cause a significant economic burden to the country (Hung et al., 
2018; WHO, 2015b). The reasons for the high prevalence of infectious diseases in low-income 
countries are manifold; they include malnutrition, poor sanitation and hygiene, a lack of health 
infrastructure and health education, and a lack of access to already existing prevention and 
treatment possibilities (Hotez and Kamath, 2009; WHO, 2015b). 
A major health-related burden is caused by the strongly poverty-related “big three” diseases, 
malaria, HIV/aids, and tuberculosis (Bourzac, 2014; Parola, 2013), nowadays also referred to 
as the “big four” when hepatitis is included (Chen et al., 2015). In 2017, approximately 940,000 
people died due to HIV infection (WHO, 2018a); an estimated 1.3 million HIV-negative and an 
additional 300,000 HIV-positive people died from tuberculosis (WHO, 2018b); and in 2015, 
1.34 million people died from hepatitis according to WHO (WHO, 2017a). The global burden 
caused by malaria will be discussed below. Fighting these diseases is one of the major 
challenges of the 21st Century. 
1.1 Malaria 
Since the beginning of the millennium, there has been remarkable progress in the fight against 
malaria. In 2000, it caused an estimated 262 million cases and 839,000 deaths. Since then, the 
use of insecticide-treated mosquito nets increased significantly, and access to appropriate 
antimalarial drugs improved slightly, averting an estimated 1.2 billion cases of malaria and 
6.2 million malaria deaths between 2000 and 2015 (WHO, 2015a). However, in 2016, malaria 
was still endemic in 91 countries, causing an estimated 216 million cases and 445,000 deaths; 
90% of these cases and deaths can be found in Africa (WHO, 2017b). Therefore, malaria is still 
one of the world’s most important infectious diseases. 
1.1.1 Plasmodium parasites 
Malaria is a vector-borne disease caused by the protozoan parasite Plasmodium (White et al., 
2014). There are more than 120 different Plasmodium (P.) species; six of them regularly infect 
human beings. With 207 million and 8.5 million estimated cases in 2016, P. falciparum and 
P. vivax, respectively, are the two most important species. P. falciparum is mainly distributed 
in sub-Saharan Africa. It induces high levels of blood stage parasites that invade critical organs 
and lead to severe anemia, especially in children (Ashley et al., 2018). Due to its usually mild 
course of infection, P. vivax has been underestimated for many years (Cowman et al., 2016). 
However, P. vivax parasites are able to produce dormant liver stages (see below) that can 
cause relapses months or even years after infection (Ashley et al., 2018), severely affecting 
the development of children. It has been shown that the course of anemia due to falciparum 
or vivax malaria are comparable (Naing et al., 2014). Due to a largely Duffy antigen negative 
population, P. vivax is less common in Africa but more widely distributed in the Americas. In 
Asia and Oceania, P. falciparum and P. vivax are equally distributed. The morphologically 
indistinguishable species P. malariae, P. ovale curtisi, and P. ovale wallikeri are distributed 
worldwide with low incidence; however, P. ovale is mainly found in Africa and Southeast Asia. 
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The course of infection is comparable to uncomplicated vivax malaria. The primary hosts of 
P. knowlesi are macaques; however, it can also cause severe malaria in humans mainly 
distributed in Southeast Asia, especially in Malaysia. Human infections with additional forms 
of simian malaria caused by P. cynomolgi and P. simium have low incidences (Ashley et al., 
2018). So far, a continuous, long-term in vitro cultivation of blood-stage P. vivax parasites is 
not possible (Thomson-Luque et al., 2017). However, the simian infection with P. cynomolgi is 
considered a disease model for human vivax malaria (Markus, 2018). 
All Plasmodium species have a complex life cycle in common that alters between the 
Anopheles mosquitoes and vertebrate hosts (Cowman et al., 2016), which is depicted in Figure 
1. The cycle begins with the transmission of sporozoites into the dermis of the host during the 
blood meal of a female Anopheles mosquito (White et al., 2014). Other possible but less 
common transmission routes are mother-to-child transmission or via blood transfusion, 
especially in resource-poor (Ashley et al., 2018). The sporozoites migrate towards the liver, 
invade hepatocytes, multiply and form schizonts. After 5.5-8 days, the schizonts burst and 
release merozoites into the blood stream, which enter red blood cells (RBC) and initiate the 
asexual cycle. For P. falciparum, P. vivax, and P. ovale, this cycle takes approximately 48 h, 
while it takes 72 h for P. malariae and P. knowlesi. The formation of dormant intrahepatic 
forms, the so-called hypnozoites, is characteristic for infections with P. vivax and P. ovale and 
enables relapses of the infection weeks or even years after primary infection (White et al., 
2014). Furthermore, there is evidence for non-hypnozoite-dependent recurrence of P. vivax 
malaria due to additional plasmodial sources, including parasites hiding in splenic dendritic 
cells, other cells in the spleen, the bone marrow, and the skin. This especially has to be taken 
into account with regard to treatment of vivax malaria (Markus, 2018). Different ligand-
receptor interactions facilitate the attachment and infiltration of the parasites into RBCs via 
several pathways. The receptor predominantly responsible for the invasion of P. vivax 
parasites resembles the Duffy blood group antigen Fya or Fyb. The Duffy-negative FyFy 
phenotype is widely distributed in the population of West Africa, leading to the carrier’s 
resistance to P. vivax malaria. A subpopulation of the parasites leaves the asexual cycle and 
develops into the sexual stages, the so-called gametocytes, which are taken up by an 
Anopheles mosquito during the next blood meal (White et al., 2014). The male gametocytes 
exflagellate in the midgut, where a zygote is formed by the fusion of male and female gametes. 
The zygote develops into a mobile ookinete capable of passing the mosquito gut wall. The 
emerging oocyst releases sporozoites which complete the life cycle by migrating into the 
mosquito’s salivary glands (Ashley et al., 2018). 
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Figure 1. Life cycle of Plasmodium falciparum 
Plasmodium parasites have a complex life cycle with a changing environment between the human host and 
Anopheles mosquitoes that consists of three stages: the mosquito stage, the liver stage, and the blood stage. The 
numbers of parasites during each stage are indicated in the boxes. (A) During the blood meal of an infected 
mosquito, it injects sporozoites into the dermis of a human being. (B) The sporozoites migrate towards the liver 
where they invade hepatocytes and form schizonts. (C) After approximately one week, the schizonts burst and 
release merozoites into the blood stream, which enter red blood cells and initiate the asexual cycle. Some 
parasites leave the cycle and develop into gametocytes, the sexual stages. (D) Gametocytes that are taken up by 
a mosquito develop into sporozoites and migrate into the salivary glands. The next bite of a mosquito completes 
the life cycle (White et al., 2014). 
1.1.2 Pathogenesis and clinical manifestation of malaria 
Initial symptoms of malaria occur as soon as parasitemia is above a threshold of about 100 
parasites per µL blood. Despite some variation for certain strains, typical durations of 
incubation are 10-14 days for P. falciparum and P. knowlesi, 2-3 weeks for P. vivax and 
P. ovale, and 18 days or longer for P. malariae (Ashley et al., 2018). Major remodeling 
processes of the human RBCs by the parasites are the predominant cause of malaria 
symptoms. The aim is to convert terminally differentiated cells into an environment that 
enables the parasites to grow and hide from the host immune system. Therefore, numerous 
proteins are exported out of the parasites into the host RBCs. A vesicle-mediated trafficking 
network from the parasitic endoplasmic reticulum across the parasite membrane and the 
parasitophorous vacuole into the host cell facilitates translocation of the proteins. Their final 
destinations are the erythrocytic cytosol, the cytoskeleton, or the membrane. One prominent, 
extensively studied protein that is exported to the surface of P. falciparum-infected cells is the 
P. falciparum erythrocyte membrane protein 1 (PfEMP1) family (Cowman et al., 2016). This 
protein allows cytoadherence to endothelial surface receptors in veins and capillaries and 
sequestration in deep capillary beds, thereby enabling escape from the splenic clearance 
(Cowman et al., 2016; White et al., 2014). Reconstructing the cell membrane allows not only 
the export of parasite-derived proteins but also the import of nutrients. Intracellular parasites 
use the contents of human RBCs as their primary source of nutrients, releasing potentially 
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toxic free heme. This waste product has to be detoxified through lipid-mediated crystallization 
to the so-called malaria pigment, the biologically inert hemozoin (White et al., 2014). 
Sequestration causes injuries to the host endothelial cells and microvascular obstruction. The 
clinical consequences depend on the affected organs. For example, they lead to a coma if the 
brain is involved, respiratory failures for the lungs, and placental malaria with maternal 
anemia, low birthweight, preterm labor, abortion, or stillbirth if the placenta is affected 
(Ashley et al., 2018). Besides this morphological damage, the human host reacts with 
increased splenic immune function and filtrating clearance, resulting in an accelerated 
removal of parasitized, but also uninfected RBCs (White et al., 2014). The loss of RBCs due to 
high spleen activity is one of the most important causes (another being intravascular 
hemolysis) of anemia during acute infection and is a very common feature of malaria (Ashley 
et al., 2018). The release of merozoites into the blood activates the immune system, which 
increases the activity of monocytes and macrophages and releases proinflammatory cytokines 
that cause the typical malaria fever (White et al., 2014). 
Depending on the intensity of the symptoms, malaria is divided into uncomplicated and severe 
malaria. The symptoms of uncomplicated malaria are rather unspecific and include not only 
flu-like symptoms such as fever, chills, body-aches, headache, and cough, but also diarrhea 
and thrombocytopenia. Severe P. falciparum malaria is diagnosed via specific clinical (e.g. 
prostration, coma, convulsions, jaundice) and laboratory (hemoglobinuria, hypoglycemia, 
acidosis, acute kidney injury, asexual parasitemia in over 10% of infected RBCs) criteria. Typical 
manifestations of severe malaria are cerebral malaria, acute lung injury that can develop into 
an acute respiratory distress syndrome, acute kidney injury, and acidosis; severe anemia is 
commonly present amongst children (Ashley et al., 2018). In contrast to P. falciparum, 
infections with P. vivax are usually not fatal, but they can also cause severe anemia and be 
followed by frequent relapses due to the formation of dormant hypnozoites in the liver (1.1.1). 
In children, these recurring infections can severely impair their development (Cowman et al., 
2016). Therefore, an early detection and appropriate treatment are essential to contain the 
consequences of P. vivax infection (Naing et al., 2014). 
1.1.3 Prevention and treatment of malaria 
There are three different approaches to deal with malaria: vector control, chemoprevention, 
and case management. The first two try to prevent malaria from occurring, while case 
management means treating an actual infection using antimalarial drugs (WHO, 2017b). The 
approaches are described below. 
Vector control 
The goal of vector control is to stop the mosquito from biting humans and thereby block the 
transmission (WHO, 2017b). A commonly used method is sleeping under insecticide-treated 
mosquito nets (ITNs) (Tizifa et al., 2018). In certain settings of sub-Saharan Africa, the use of 
ITNs was able to reduce the malaria incidence rate by 50% and the mortality rate in children 
under the age of 5 by 55%. However, the distribution of ITNs is still not sufficient; e.g., there 
were twelve countries in sub-Saharan Africa with less than 50% of the at-risk population 
having access to ITNs (WHO, 2017b). The second major strategy is indoor residual spraying 
(IRS). It has been proved to successfully eradicate malaria and control epidemics in several 
countries. However, IRS is costly, especially on a large scale, and it is not without risk to human 
health and the environment (Tizifa et al., 2018). Moreover, Anopheles mosquitoes are 
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becoming increasingly resistant to all four classes of insecticides commonly used in both ITN 
and IRS (WHO, 2017b). One of the oldest strategies to fight malaria is larval source 
management, i.e. dealing with aquatic habitats that serve as potential breeding sites. 
Furthermore, there are numerous strategies under development such as house improvement, 
toxic sugar feeding, the release of genetically modified mosquitoes, and many more (Tizifa et 
al., 2018). One novel, intensively studied system to manipulate natural Anopheles populations 
is the so-called gene drive system. It is based on site-specific selfish genes exploiting the host’s 
gene repair system to introduce themselves into specific target sequences. Using this ‘super-
Mendelian’ inheritance, the selfish genes can spread throughout entire populations. First used 
were homing endonuclease genes (HEG) encoding enzymes that recognize and cleave specific 
sequences located on chromosomes without a copy of the HEG. Cleaved chromosomes are 
repaired by the recombinational repair system of the cell using the intact HEG containing 
chromosome as a template. Using this approach, both chromosomes contain HEG after the 
repair, heterozygotes are transformed into homozygotes. HEGs can be engineered in a way 
that the recognition site is located in the middle of an essential gene that is destroyed after 
the recombinational repair (Burt, 2003). Newly developed RNA-guided gene drives based on 
the CRISPR-Cas9 endonuclease simplified this before rather complicated approach (Esvelt et 
al., 2014). The use of this technique in the malaria vector Anopheles could significantly 
contribute to the control or even elimination of malaria (Gantz et al., 2015; Hammond et al., 
2016). Targeting a gene that controls the differentiation of the two sexes in Anopheles 
gambiae in fact enabled the creation of 100% prevalence of sterile females within 7-11 
generations, resulting in a total collapse of the population (Kyrou et al., 2018). However, one 
potential issue is the occurrence of nuclease-resistant variants that block the gene drive 
through the population (Bull and Malik, 2017; Hammond et al., 2016). In Drosophila 
melanogaster, evolution of resistance was mainly observed in the germline, but also after 
fertilization in the embryo. At the moment, this severely limits the applicability of the 
approach (Champer et al., 2017). Moreover, the use of gene drive systems is heavily discussed 
with to respect to safety, but also ethical considerations. It has to be ensured that an 
accidental release of organisms carrying gene drive constructs into the environment is 
excluded (Akbari et al., 2015). 
Moreover, there are major efforts underway to study mosquito behavior. Detailed knowledge 
on flight, mating, feeding, and oviposition behavior of the vector can help researchers develop 
new control strategies, e.g., swarm spraying (Spitzen and Takken, 2018; Tizifa et al., 2018). 
Chemoprevention 
The goal of chemoprevention is to suppress the outbreak of the disease after an infected 
mosquito’s bite with drugs (WHO, 2017b). Chemoprophylaxis is especially recommended for 
pregnant women, young children, and travelers (Ashley et al., 2018). In 2012, WHO 
recommended a seasonal malaria chemoprevention (SMC) for P. falciparum malaria control 
in the highly seasonal transmission areas across the Sahel sub-region. SMC comprises a 
monthly administration of sulfadoxine pyrimethamine and amodiaquine for up to four months 
to children between 3 and 59 months of age (WHO, 2012). Additionally, an intermittent 
preventive treatment of malaria in pregnancy is recommended (WHO, 2017b). So far, SMC has 
proved to be highly successful, significantly reducing the incidence of both uncomplicated and 
severe malaria by 82%; however, the delivery of the medicine to children remains a logistical 
challenge. Moreover, there is the threat of malaria parasites becoming resistant to sulfadoxine 
pyrimethamine and amodiaquine in the future (Greenwood et al., 2017). For travelers, doctors 
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should choose a chemoprevention strategy based on the risks of infection, parasite drug 
resistance, and drug toxicity. Atovaquone-proguanil, doxycycline, mefloquine, and 
primaquine are commonly used (Kolifarhood et al., 2017). 
Developing a vaccine against malaria is challenging. RTS,S/AS01, also known as Mosquirix, is 
the first vaccine that has received a positive opinion from the European Medicines Agency to 
be used as vaccination in young children (EMA, 2015). It targets sporozoite stages via the 
P. falciparum circumsporozoite protein, a surface protein that is expressed at the pre-
erythrocytic stage of the parasite (Cohen et al., 2010). A large phase 3 clinical trial conducted 
in seven countries in sub-Saharan Africa demonstrated significant protection against 
P. falciparum malaria infection over a 3-4 years period. In older children (5-17 months), the 
vaccine efficacy was 36.3% with a booster dose at month 20 and 28.3% without a booster. The 
efficacy in infants (6-12 weeks) was lower: 25.9% with a booster and 18.3% without (RTS,S 
Clinical Trials Partnership, 2015). Efficacy varies between Plasmodium strains (Neafsey et al., 
2015), and the vaccination quickly loses its efficacy over time. A seven-year follow-up study 
revealed an efficacy of only 4.4% (Olotu et al., 2016). However, the vaccine is still able to avert 
a substantial number of clinical malaria cases and can make an important contribution to 
fighting the disease, especially in combination with other strategies (RTS,S Clinical Trials 
Partnership, 2015). In addition to RTS,S/AS01, there are several other vaccines under 
development, e.g. a P. falciparum sporozoite vaccine that aims to induce sporozoite-based 
immunity through intravenous injection of irradiation-attenuated sporozoites (Richie et al., 
2015; Sissoko et al., 2017). Another approach, targeting the merozoite stage proteins, aims to 
reduce the asexual replication rate of the parasites. PfRh5, which is critical for parasites trying 
to invade RBCs, is currently of particular interest (Ashley et al., 2018; Crosnier et al., 2011; 
Drew and Beeson, 2015). In contrast to targeting the asexual stages, transmission-blocking 
vaccines target sexual stage antigens in order to generate antibodies that are ingested during 
the mosquito blood meal, potentially providing immunity at population level (Sinden, 2017). 
In areas where malaria transmission is limited to a few months per year, mass vaccination 
campaigns shortly before the transmission season begins might be an effective way to take 
advantage of malaria vaccines with an initially high efficacy rate such as RTS,S/AS01 
(Greenwood et al., 2017). 
Case management 
After a prompt diagnosis, an effective treatment is essential to prevent a severe form of 
malaria from developing. WHO currently recommends an artemisinin-based combination 
therapy (ACT) for treating uncomplicated P. falciparum malaria (WHO, 2017b). Commonly 
used combinations are artesunate-amodiaquine, dihydroartemisinin-piperaquine, 
artesunate-mefloquine, artemether-lumefantrine, and artesunate plus sulfadoxine-
pyrimethamine (Ashley et al., 2018). The primary reason for applying combination therapies 
is to reduce the risk of resistance development (White, 1999). Artemisinin quickly reduces a 
large amount of parasites, while the partner drug clears the rest. Using chloroquine or an ACT 
is recommended for uncomplicated P. vivax malaria. Often, primaquine is used to remove 
latent liver stage infections and prevent a recurrence of the infection (WHO, 2017b). 
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Figure 2. Global distribution of Plasmodium falciparum treatment failures 
The local occurrence of drug resistant P. falciparum parasites is shown. Laos, Thailand, Vietnam, and Cambodia 
have had cases of ACT-resistant parasites. Fortunately, 13 countries are currently close to eliminating malaria as 
defined in the World Malaria Report 2016 (WHO, 2016). The global number of malaria cases and especially the 
number of malaria deaths (shown with 95% upper and lower uncertainty intervals) declined dramatically from 
2000 to 2015. ACT: artemisinin-based combination therapy (Ashley et al., 2018). 
Partial resistance to artemisinin does not automatically result in complete treatment failure, 
but it does increase the challenge for the partner drug and thereby the risk of resistance 
developing against it. Artemisinin resistance has been observed in several countries of 
Southeast Asia (WHO, 2017b). High rates of ACT failures (over 10%) have been reported in 
Cambodia, Thailand, Laos, and Vietnam (Figure 2) (Ashley et al., 2018; WHO, 2017b). In severe 
malaria, medical personnel must pay special attention to managing symptoms such as severe 
anemia, hypoglycemia, hypovolemia, acidosis, and others described above (Ashley et al., 
2018). 
1.2 Pentose phosphate pathway 
The pentose phosphate pathway (PPP) plays a central role in cellular biosynthetic metabolism. 
Along with the glycolysis and the tricarboxylic acid cycle, it was one of the first pathways 
discovered. Evolutionarily speaking, the biochemical reactions are presumably very old 
(Stincone et al., 2015). There are indications that the reactions that enzymes nowadays 
catalyze have descended from enzyme-free, metal-catalyzed sugar phosphate 
interconversions in the reaction milieu of the prebiotic Archean ocean (Keller et al., 2014). 
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In most tissues, the majority of glucose (80-90%) is oxidized via glycolysis. The PPP, also known 
as the hexose monophosphate shunt, represents an alternative cytosolic pathway for oxidizing 
the remaining 10-20% of glucose. It has two major functions (Wamelink et al., 2008): 
− Production of nicotinamide adenine dinucleotide phosphate (NADPH): this electron donor 
is essential in many biosynthetic pathways and for protecting against oxidative stress. 
− Synthesis of ribose 5-phosphate: this is essential for nucleotide and nucleic acid synthesis 
(Wamelink et al., 2008). 
The PPP can be divided into two branches: oxidative and non-oxidative. 
 
Figure 3. Schematic representation of the pentose phosphate pathway and glycolysis 
The pentose phosphate pathway (PPP, left, gray background) is divided into an oxidative and non-oxidative 
branch. The reactions, potential reversibility of the reactions, and connections between the PPP and glycolysis 
(right) are indicated by arrows. Enzymes converting sedoheptulose 7-phosphate can be distinguished between * 
bacteria, ** fungi, and *** mammals. 6PGDH: 6-phosphogluconate dehydrogenase; 6PGL: 
6-phosphogluconolactonase; ADP: adenosine diphosphate; ATP: adenosine triphosphate; FBA: fructose 
bisphosphate aldolase; G6PDH: glucose 6-phosphate dehydrogenase; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase; GPI: glucose phosphate isomerase; HK: hexokinase; NAD+/NADH: oxidized/reduced 
nicotinamide adenine dinucleotide; NADP+/NADPH: oxidized/reduced nicotinamide adenine dinucleotide 
phosphate; PFK: phosphofructokinase; PK: pyruvate kinase; RPE: ribulose 5-phosphate epimerase; RPI: ribose 5-
phosphate isomerase; SH17BPase: sedoheptulose 1,7-bisphosphatase; SHI: sedoheptulose 7-phosphate 
isomerase; SHPK: sedoheptulokinase; TAL: transaldolase; TKL: transketolase; TPI: triosephosphate isomerase 
(Stincone et al., 2015). 
The oxidative branch 
The oxidative branch consists of three irreversible reactions, indicated by the one-way arrows 
in Figure 3 (Stincone et al., 2015). First, glucose 6-phosphate dehydrogenase (G6PD, EC 
1.1.1.49) catalyzes the dehydrogenation of glucose 6-phosphate (G6P) to 6-phosphoglucono-
δ-lactone and produces one molecule of NADPH. 6-Phosphogluconolactonase (6PGL, EC 
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3.1.1.31) rapidly hydrolyzes 6-phosphoglucono-δ-lactone, yielding one 6-phosphogluconate 
(6PG) (Wamelink et al., 2008). This hydrolysis can also occur spontaneously; however, the 
activity of 6PGL is necessary for this reason: the δ form of 6-phosphogluconolactone is the 
only product of the G6PD reaction. Intermolecular rearrangements lead to the γ form. While 
only the δ form can undergo spontaneous hydrolysis and serve as a substrate for 6PGL, the γ 
form cannot be spontaneously hydrolyzed and also cannot be used as a substrate by 6PGL; it 
therefore represents a “dead end” on the pathway and accrues. Moreover, the accumulation 
of 6-phosphoglucono-δ-lactone may be toxic due to its reactivity with endogenous cellular 
nucleophiles. Therefore, 6PGL activity accelerates the spontaneously occurring hydrolysis of 
the δ form and prevents the formation and accumulation of the “dead end” γ form (Miclet et 
al., 2001). 6-Phosphogluconate dehydrogenase (6PGD, EC 1.1.1.44) oxidatively decarboxylates 
the resulting 6PG, producing ribulose 5-phosphate, CO2, and one additional molecule NADPH 
(Wamelink et al., 2008). In summary, two NADPH molecules are generated for each molecule 
of G6P during the oxidative branch of the PPP (Stincone et al., 2015). 
The non-oxidative branch 
The reactions of the non-oxidative branch are reversible, as indicated by the bidirectional 
arrows in Figure 3 (Stincone et al., 2015). Ribulose 5-phosphate, the product of the oxidative 
branch, is either epimerized to xylulose 5-phosphate by ribulose 5-phosphate epimerase or 
isomerized to ribose 5-phosphate by ribose 5-phosphate isomerase. Ribose 5-phosphate can 
be used for the synthesis of nucleotides and nucleic acids. However, in many situations, more 
NADPH is needed for biosynthetic processes than ribose 5-phosphate for nucleotide synthesis. 
In these cases, transketolase converts ribose 5-phosphate and xylulose 5-phosphate into 
sedoheptulose 7-phosphate and glyceraldehyde 3-phosphate, respectively. Transaldolase 
further metabolizes these two products to erythrose 4-phosphate and fructose 6-phosphate, 
respectively. Transketolase also converts erythrose 4-phosphate and xylulose 5-phosphate to 
glyceraldehyde 3-phosphate and fructose 6-phosphate, respectively. Therefore, transketolase 
and transaldolase build a reversible connection between the PPP and glycolysis (Wamelink et 
al., 2008), since glucose 6-phosphate isomerase can convert fructose 6-phosphate to G6P, the 
starting substrate for the oxidative PPP (Stincone et al., 2015). 
Localization of the PPP 
As already indicated above, the PPP is located in the cytosol in most organisms; however, 
there are exceptions (Stincone et al., 2015). The pathway can be distributed between the 
cytosol and other organelles (e.g. the plastid, peroxisomes, or glycosomes). This distribution 
can be observed in some plants and parasitic protozoa (Hannaert et al., 2003; Kruger and von 
Schaewen, 2003). Part of the PPP can also occur in the endoplasmic reticulum. In vesicles 
formed in the endoplasmatic reticulum, five enzymes of the PPP were found, including a 
special enzyme was found called hexose 6-phosphate dehydrogenase (H6PD); it is similar to 
G6PD but has a broader range of substrates and is not selective regarding the choice of 
nucleotide cofactor (NAD+ or NADP+) (Bublitz and Steavenson, 1988; Senesi et al., 2010; 
Stincone et al., 2015). 
1.2.1 Glucose 6-phosphate dehydrogenase 
G6PD is a cytosolic housekeeping enzyme that is expressed in all cells of the body. As described 
above, it catalyzes the first, rate-limiting step of the oxidative PPP, the oxidation of G6P to 
6-phosphoglucono-δ-lactone during the reduction of its cofactor NADP+ to NADPH (Gomez-
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Manzo et al., 2016; Luzzatto et al., 2016). G6PD is highly conserved in all living organisms 
except for Archaebacteria since they are not extensively exposed to oxygen in their 
environment; therefore, they do not have to defend against oxidative stress (Luzzatto et al., 
2016; Notaro et al., 2000). 
1.2.1.1 Human glucose 6-phosphate dehydrogenase and its deficiency 
Structure and function of human G6PD 
In human beings, the g6pd gene is located close to the telomeric region of the distal arm of 
the X chromosome (band Xq28). The complete sequence has a size of 18.5 kb, consisting of 13 
exons and 12 introns. It encodes a product of 1,545 bp. Exon 1 and a part of exon 2 are not 
translated into protein; therefore, the gene results in a protein with 515 amino acids and 
59 kDa per monomer (Cappellini and Fiorelli, 2008; Gomez-Manzo et al., 2016). The enzyme 
is active as a homodimer or a homotetramer (Cohen and Rosemeyer, 1969). Each subunit has 
one tightly bound NADP+ in addition to the binding sites of NADP+ and G6P, thereby enhancing 
its structural stability (Au et al., 2000). Under physiological conditions, hG6PD operates in RBCs 
at only approximately 1% of its maximal capacity. Therewith, oxidative stress leading to 
oxidation of NADPH (see 1.2.3) results in an activation of hG6PD (Preuss et al., 2012b). 
Genetics and molecular basis of G6PD deficiency 
G6PD deficiency is the most common enzymopathy, affecting 400 million people worldwide. 
There are more than 400 different variants of G6PD caused by 217 mutations. Most of them 
(83.9%) are missense variants with substitutions of single nucleotides; 8.7% are multiple 
mutations with two or more substitutions; 5.1% of the mutants are caused by deletions; and 
2.3% of the mutations affect introns (Gomez-Manzo et al., 2016). There are many studies 
indicating that due to its X-linked heredity, G6PD deficiency is more common in males than in 
females (Cappellini and Fiorelli, 2008; Gomez-Manzo et al., 2016). However, there are 
considerations indicating that this statement is not correct for the following reason: In males, 
there are two genotypes (hemizygous normal and hemizygous deficient), while there are three 
genotypes in females (homozygous normal, homozygous deficient, and heterozygous). In 
populations, homozygous females can be found less frequently than hemizygous males, while 
heterozygous females are much more common. With wide variations in heterozygous 
females, one half of the RBCs are normal, and the other half are G6PD deficient. Therefore, 
the phenotype of heterozygous women varies from normal to severely G6PD deficient with 
different clinical implications (Luzzatto et al., 2016). 
Clinical consequences of G6PD deficiency 
Mutations in the g6pd gene are associated with more or less severe enzyme deficiency 
(Gomez-Manzo et al., 2016); however, there is no complete loss of activity because this would 
presumably be lethal (Longo et al., 2002; Pandolfi et al., 1995). Depending on the mutation, 
there are different quantitative, but also qualitative changes in the properties of the enzyme. 
Based on the degree of deficiency and the clinical manifestations, the G6PD variants are 
divided into five classes (Table 1). A cluster of the most severe class I deficient variants is 
caused by different mutations in the dimerization domain of the enzyme, influencing the 
stability of the dimer. These variants are associated with chronic non-spherocytic hemolytic 
anemia (Luzzatto et al., 2016). 
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Table 1. Classes of G6PD deficiency 
The residual activity of classes IV and V slightly varies depending on the literature (Cappellini and Fiorelli, 2008; 
Luzzatto et al., 2016). 
 Residual activity Symptoms 
Class I < 10% Associated with chronic, non-spherocytic hemolytic anemia 
Class II < 10%  Associated with acute hemolytic anemia 
Class III 10-60% None in the steady state 
Class IV 60-100% None 
Class V > 100% None 
 
The central role of NADPH in metabolism is described below. In most cells, there are several 
sources of this electron donor (see 1.2.3); however, the situation in RBCs is different: they do 
not have a nucleus or mitochondria. For them, the only source of NADPH is the PPP (Gomez-
Manzo et al., 2016; Preuss et al., 2012b). One of the major tasks of RBCs is to transport oxygen. 
Together with the iron contained in hemoglobin, endogenous formation of free radicals via 
the Fenton reaction is possible (Müller, 2004). Defense against this stress requires a significant 
amount of NADPH (see 1.2.3). Therefore, it is obvious that a G6PD deficiency has more severe 
consequences for erythrocytes than for other cells (Luzzatto et al., 2016). Nevertheless, most 
G6PD deficient individuals stay asymptomatic throughout their life; often they are not even 
aware of their deficiency. Oxidative stress triggered by different events such as drug intake, 
infections, or the ingestion of fava beans can manifest as acute hemolysis (Cappellini and 
Fiorelli, 2008; Luzzatto et al., 2016). Due to the connection to fava beans, this manifestation 
is also called favism (Luzzatto and Arese, 2018). Other symptoms besides acute hemolytic 
anemia include not only neonatal jaundice and chronic, non-spherocytic hemolytic anemia, 
but also more unspecific symptoms such as fatigue and back pain. Markers include increased 
lactate dehydrogenase, unconjugated bilirubin, and reticulocytosis (Cappellini and Fiorelli, 
2008; Luzzatto et al., 2016). 
G6PD deficiency and malaria 
The distribution areas of malaria and G6PD deficiency are strikingly similar. The highest 
frequencies of the deficiency were detected in Africa, Asia, the Mediterranean region, and in 
the Middle East. This led to the so-called malaria protection hypothesis (Cappellini and Fiorelli, 
2008). It has been shown that the risk of severe P. falciparum malaria is reduced in G6PD 
deficient patients (Bienzle et al., 1972; Clark et al., 2009; Guindo et al., 2007; Ruwende et al., 
1995). Moreover, there is evidence for partial resistance to not only P. falciparum but also 
P. vivax (Louicharoen et al., 2009). Accordingly, the growth of parasites in cell culture is slower 
in G6PD deficient RBCs than in normal RBCs (Cappadoro et al., 1998; Miller et al., 1984; Roth 
et al., 1983). Already in 1969 it was shown that parasitic growth is 2-80 times lower in G6PD 
deficient RBCs than in healthy cells (Luzzatto et al., 1969). However, the mechanism of 
resistance is not yet fully understood. Most likely the immune response of the host differs 
between deficient and healthy cells. G6PD deficient erythrocytes containing ring stage 
parasites are more intensely phagocytosed than normal infected cells, most likely due to the 
deficiency causing impaired antioxidative defense (see also 1.2.3). The binding of autologous 
IgG and complement C3 fragments (Cappadoro et al., 1998) – a factor that triggers 
phagocytosis (Turrini et al., 1992) – is significantly higher in G6PD deficient, ring stage infected 
RBCs than in normal, ring stage infected cells (Cappadoro et al., 1998). Band 3 cross-linking 
appears earlier in G6PD deficient, oxidatively damaged cells than in healthy cells, leading to 
12 
 Introduction 
an earlier occurrence of band 3 auto-antibodies and earlier recognition by the immune system 
(Beppu et al., 1990; Giribaldi et al., 2001). This indicates that similar mechanisms remove 
G6PD deficient, infected RBCs as senescent and oxidatively stressed cells (Kay, 1984; Low et 
al., 1985; Lutz et al., 1988).  
G6PD deficiency impacts not only a potential infection with malaria, but also the drug regime 
of infected, deficient patients. Primaquine is currently the only available drug that eliminates 
the hypnozoites of P. vivax and P. ovale. It is also able to rapidly sterilize mature gametocytes 
of P. falciparum. However, the main adverse effect is that it triggers dose-dependent 
hemolysis in G6PD deficient patients. The lack of sufficient testing for G6PD deficiency in 
malaria-endemic areas puts patients at risk of hemolysis if primaquine is applied, resulting in 
a current underuse of this drug (Recht et al., 2018). Nevertheless in 2015, WHO recommended 
adding a single dose of primaquine (0.25 mg·kg-1) as a gametocytocide to the ACT for treating 
P. falciparum malaria. This dose effectively blocks transmission and is unlikely to cause severe 
adverse effects, regardless of the G6PD variants (Bancone et al., 2016; WHO, 2015c). 
1.2.1.2 Plasmodial glucose 6-phosphate dehydrogenase 6-phosphogluconolactonase 
Structure and function of plasmodial GluPho 
In 1994, O'Brien et al. isolated the gene for G6PD from P. falciparum. It is encoded on 
chromosome 14 and consists of one exon with 5.1 kb; the coding region has 2,730 bp with an 
AT content of 77.5% (O'Brien et al., 1994). This is in accordance with the generally high AT 
composition (80.6%) of the plasmodial genome (Gardner et al., 2002). The product consists of 
910 amino acids with a molecular weight of 107 kDa per monomer (O'Brien et al., 1994). 
    h     AASYQRLNS--------------------------------------------------- 123 
    Pb    PESFENFDVYITQEERIALGCCGQKGNEKHKQVNVTSQFPNNHTSINII---NNIDNGCE 464 
    Pv    SESFERFNKYLTQLERENLIGTAPTS---WAAAAGNASFANDTDKVEHHPDEAILAKGTG 464 
    Pk    SESFEKFNKYLTQLEREDLVGVSNTI---WGEAAWKESFMNTAHSLELHSDEPNCEKGAS 464 
    Pf    SESFENFNKYLTTIEEEEAKKKYYAT---CYKMNGSD---------------YNISNNVA 472 
    Pm    SESFENFNKYLIEVEQEAHSNEYTCY----YNII-----------------------GED 442 
    Po    PESFEKFNKYLNELEQEALASGFVDN----QKIFFQE---------------GNMKNGEE 449 
 
    h     ------------------------------------------------------------ 123 
    Pb    SPMLTDSPKRYPCSSSYSSTSGTAVCPYSSQHDVKPSNNGCPYLSSQANTSDSSGCP-YI 524 
    Pv    A----ATPGEAPGGANGPA-----------THGEAHGGANGLST------PMQGKAVPTD 503 
    Pk    I----ATPVEVH------------------------GDQGAPSI------PMQSNLSHTD 490 
    Pf    E-------------DNISI-----------DDEN--K-----TN------EYFQMCTPKN 495 
    Pm    K-------------SCSSD-----------LHKR--G-----TN------DEWSRCPPTD 465 
    Po    K-------------INGIP-----------NEDK--G-----EN------ELGKSAPTAN 472 
 
    h     -----HMNALHLGSQANRLFYLA 141 
    Pb    SYHTNKSGHLGCPYTITRMLYLA 547 
    Pv    DTSDEGHSGANHPFAINRILYLA 526 
    Pk    DTLDQVQSGTKCPFAINRVLYLA 513 
    Pf    CPDNVFSSNYNFPYVINRMLYLA 518 
    Pm    ATDV-AHSTANYTYVINRMLYLA 487 
    Po    SSED-NFSSYNHSYIANRMLYLA 494 
Figure 4. Amino acid alignment of the insertion in the G6PD encoding region of different Plasmodium species 
The insertion in the G6PD gene exists in all shown Plasmodium species; however, they differ in size and sequence 
(Clarke et al., 2003). Conserved residues are indicated in gray. h: human (UniProtKB - P11413); Pb: Plasmodium 
berghei (PBANKA_1317500); Pv: Plasmodium vivax (PVX_117790); Pk: Plasmodium knowlesi (PKNH_1228300); 
Pf: Plasmodium falciparum (PF3D7_1453800); Pm: Plasmodium malariae (PmUG01_12063200); Po: Plasmodium 
ovale (PocGH01_12061100). 
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When discovered, this enzyme was noticeably much larger than G6PDs from other species 
known at that time. The C-terminal amino acids 310-910 have 39% homology to hG6PD. 
However, an insertion of 62 amino acids is not homologous (O'Brien et al., 1994). This insertion 
is also found in other Plasmodium species; however, they differ in size and sequence (Figure 
4) (Clarke et al., 2003). Origin and function of the insertions are so far unknown. It has been 
shown for P. berghei that it is essential for the G6PD activity. Interestingly, after replacement 
of the P. berghei insertion with the insertion of P. falciparum, some of the P. berghei G6PD 
activity was preserved (Clarke et al., 2003), although its original insertion is with 113 amino 
acids remarkably longer than the P. falciparum insertion with 62 amino acids (Figure 4). 
Further experiments need to be performed to fully understand the function of these 
insertions. 
The function of the additional N-terminal amino acids was also unknown for a long time 
(O'Brien et al., 1994; Shahabuddin et al., 1994), but the enzyme was assumed to be 
bifunctional (O'Brien et al., 1994; Scopes et al., 1997). Clarke et al. could finally show in 2001 
that the P. berghei enzyme, which has the same structure as the P. falciparum one, exerts 
both G6PD and 6PGL activity. It was thereby confirmed that a bifunctional enzyme combining 
glucose 6-phosphate dehydrogenase and 6-phosphogluconolactonase, called GluPho, 
catalyzes the first two steps of the PPP in Plasmodium (Clarke et al., 2001; Jortzik et al., 2011). 
Schematics of PfGluPho and the human homologs are shown in Figure 5 (Preuss et al., 2012b). 
 
Figure 5. Schematics of P. falciparum glucose 6-phosphate dehydrogenase 6-phosphogluconolactonase and 
its human counterparts 
In P. falciparum, the first two steps of the oxidative pentose phosphate pathway are catalyzed by the bifunctional 
enzyme GluPho that combines the G6PD and the 6PGL reaction; two distinct enzymes catalyze these reactions 
in human beings. The insertion in the G6PD part of PfGluPho is specific for Plasmodium. The figure was modified 
after Preuss et al., 2012b. 
In accordance with PfGluPho isolated from parasites (Ling and Wilson, 1988; O'Brien et al., 
1994), recombinant PfGluPho is active in tetrameric form with a molecular mass of 443 kDa 
that is independent on the presence of substrates, product inhibitors, pH, or reducing agents. 
The G6PD activity of PfGluPho most likely follows a rapid equilibrium random bi bi system, 
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meaning that both substrates have to bind before product formation occurs; however, there 
is no fixed order in which they have to bind (Jortzik et al., 2011). In cocrystallization trials or 
inhibition studies, for example, this knowledge is of importance. 
GluPho of P. vivax has not yet been characterized. The gene is located on chromosome 12, has 
only one exon with 2,784 bp, and encodes a protein with 927 amino acids (PlasmoDB 
PVX_117790). Regarding the primary sequences, PfGluPho and PvGluPho have 71.2% identical 
and 79.9% similar amino acids (Appendix 1), although there is a remarkable difference in AT 
content (80.6% in P. falciparum, 57.7% in P. vivax (Carlton et al., 2008)). 
Importance of GluPho for Plasmodium parasites 
Prior to the validation of PfGluPho as a drug target (see below), there had been several 
indications that this bifunctional enzyme was important for Plasmodium parasites. An initial 
indicator was that human G6PD deficiency leads to partial malaria resistance (see 1.2.1.1). 
Furthermore, the total activity of the oxidative PPP was noticeably 78-fold higher in infected 
RBCs than in healthy cells. The parasites were found to cause 82% of the PPP activity (Atamna 
et al., 1994). Furthermore, RNA-mediated gene silencing of PfGluPho resulted in an arrest of 
parasite growth at the trophozoite stage, increased gametocyte formation, and enhanced 
transcription of thioredoxin reductase (TrxR) (Crooke et al., 2006). In 2015, attempted double 
crossover disruption of the gene for PfGluPho finally proved this enzyme to be essential for 
the growth of asexual blood stage parasites, thereby validating it as a promising drug target 
(Allen et al., 2015). 
Naturally occurring PfGluPho variants 
Exposure to Plasmodium parasites for several hundred years has left marks on the human 
genome. One very prominent consequence — G6PD deficiency — has already been described 
above in detail (1.2.1.1). There are several other genetically encoded disorders that are 
associated with resistance to malaria such as sickle cell disease, thalassemia, hemoglobin C 
and E, pyruvate kinase deficiency, and the Duffy-negative phenotype (see 1.1.1) (Lopez et al., 
2010). However, not only does the human genome show signs of exposure to Plasmodium but 
also vice versa; during recent years, there have been extensive efforts to identify naturally 
occurring mutations in the plasmodial genome (Kirchner et al., 2016; Neafsey et al., 2008; 
Volkman et al., 2007) that might increase the parasites’ ability to deal with strong evolutionary 
selection pressure. Potentially, the mutations could lead to a failure of drug treatments 
(Haldar et al., 2018) or resistance to the host’s immune system. Analyzing these variations in 
detail will be a promising field for effective malaria surveillance and drug development 
(Kirchner et al., 2016). Interestingly, several mutations in the gene that encodes GluPho have 
been identified while sequencing the plasmodial genome from the blood of malaria patients 
(PlasmoDB). Due to its central role in survival of the parasites (see above), these mutations 
might lead to improved parasitic resistance to oxidative stress and the host’s immune system. 
We selected several of these naturally occurring PfGluPho variants to investigate whether they 
lead to kinetic benefits compared to the wild type (wt) enzyme. 
1.2.2 6-Phosphogluconate dehydrogenase 
6PGD catalyzes the third step of the oxidative PPP. As described in 1.2, it decarboxylates its 
substrate 6PG to ribulose 5-phosphate while producing CO2 and one molecule of NADPH 
(Stincone et al., 2015). Consequently, it contributes as much NADPH as it does G6PD. 
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Human 6-phosphogluconate dehydrogenase 
The gene for human 6PGD is located on chromosome 1 (band 1p36.22). The complete 
sequence has a size of 21.9 kb consisting of 18 exons and 18 introns and encodes a protein 
with 483 amino acids and 53.1 kDa per monomer (https://www.genecards.org/cgi-
bin/carddisp.pl?gene=PGD). The enzyme is usually active in a dimeric form (Pearse and 
Rosemeyer, 1974b). 
In contrast to the high prevalence of hG6PD deficiency (1.2.1.1), a deficiency of h6PGD is 
rather rare; only a few cases are known, the first having been described in 1964 (Brewer and 
Dern, 1964). However, if affected, the decreased enzyme activity can lead to clinical symptoms 
such as chronic non-spherocytic hemolytic anemia, jaundice, and decreased levels of reduced 
glutathione (Caprari et al., 2001; Vives Corrons et al., 1996). 
Plasmodial 6-phosphogluconate dehydrogenase 
The gene for Pf6PGD is located on chromosome 14. Similar to PfGluPho and PvGluPho, it has 
no introns. With a total length of 1,407 bp it encodes a protein of 468 amino acids (PlasmoDB 
PF3D7_1454700). Plasmodial 6PGD has not yet been characterized. 
1.2.3 The role of NADPH for Plasmodium parasites 
Maintaining cellular redox balance is essential for the malarial parasites to survive. This has 
already been indicated by the finding that G6PD deficiency — disturbing the redox balance — 
leads to partial resistance against malaria (see 1.2.1.1) (Becker et al., 2004). The following 
section describes the sources of oxidative stress for the parasites and the role of NADPH in 
defending against this stress. 
Sources of oxidative stress for Plasmodium parasites 
During their complex life cycle with changing environments between Anopheles mosquitoes 
and the human host, Plasmodium parasites are continuously exposed to oxidative stress from 
different sources, including mosquitoes and human beings, but also from the parasites 
themselves (Becker et al., 2004; Percario et al., 2012). Reactive oxygen species (ROS) include, 
amongst many others, superoxide anions (O2•-), hydroxyl radicals (•OH), hydrogen peroxide 
(H2O2), and singlet oxygen (1O2). At low concentrations, they serve as signaling molecules, 
while an excess can lead to severe oxidative damage to DNA, proteins, or lipids (Sharma et al., 
2012). 
As described in 1.1.1, part of the plasmodial life cycle takes place in human erythrocytes, 
which contain large amounts of oxygen and iron; therefore, the conditions required for ROS 
formation via the Fenton reaction are endogenously given in these cells (Müller, 2004). The 
immune system of the human host reacts heavily to infection with the parasites, increasing 
phagocytosis of infected RBCs and parasites (Cappadoro et al., 1998; Osier et al., 2014) and 
producing larger amounts of reactive oxygen and nitrogen species. This plays a major role in 
the development of systemic complications in malaria patients (Becker et al., 2004). Similarly, 
the immune system of Anopheles mosquitoes also reacts to the parasites. Ookinete invasion 
in the midgut leads to reduced detoxification of ROS through a lower expression of the 
mosquitoes’ midgut catalase, resulting in increased exposure of the parasites to hydrogen 
peroxide (Molina-Cruz et al., 2008). Furthermore, the parasites themselves produce large 
amounts of oxidative products due to their high metabolic rate. One central source of 
oxidative stress is the degradation of human hemoglobin by the parasites as their primary 
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source of nutrients (Becker et al., 2004). Inside the food vacuole, hemoglobin is digested to 
amino acids, accompanied by the production of free heme. Most of the free heme is detoxified 
into crystalline hemozoin, also known as malaria pigment; however, small amounts escape 
neutralization, produce superoxide anions, hydroxyl radicals, and hydrogen peroxide, and are 
responsible for oxidative damage to DNA as well as lipid peroxidation (Atamna and Ginsburg, 
1993; Egan et al., 2002; Francis et al., 1997). 
Importance of NADPH for Plasmodium parasite survival 
As a defense against oxidative stress, Plasmodium parasites have a complex antioxidative 
system located in several subcellular compartments (Kehr et al., 2010). The major 
antioxidative systems — the glutathione and thioredoxin systems — dependent on the supply 
of NADPH as an electron donor (Gomez-Manzo et al., 2016; Jortzik and Becker, 2012; Preuss 
et al., 2012b). Therefore, the amount of NADPH (usually below 100 µM) exceeds the amount 
of NADP+ under physiological conditions (Becker et al., 2003; Wamelink et al., 2008). 
Tripeptide glutathione, consisting of glutamic acid, cysteine, and glycine, is the most abundant 
and important low molecular weight thiol in most living organisms (Dalle-Donne et al., 2009). 
The reduced form (GSH) reaches a concentration of approximately 2 mM in the cytosol of the 
parasites, while the oxidized form (GSSG) generally has less than 10 µM (Becker et al., 2003). 
Amongst other functions, GSH plays an essential role in detoxifying free, protein-bound, and 
membrane-associated heme by destroying the tetrapyrrole ring (Atamna and Ginsburg, 1995). 
Moreover, it scavenges radicals that can cause damages in human RBCs (Becker et al., 2003; 
Dalle-Donne et al., 2009). NADPH-dependent glutathione reductase (GR) is mainly responsible 
for reducing GSSG to GSH (Becker et al., 2003; Jortzik and Becker, 2012). The finding that 
glutathione synthesis is essential for parasitic development in P. berghei underscores the 
glutathione system’s importance to the parasites (Vega-Rodriguez et al., 2009); a lack of GR 
leads to an arrest of parasitic development in the mosquito (Buchholz et al., 2010; Pastrana-
Mena et al., 2010); in P. falciparum, a disruption of enzymes in the glutathione synthesis 
pathway has so far been unsuccessful, indicating an essential role in parasite development 
(Patzewitz et al., 2012). 
Thioredoxin (Trx) is a small, redox-active protein that functions as a cellular redox messenger. 
Using its CXXC active site motif, reduced PfTrx is able to transfer reducing equivalents to target 
proteins such as thioredoxin-dependent peroxidases or GSSG. TrxR reduces thioredoxin using 
its CXXXXC motif in an NADPH-dependent manner (Jortzik and Becker, 2012; Kanzok et al., 
2000). In P. falciparum, there are three different isoforms of classic Trx, including cytosolic 
PfTrx1 (Jortzik and Becker, 2012; Kehr et al., 2010). Among its numerous functions, PfTrx1 can 
directly fight against oxidative stress by detoxifying hydrogen peroxide (Rahlfs et al., 2003) 
and reduce both GSSG and S-nitrosoglutathione (GSNO, see 1.3.2) (Kanzok et al., 2000). 
P. falciparum parasites express one cytosolic and one mitochondrial isoform of TrxR, which 
also catalyze the reduction of a range of low molecular weight compounds in addition to Trx 
(Jortzik and Becker, 2012; Kehr et al., 2010). TrxR of P. falciparum has been shown to be 
essential for the survival of intraerythrocytic parasites (Krnajski et al., 2002). 
The fact that two of the major antioxidative systems – both essential for Plasmodium parasites 
– depend on NADPH underscores the importance of the PPP as the primary source of this 
reducing equivalent (Preuss et al., 2012b). 
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Alternative NADPH sources besides the pentose phosphate pathway 
In addition to the PPP, there are also other enzymes in the metabolism that can produce 
NADPH. Some examples of cytosolic enzymes are the cytosolic isoforms of isocitrate 
dehydrogenase, glutamate dehydrogenase, methylenetetrahydrofolate dehydrogenase, and 
aldehyde dehydrogenase (Fan et al., 2014; Lee et al., 2002; Stincone et al., 2015; Storm et al., 
2011; Wermuth et al., 1977). Furthermore, de novo biosynthesis of NADPH through the 
phosphorylation of NAD+/NADH, catalyzed by NAD kinases, has to be taken into account 
(Bieganowski et al., 2006; Pollak et al., 2007). NADPH is assumed to be unable to diffuse across 
membranes, highlighting the importance of compartment-specific NADPH recycling and de 
novo biosynthesis (Pollak et al., 2007). Due to its cytosolic localization (in most organisms, see 
1.2), the PPP contributes significantly to this NADPH pool. Human RBCs have neither a nucleus 
nor mitochondria, underscoring the importance of the PPP for these cells as their major source 
of NADPH (Beutler, 1994; Stincone et al., 2015). Plasmodium parasites possess isocitrate 
dehydrogenase and glutamate dehydrogenase. In theory, these enzymes could significantly 
contribute to the NADPH supply (Werner et al., 2005; Wrenger and Muller, 2003). However, 
the contribution from isocitrate dehydrogenase is still unclear. Glutamate dehydrogenase has 
been shown not to contribute much to the NADPH supply required for oxidative defense and 
to be dispensable for the parasite’s asexual stage growth (Storm et al., 2011). This supports 
the central role of PfGluPho for the parasites (Allen et al., 2015). 
1.2.4 Pentose phosphate pathway as a drug target 
The enzymes of the PPP are considered promising targets for treating different diseases. Well 
known and commonly used antimalarial drugs such as artemisinin exert their effects by 
disturbing the cellular redox balance (Cumming et al., 1997; Kavishe et al., 2017). The 
following chapter describes the potential of G6PD and 6PGD as promising antiparasitic and 
anticancer drug targets. 
1.2.4.1 The pentose phosphate pathway as a target for antiparasitic drugs 
The essential need for a sufficient supply of the electron donor NADPH to maintain the cellular 
redox balance of Plasmodium parasites has been described in 1.2.3. The oxidative PPP is the 
main source of NADPH for the parasites (Preuss et al., 2012b; Stincone et al., 2015); therefore, 
this pathway is considered a promising target for the development of new antimalarial drugs 
(Allen et al., 2015). 
PfGluPho as a drug target 
After several indications of the importance of PfGluPho to the parasites (1.2.1), its essentiality 
for the survival of asexual blood stage parasites was finally proved in 2015 (Allen et al., 2015). 
Moreover, there are major differences between the plasmodial enzyme and the human 
homologs, underscoring the applicability of PfGluPho as a target for new antimalarial drugs 
(Allen et al., 2015; Jortzik et al., 2011). The most obvious structural difference is that in 
Plasmodium, the two enzymes that catalyze the G6PD and 6PGL reactions in the oxidative PPP 
are fused to the bifunctional GluPho, while two distinct enzymes in human beings catalyze 
these two steps (Figure 5) (Preuss et al., 2012b). The structure of hG6PD is – in contrast to 
PfGluPho and PvGluPho – well known (Au et al., 2000). PfGluPho is active in a tetrameric form 
(Jortzik et al., 2011), while hG6PD exists as a monomer, dimer, or tetramer depending on the 
ionic strength, pH, and presence of substrates (Wrigley et al., 1972). One additional structural 
difference is the Plasmodium-specific insertion (Figure 4) that was shown to be essential for 
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the G6PD activity of PbGluPho (Clarke et al., 2003). Besides the structural differences, there 
are also some functional ones. PfGluPho follows a rapid equilibrium, random bi bi mechanism, 
meaning both substrates have to bind before the product can begin to form. The binding order 
of the substrates is not fixed; however, they cannot bind simultaneously (Jortzik et al., 2011). 
Human G6PD follows a rapid equilibrium, random order mechanism in which both substrate 
binding sites can act independently from each other (Wang et al., 2002). Furthermore, the 
affinity of PfGluPho to its substrates is higher than the affinity of the human counterparts 
(Jortzik et al., 2011). Taken together, these differences enable the development of compounds 
that specifically inhibit the plasmodial enzyme. 
Pf6PGD as a drug target 
Pf6PGD contributes to the plasmodial supply of NADPH in the same amounts as PfGluPho 
(Stincone et al., 2015). By using RNA interference, 6PGD could be shown to be essential for 
the parasitic protozoan Trypanosoma (T.) brucei, which causes human African 
trypanosomiasis. One possible explanation is that the inhibition of 6PGD leads to the 
accumulation of the substrate 6PG, which inhibits the phosphoglucose isomerase, the key 
enzyme of glycolysis (Hanau et al., 2004; Marchand et al., 1989). Due to the connection of 
glycolysis to the PPP, inhibiting the isomerase will force more glucose into the PPP, resulting 
in a feedback loop with increasing 6PG concentrations and greater inhibition of glycolysis. 
Since the blood stages of the trypanosomes depend on energy production through glycolysis, 
this loop is expected to be lethal for the parasites (Hanau et al., 2004). In Saccharomyces and 
Drosophila, simultaneous inhibition of G6PD could be shown to relieve the fatal effect of 6PGD 
inhibition, most likely because during G6PD inhibition, there is no accumulation of 6PG 
(Gvozdev et al., 1976; Lobo and Maitra, 1982). Therefore, 6PGD is considered a promising 
target for drugs against African trypanosomes (Hanau et al., 2004). However, it has so far not 
been possible to confirm Pf6PGD as a suitable target for the development of new antimalarial 
drugs. 
1.2.4.2 The human pentose phosphate pathway as a target for anticancer drugs 
Compared to healthy cells, cancer cells have altered requirements in their metabolism. The 
rapidly dividing cells have a great need for nucleic acid biosynthesis and the production of 
NADPH, which are essential for fatty acid synthesis, defense against oxidative stress, etc. Due 
to their accelerated metabolism, cancer cells are usually exposed to significantly higher 
concentrations of ROS than normal cells (Cho et al., 2018; De Santis et al., 2018; Patra and 
Hay, 2014). The PPP is responsible for generating the precursors to nucleic acid formation and 
is a major contributor to the supply of NADPH (Stincone et al., 2015). Accordingly, both G6PD 
and 6PGD activity have been shown to increase in many cancer cells (Dutu et al., 1980; Hong 
et al., 2018; Jonas et al., 1992). Thus, G6PD deficiency (1.2.1.1) is inversely correlated to cancer 
incidence and mortality (Cocco et al., 1987; Dore et al., 2016; Dore et al., 2018). Cancer cells 
have developed various mechanisms to regulate the PPP in order to meet their needs; one 
example is modulating the tumor suppressor p53 (Patra and Hay, 2014). One of the 
physiological roles of p53 is to inhibit the expression of the glucose transporter genes for 
GLUT1 and GLUT4 (Schwartzenberg-Bar-Yoseph et al., 2004). A loss of p53 enhances glucose 
uptake in cancer cells, thereby increasing the flux through glycolysis and the PPP and helping 
the cancer cells to survive. For this reason, modulation of p53 is common in many human 
cancer cell lines (De Santis et al., 2018; Patra and Hay, 2014). Besides the inactivation of 
oncosuppressors, the activation of oncogenes can also lead to enhanced G6PD activity 
19 
 Introduction 
(Tarrado-Castellarnau et al., 2016). In addition to the role of the PPP during tumor 
development and growth, it also plays a role in tumor cells’ resistance to cancer therapies. In 
response to ionizing radiation or chemotherapies, the levels of ROS increase, leading to an 
increase in PPP activity. This augmented activity reduces oxidative stress and can thereby lead 
to the cancer cells resisting the treatment (Patra and Hay, 2014). Accordingly, it has been 
shown that inhibition of either G6PD or 6PGD can reverse resistance to anticancer drugs (Hong 
et al., 2018; Ma and Cheng, 2018; Zheng et al., 2017). 
These observations strongly indicate that a specific inhibition of both the G6PD and the 6PGD 
reaction could be promising strategies for anticancer therapy (Cho et al., 2018; Elf et al., 2017; 
Lin et al., 2015). So far, only a few inhibitors for these enzymes are known (Jang et al., 1997; 
Mele et al., 2018; Preuss et al., 2013). One example of a well-known hG6PD inhibitor is 
dehydroepiandrosterone (DHEA) (Gordon et al., 1995; Schwartz et al., 1986). 
1.3 Post-translational protein modifications 
Post-translational modifications (PTM) are important regulators of protein functions. They 
have fundamental control over various aspects such as gene expression, cell signaling and 
interactions between cells, protein trafficking, cell proliferation and differentiation, or enzyme 
localization, activity, and stability. Therefore, they play major roles in both physiological and 
pathophysiological events (Doerig et al., 2015; Jortzik et al., 2012). Although cysteine only 
accounts for 2% or less of the total amino acids in eukaryotic, eubacterial, and archaeal 
proteins (Pe'er et al., 2004), it contributes significantly to biochemical reactions based on thiol-
dependent catalysis due to its special chemical characteristics. It is able to form disulfide 
bonds that influence the structure of a protein, bind metal ions, and, importantly, it is able to 
mediate redox regulation and signaling reacting to the redox potential of the cells. Amongst 
many possible cysteine modifications, S-glutathionylation and S-nitrosation are two of the 
most prominent ones (Jortzik et al., 2012). 
1.3.1 Protein S-glutathionylation 
As indicated in 1.2.3, glutathione has important antioxidative properties and is involved in the 
detoxification of various reactive oxygen species. The glutathione redox couple, i.e. GSH and 
GSSG, is one important regulator of redox-dependent cellular functions. Glutathione can 
mediate signaling processes to proteins by modifying the oxidation status of cysteines, the so-
called S-glutathionylation. In this process, glutathione is reversibly bound to the thiol groups 
of cysteine residues, generating S-glutathionylated proteins (Becker et al., 2003; Dalle-Donne 
et al., 2009). The modification is favored to cysteine residues with a basic three-dimensional 
environment – caused, e.g., by positively charged arginine, histidine, or lysine residues in the 
proximity – and a therefore low pKa value. The pKa of cysteine thiols is typically around 8.5; 
however, it may vary between 3.5 and over 12, depending on the environment. A low pKa 
value is often associated with a stable thiolate anion, thereby enabling the formation of 
S-glutathionylation (Zhang et al., 2018). 
There are several possible mechanisms for how the modification can be generated (Figure 6). 
Non-enzymatic possibilities include the thiol-disulfide exchange between reduced protein 
thiols and GSSG or GSNO, or direct interaction of GSH with oxidized protein intermediates 
such as S-nitrosyl, sulfenic acid, or a thiyl radical. Sulfenic acids are highly unstable and can be 
further oxidized to sulfinic acid, followed by the irreversible overoxidation to sulfonic acid 
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(Belcastro et al., 2017; Jortzik et al., 2012). Therefore, S-glutathionylation of sulfenic acids can 
protect the protein from irreversible deactivation (Zhang et al., 2018). Moreover, the enzymes 
glutaredoxin and glutathione S-transferase (GST) can promote the modification. Glutaredoxin, 
sulfiredoxin, thioredoxin, GST, or free GSH can remove it (Jortzik et al., 2012; Zhang et al., 
2018). As described above, during periods of oxidative stress, the modification protects thiols 
from irreversible oxidation and serves in addition as a storage form of GSH (Becker et al., 2003; 
Dalle-Donne et al., 2009). 
 
Figure 6. S-glutathionylation and deglutathionylation of proteins 
S-glutathionylation can be mediated both non-enzymatically and enzymatically. For non-enzymatic reactions, 
there are the following possibilities: (I) Thiol-disulfide exchange can directly occur between a protein thiol (PSH) 
and glutathione disulfide (GSSG). (II) Reactive oxygen species (ROS) can oxidize PSH to sulfenic acid (PSOH) which 
can interact with reduced glutathione (GSH). This prevents the protein from irreversible overoxidation over 
sulfinic acid (SO2H) to sulfonic acid (SO3H) what would indicate an irreversible deactivation. (III) PSH can be 
oxidized to a thiyl radical (PS•) that is able to react with GSH to a thiyl radical glutathionyl intermediate (PSSG•). 
PSSG• can further react with O2 to PSSG. (IV) In addition to GSSG, PSH can also react with S-nitrosoglutathione 
(GSNO) to PSSG. In addition, S-glutathionylation can also be mediated by enzymes such as the glutathione 
S-transferase P (GSTP). Deglutathionylation can conducted by glutaredoxin (Grx), sulfiredoxin (Srx), or the 
glutathione S-transferase omega (GSTO) (Zhang et al., 2018). 
In 2011, a large-scale proteomic approach was performed, identifying 493 targets of 
S-glutathionylation in P. falciparum (Kehr et al., 2011). This means, even under physiological 
conditions, approximately 10% of the proteome from P. falciparum was found to be 
S-glutathionylated, underscoring the importance of this modification for the redox-regulatory 
mechanism (Jortzik et al., 2012). 
1.3.2 Protein S-nitrosation 
Nitric oxide (NO) is a gaseous radical known to have important signaling functions in cellular 
metabolism. It is continuously synthesized from L-arginine by three isoforms of the nitric oxide 
synthase (NOS), the so-called endothelial NOS, the neuronal NOS, and the inducible NOS. NO 
is involved in numerous physiological processes such as platelet adhesion, vasorelaxation, 
endothelial regeneration, and inhibition of leukocyte chemotaxis. Furthermore, it plays a role 
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in pathophysiological events such as cardiovascular diseases (Belcastro et al., 2017), cancer 
(Yarlagadda et al., 2017), and degenerative diseases (Zhang et al., 2017). During their life cycle, 
Plasmodium parasites encounter nitrosative stress derived from the human host and 
Anopheles mosquitoes since the production of NO is part of the immune system (Ferrari et al., 
2011; Jeney et al., 2014; Peterson et al., 2007b). The expression of NOS due to, e.g., hemozoin 
formation (Akman-Anderson et al., 2007; Jaramillo et al., 2003) can lead to inflammatory 
levels of NO deteriorating the development of the parasites (Luckhart et al., 1998; Peterson 
et al., 2007b). In the human host, Plasmodium infection leads to the expression of the 
inducible NOS in macrophages, contributing to the clearance of the parasites from RBCs 
(Ranjan et al., 2016). Under physiological conditions, NO concentrations are low (around 
10 nM). However, activation of the inducible NOS in response to pathophysiological processes 
can result in concentrations over 1 µM (Belcastro et al., 2017). 
Protein S-nitrosation is defined as the reversible addition of a nitrosyl group to a reactive 
cysteine thiol of a protein, resulting in a protein S-nitrosothiol (Jortzik et al., 2012). In many 
publications, this process is described as S-nitrosylation; however, technically speaking, 
S-nitrosylation means the coordination of NO to transition metal ions in enzymes (Belcastro 
et al., 2017). Therefore, the covalent bond between NO and cysteines is called S-nitrosation 
in this thesis. As described above (1.3), the modification can have various impacts on the 
properties of the affected protein. The NO moiety can be removed both enzymatically (e.g. 
via GSNO reductase and superoxide dismutase) and nonenzymatically (via thioredoxin and 
glutathione). In addition to the direct reaction of the nitrosyl group with cysteine thiols, 
S-nitrosation can occur via the transfer of NO from one S-nitrosated protein to another protein 
thiol, called transnitrosation (Jortzik et al., 2012). A naturally occurring low molecular weight 
S-nitrosothiol is GSNO (Broniowska et al., 2013). There are several possibilities for how GSNO 
can be generated, e.g., through the degradation of protein S-nitrosothiols by glutathione 
(Benhar et al., 2009; Broniowska et al., 2013). In addition to its reactivity with cysteine thiols, 
GSNO is able to transnitrosate proteins (Broniowska et al., 2013). 
1.3.3 Protein phosphorylation 
Protein phosphorylation is one of the most important regulators of cellular functions. It is 
defined as the covalent attachment of a phosphate group to a target molecule (Doerig et al., 
2015). However, since this modification was not a major subject of this study, this section 
should only give a short overview. 
Protein kinases and phosphatases are mediators of reversible protein phosphorylation, 
mediating changes to central cellular functions such as proliferation and differentiation of 
cells, as well as cell migration and homeostasis, e.g., by modifying enzyme activities. In 
eukaryotes, the targets of protein kinases are usually serine, threonine, or tyrosine – residues 
that have an alcohol group; however, histidine and aspartic acid can also be phosphorylated, 
especially in prokaryotes (Doerig et al., 2015). 
To study phosphorylation it is possible to mimic this modification by mutation of the 
respective residue to glutamic acid (Kim et al., 2015). 
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1.4 Objectives of the study 
Malaria is still one of the world’s most deadly infectious diseases, causing almost half a million 
deaths per year (WHO, 2017b). Effective treatment of the disease is threatened by increasing 
resistance of Plasmodium strains to commonly used drugs; therefore, there is an urgent need 
to characterize new drug targets and develop new antimalarial drugs (Ashley et al., 2018; 
WHO, 2017b). 
Plasmodium parasites are continuously exposed to oxidative stress from different sources; 
maintaining the cellular redox balance is crucial for their survival. Some antimalarial drugs that 
act by increasing oxidative stress are already being used (Becker et al., 2004). The most 
important antioxidative systems of Plasmodium parasites depend on NADPH as an electron 
donor (Jortzik and Becker, 2012; Mohring et al., 2014). Since the oxidative PPP is the major 
source of NADPH for the parasites, it seems reasonable that inhibiting this pathway might be 
an effective strategy for new antimalarial drugs (Allen et al., 2015; Haeussler et al., 2018). 
There are two NADPH-producing steps in the oxidative PPP which are considered potential 
targets for new antimalarial drugs: the G6PD reaction, catalyzed in Plasmodium by the 
bifunctional GluPho (Jortzik et al., 2011), and the 6PGD reaction (Haeussler et al., 2018). 
The two most detrimental Plasmodium species are P. falciparum and P. vivax (Ashley et al., 
2018). However, due to its usually mild course of infection, P. vivax has been underestimated 
for many years (Cowman et al., 2016). Moreover, long-term in vitro cultivation of blood stage 
P. vivax parasites is still not possible (Thomson-Luque et al., 2017). Therefore, limited 
information on P. vivax is available. The redox system of P. vivax shows high homologies to 
P. falciparum, including the presence of a bifunctional GluPho in the PPP (Mohring et al., 
2014). PfGluPho has already been characterized, and a first set of inhibitors has been 
identified (Jortzik et al., 2011; Preuss et al., 2012a). In contrast, there was no information on 
Pf6PGD and PvGluPho/PvG6PD in the literature. Attempts to transfer our knowledge of the 
P. falciparum redox system and its inhibitors to P. vivax can therefore be very valuable in 
facilitating drug discovery against vivax malaria. The aim of this thesis was to address the 
following topics: 
− Recombinant production, purification, and characterization of naturally occurring 
PfGluPho variants, Pf6PGD wt and mutants, h6PGD, and PvGluPho/PvG6PD 
− Crystallization of PfGluPho and Pf6PGD to solve their three-dimensional structures and to 
enable structure-based drug design and optimization 
− Investigation of the impact of two post-translational modifications – S-glutathionylation 
and S-nitrosation – on PfGluPho, Pf6PGD, and PvG6PD 
− Characterization of compounds optimized for PfGluPho and identification of inhibitors for 
Pf6PGD and PvG6PD 
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2 Materials 
2.1 Instruments 
Instrument Company 
Äkta FPLC system (pump P-920, monitor 
UPC-900, injection valve INV-907, mixer M-
925, fraction collector Frac-900, column 
material Superdex 200 prep grade) 
GE Healthcare, Freiburg 
Autoclave Webeco, Bad Schwartau 
Autoclave VX-95 Systec, Wettenberg 
BioRAPTR Microfluidic Workstation  Beckman Coulter, Brea, CA, USA 
BioSpectrometer basic Eppendorf, Hamburg 
Centrifuge 5415R Eppendorf, Hamburg 
Centrifuge Megafuge 1.0 R Heraeus Instruments, Hanau 
Centrifuge MiniSpin Eppendorf, Hamburg 
Centrifuge Sorvall RC 6+ (rotor SS-34 and 
F9S-4x1000y) 
Thermo Scientific, Dreieich 
CLARIOstar plate reader BMG Labtech, Ortenberg 
Crystallization robot Honeybee 961 
(peristaltic pump Masterflex® US®, vacuum 
pump 6035A080-02) 
Digilab, Marlborough, MA, USA 
Dry block heater 2 IKA®-Werke, Staufen im Breisgau 
Echo 555 Liquid Handler Labcyte, San Jose, CA, USA 
Electrophoresis Chamber B1, B1A, B2 Owl Separation System Inc., Portsmouth, 
NH, USA 
Electrophoresis Chamber Mini-PROTEAN 3 
cell 
Bio-Rad, Munich 
Electrophoresis Power Supply-EPS 200 Pharmacia Biotec, Dübendorf Switzerland 
Electroporator Gene Pulser Xcell Bio-Rad, Munich 
EvolutionTM 300 UV-Vis-Spectrophotometer Thermo Scientific, Dreieich 
FAS Digi Gel Imaging System Nippon Genetics, Düren 
Heating block neoBlock II neoLab, Heidelberg 
Heating block Thermomixer comfort Eppendorf, Hamburg 
High-purity water system OPTILAB-Plus MembraPure, Henningsdorf 
Icemaker F80C Icematic Deutschland, Meerbusch 
Incubation shaker KS 500 Junke & Kunkel, IKA®-Werke, Staufen im 
Breisgau 
Incubation shaker SM25 Edmund Bühler GmbH, Tübingen 
Incubation system (incubator: CERTOMAT® 
H, shaker: CERTOMAT® R) 
B. Braun, Melsungen 
Incubation system (incubator: mytron, 
shaker: Orbital) 
Thermo Scientific, Dreieich 
Incubator shaker Innova® 44 Eppendorf, Hamburg 
Intas ECL ChemoStar Intas Science Imaging Instruments GmbH, 
Göttingen 
Magnetic stirrer CAT M15 MAGV Laborbedarf, Rabenau-Londorf 
Magnetic stirrer color squid IKA®-Werke, Staufen im Breisgau 
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Magnetic stirrer HI 300N Hanna Instruments, Kehl am Rhein 
Magnetic stirrer RCTbasic IKA®-Werke, Staufen im Breisgau 
Microprocessor pH Meter Knick, Berlin 
Multichannel pipette Discovery 1-10 µL HTL Lab Solutions, Warsaw, Poland 
Multichannel pipette Discovery 20-200 µL HTL Lab Solutions, Warsaw, Poland 
Multichannel pipette Transferpette S-12 Brand GmbH, Wertheim 
MultidropTM Combi Reagent Dispenser Thermo Fisher Scientific, Waltham, MA, 
USA 
OptiMax X-ray Processor M&S Laborgeräte, Wiesloch 
PCR cycler Mastercycler Eppendorf, Hamburg 
PCR cycler Mastercycler gradient Eppendorf, Hamburg 
Peltier Cryobath System TPS 1500 W Thermo Scientific, Dreieich 
PHERAstar FS microplate reader BMG Labtech, Cary, NC, USA 
Pipette Eppendorf Research plus Eppendorf, Hamburg 
Pipette Gilson Pipetman P10, P20, P100, 
P200, P1000 
Gilson, Middleton 
Pipetting robot Lissy Zinsser Analytic, Frankfurt 
Power Pac 300 and 1000 Bio-Rad, Munich 
Precision scale ABT 120-5 DM Kern & Sohn, Balingen 
Rotilabo®-X-ray-cassette Roth, Karlsruhe 
Scale 440-47N Kern & Sohn, Balingen 
Scale 474-32 Kern & Sohn, Balingen 
Shaker KS 500 IKA®-Werke, Staufen im Breisgau 
Shaker Unimax 2010 Heidolph Instruments, Schwabach 
Spectrophotometer Beckman DU 650 Thermo Scientific, Dreieich 
Spectrophotometer BioPhotometer Eppendorf, Hamburg 
Stereomicroscope SMZ1000 Nikon GmbH, Düsseldorf 
Stereomicroscope system (M165 C, KL 1500 
LED, camera EC 3 
Leica Microsystems, Wetzlar 
Tecan Infinite M200 multiplate reader Tecan, Männedorf, Switzerland 
TPS 1500W Peltier Cryobath System 
Recirculator 
Thermo Scientific, Dreieich 
Trans-Blot® Turbo™ Transfer System Bio-Rad, Munich 
Ultrasound homogenizer Sonoplus HD 2070 Bandelin electronic, Berlin 
Ultrasound waterbath Sonorex RK100 Bandelin electronic, Berlin 
Vacuum pump Vacubrand CVC 3000 VWR, Darmstadt 
Viewlux plate reader Perkin Elmer, Waltham, MA, USA 
Vortex mixer MS2 Minishaker IKA®-Werke, Staufen im Breisgau 
Western blot Trans-Blot® SD semi-dry 
transfer cell 
Bio-Rad, Munich 
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2.2 Chemicals 
All chemicals used were of the highest purity available. 
Chemical Company 
1,2-Propanediol Sigma-Aldrich, Steinheim 
1,4-Dithiothreitol (DTT) Roth, Karlsruhe 
2-Methyl-2,4-pentanediol (MPD) Roth, Karlsruhe 
6-Aminohexanoic acid Merck, Darmstadt 
6PG Sigma, Steinheim 
Acetic acid Roth, Karlsruhe 
Acrylamide/Bisacrylamide (Rotiphorese Gel 
30 (37.5:1)) 
Roth, Karlsruhe 
Agar-agar Roth, Karlsruhe 
Agarose (peqGold Universal Agarose) Roth, Karlsruhe 
Ammonium acetate Roth, Karlsruhe 
Ammonium dihydrogen phosphate Sigma, Steinheim 
Ammonium persulfate (APS) Roth, Karlsruhe 
Ammonium phosphate Sigma, Steinheim 
Ammonium sulfate Roth, Karlsruhe 
Betaine Sigma, Steinheim 
Bicine Roth, Karlsruhe 
Bis-Tris Roth, Karlsruhe 
Bovine serum albumin (BSA) Roth, Karlsruhe 
Calcium chloride Applichem, Darmstadt 
Carbenicillin Roth, Karlsruhe 
Chloramphenicol Roth, Karlsruhe 
Coomassie Brilliant Blue R250 Sigma, Steinheim 
Coumaric acid Sigma, Steinheim 
Cystatin Sigma, Steinheim 
Dimethyl sulfoxide (DMSO) Roth, Karlsruhe 
Dipotassium phosphate Roth, Karlsruhe 
DNA-Dye NonTox Applichem, Darmstadt 
Ethanol Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Roth, Karlsruhe 
Ethylene glycol Roth, Karlsruhe 
FOScholine®12 Cube Biotech GmbH, Monheim am Rhein 
G6P Sigma, Steinheim 
Glutathione (GSH) Sigma, Steinheim 
Glutathione disulfide (GSSG) Sigma, Steinheim 
Glycerol Roth, Karlsruhe 
Glycyl-glycyl-glycine (Gly-Gly-Gly) Sigma, Steinheim 
Hepes Roth, Karlsruhe 
Hydrochloric acid (fuming, 37%) Roth, Karlsruhe 
Hydrogen peroxide Roth, Karlsruhe 
Imidazole Roth, Karlsruhe 
Iodoacetyl-PEG2-biotin Thermo Scientific, Dreieich 
Iodoacteamide (IAA) Sigma, Steinheim 
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Isopropanol Roth, Karlsruhe 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) Roth, Karlsruhe 
Kanamycin sulfate Roth, Karlsruhe 
Lithium chloride Roth, Karlsruhe 
Lithium nitrate Roth, Karlsruhe 
Luminol Sigma, Steinheim 
Magnesium chloride Sigma, Steinheim 
MES Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
Milk powder Roth, Karlsruhe 
MME 550 Fluka 
Monopotassium phosphate Roth, Karlsruhe 
MOPS Roth, Karlsruhe 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) 
Sigma, Steinheim 
N,N-Dimethyldodecylamine N-oxide Cube Biotech GmbH, Monheim am Rhein 
NADP+ Biomol, Hamburg 
NADPH Biomol, Hamburg 
n-Decyl-β-D-maltopyranoside Cube Biotech GmbH, Monheim am Rhein 
n-Dodecyl-β-D-maltoside SERVA Electrophoresis GmbH, Heidelberg 
Neocuproine Aldrich, Steinheim 
N-Ethylmaleimide (NEM) Sigma, Steinheim 
Nicotinamide adenine dinucleotide (NAD+) Biomol, Hamburg 
Ni-NTA agarose Invitrogen, Karlsruhe 
n-Octyl-β-D-glucopyranoside Cube Biotech GmbH, Monheim am Rhein 
PEG (polyethylene glycol) 1,500 Roth, Karlsruhe 
PEG 3,350 Sigma-Aldrich, Steinheim 
PEG 4,000 Roth, Karlsruhe 
PEG 400 Roth, Karlsruhe 
PEG 6,000 Roth, Karlsruhe 
PEG 600 Aldrich, Steinheim 
PEG 8,000 Roth, Karlsruhe 
Pepstatin A Sigma, Steinheim 
Phenylmethanesulfonyl fluoride (PMSF) Roth, Karlsruhe 
Polyethylene glycol sorbitan monolaurate 
(TWEEN 20) 
Sigma, Steinheim 
Ponceau S Sigma, Steinheim 
Potassium chloride Roth, Karlsruhe 
Potassium citrate Roth, Karlsruhe 
Resazurin Sigma, St. Louis, MO, USA 
S-Nitrosoglutathione (GSNO) Sigma-Aldrich, Steinheim 
Sodium acetate Roth, Karlsruhe 
Sodium ascorbate (NaAsc) Sigma, Steinheim 
Sodium bromide Sigma, Steinheim 
Sodium chloride Roth, Karlsruhe 
Sodium citrate Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Sigma, Steinheim 
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Sodium hydroxide Roth, Karlsruhe 
Talon Metal Affinity Resin Clontech, Takara Bio Europe SAS, Saint-
Germain-en-Laye, France 
Trichloroacetic acid (TCA) Sigma, Steinheim 
Tris-(hydroxymethyl)-aminomethan (Tris) Roth, Karlsruhe 
Tris-HCl Roth, Karlsruhe 
Triton X-100 Roth, Karlsruhe 
Tryptone/Peptone Roth, Karlsruhe 
Xylitol Sigma, Steinheim 
Yeast extract Oxoid, Basingstroke, England 
 
Inhibitor Source 
Coruleoellagic acid (CEA) Kindly provided by Herbert Zimmermann, Heidelberg 
Ellagic acid (EA) Sigma-Aldrich, Steinheim 
Flavellagic acid (FEA) Kindly provided by Herbert Zimmermann, Heidelberg 
ML304 Kindly provided by Anthony Pinkerton, La Jolla, CA, USA 
MMV Malaria Box Medicines for Malaria Venture (MMV), Geneva, 
Switzerland 
Novel G6PD inhibitors Kindly provided by Dieter E. Kaufmann, Clausthal-Zellerfeld 
SBI-0797750 and derivatives Kindly provided by Anthony Pinkerton, La Jolla, CA, USA 
 
2.3 Consumables 
Consumable Company 
Cannula 0.7 x 50 mm Unimed, Lausanne, Switzerland 
Chemiluminescence film Amersham 
hyperfilmTM ECL 
GE Healthcare, Freiburg 
Clear tape HDClear ShurTec Brands, Avon, OH, USA 
Cover slips, round 21 mm Ø Menzel, Brunswick 
Crystallization plate 24 well, CryschemTM M 
plate 
Hampton Research, Aliso Viejo, CA, USA 
Crystallization plate 24 well, VDX plate Hampton Research, Aliso Viejo, CA, USA 
Crystallization plate 96 well, MRC 2 well Jena Bioscience, Jena 
DNA ladder GeneRuler 1 kb Thermo Scientific, Dreieich 
Echo qualified 384 low dead volume 
microplate 
Labcyte, San Jose, CA, USA 
FalconTM tube 15 mL, 50 mL Greiner Bio-One, Frickenhausen 
Filter holders 0.2 µM Whatman GmbH, Dassel 
Masterblock 96 well, PP, V-bottom Greiner Bio-One, Frickenhausen 
Membrane filter ME 25, 0.45 µM Whatman GmbH, Dassel 
Micropipettes 5 µL, 10 µL Brand GmbH, Wertheim 
Microplate 1,536-well, PS, solid bottom, 
black 
Corning, Corning, NY, USA 
Microplate 384-well, PP, flat bottom, 
natural 
Greiner Bio-One, Frickenhausen 
Microplate 384-well, PP, V-bottom, natural Greiner Bio-One, Frickenhausen 
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Microplate 96-well, PP, half area, flat 
bottom, transparent 
Greiner Bio-One, Frickenhausen 
Microplate 96-well, PP, V-bottom, 
transparent 
Greiner Bio-One, Frickenhausen 
Microscope lens paper Glaswarenfabrik Karl Hecht, Sondheim 
Multiply PCR tube 0.2 mL  Sarstedt, Numbrecht 
Nitrocellulose blotting membrane, 0.45 µm GE Healthcare, Freiburg 
Parafilm ’M’ laboratory film Bemis, Neenah, WI, USA 
Pasteur pipette 150 mm Hirschmann Laborgeräte, Eberstadt 
Petri dish, 15 cm Ø Sarstedt, Numbrecht 
Pipette tips and tubes, disposable Eppendorf, Hamburg 
Pipette tips OmnitipTM FastRack 10 µL, 
200 µL 
Ulplast, Warsaw, Poland 
Plate sealer EASYsealTM, clear Greiner Bio-One, Frickenhausen 
Plate sealer SILVERseal Greiner Bio-One, Frickenhausen 
Precision wipes tissue Kimberly-Clark GmbH, Koblenz 
Protein ladder Unstained Protein Molecular 
Weight Marker 
Thermo Scientific, Dreieich 
Restore Plus Western Blot Stripping Buffer Thermo Scientific, Dreieich 
Roti®-PVDF membrane Roth, Karlsruhe 
Semi-micro cuvettes, polystyrol Sarstedt, Numbrecht 
Serological pipette 5 mL, 10 mL, 25 mL Greiner Bio-One, Frickenhausen 
Silicone oil 550 Merck, Darmstadt 
Syringe 1 mL PlastipakTM Becton Dickinson, Madrid, Spain 
Syringe 10 mL B. Braun, Melsungen 
UV-Cuvettes micro Brand GmbH, Wertheim 
Vivaspin 20,000 MWCO, 30,000 MWCO Sartorium Stedim Biotech, Göttingen 
ZebaTM Spin Desalting Columns, 7 K MWCO, 
0.5 mL, 2 mL 
Thermo Scientific, Dreieich 
 
2.4 Biological materials 
2.4.1 Vectors 
Vector Antibiotic resistance Company 
pET28a(+) Kanamycin Novagen, Darmstadt 
pQE30 Carbenicillin Qiagen, Hilden 
pRAREII Chloramphenicol Novagen, Darmstadt 
pBluescript SK (+) Carbenicillin Stratagene, San Diego, CA, USA 
 
2.4.2 E. coli strains 
E. coli strain Genotype Source 
BL21 (DE3) F'-ompT hsdSB (rB-mB-) gal dcm (DE3) Invitrogen, Karlsruhe 
C41 (DE3) F-- ompT gal hsdSB (rB-mB-) dcm lon (DE3) Avidis SA, St. Beauzire,  
France 
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C43 (DE3) F-- ompT gal hsdSB (rB-mB-) dcm lon (DE3) Avidis SA, St. Beauzire,  
France 
KRX [F', traD36, ΔompP, proA+B+, lacIq, Δ(lacZ)M15] 
ΔompT, endA1, recA1, gyrA96 (Nalr), thi-1, 
hsdR17 (rk–, mk+), e14– (McrA–), relA1, supE44, 
Δ(lac-proAB), Δ(rhaBAD)::T7 RNA polymerase 
Promega, Mannheim 
Lemo21 
(DE3) 
fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS/ 
pLemo(CamR) λ DE3 = λ sBamHIo ∆EcoRI-
B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
pLemo = pACYC184-PrhaBAD-lysY 
New England Biolabs, 
Frankfurt am Main 
M15 F-, Φ80ΔlacM15, thi, lac-, mtl-, recA+, KmR Qiagen, Hilden 
SHuffle T7 F' lac, pro, lacIq / Δ(ara-leu)7697 araD139 
fhuA2 lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC* 
galE (or U) galK λatt::pNEB3-r1-cDsbC (SpecR, 
lacIq) ΔtrxB rpsL150(StrR) Δgor Δ(malF)3 
New England Biolabs, 
Frankfurt am Main 
SHuffle T7 
Express 
fhuA2 lacZ::T7 gene1 [lon] ompT ahpC gal 
λatt::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB 
sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] 
R(zgb-210::Tn10 --TetS) endA1 Δgor ∆(mcrC-
mrr)114::IS10 
New England Biolabs, 
Frankfurt am Main 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F' proAB lacIq ZΔM15 Tn10 (Tetr)] 
Stratagene, Amsterdam, 
The Netherlands 
 
2.4.3 Antibodies 
Antibody Company 
Anti-glutathione monoclonal antibody Virogen, Watertown, MA, USA 
Anti-6xHis-tag monoclonal antibody Dianova, Hamburg 
Horseradish peroxidase (HRP) anti-mouse antibody Thermo Scientific, Dreieich 
Monoclonal biotin antibody (33): sc-101339 Santa Cruz Biotechnology, Dallas, TX, 
USA 
 
2.4.4 Enzymes 
Restriction enzyme Restriction site Company 
BamHI 5'...G^GATCC...3' Thermo Scientific, Dreieich 
DpnI 5'...GACH3^ATTC...3' Thermo Scientific, Dreieich 
HindIII 5'...A^AGCTT...3' Thermo Scientific, Dreieich 
SalI 5'...G^TCGAC...3' Thermo Scientific, Dreieich 
 
Enzymes for molecular biology Function Company 
T4-DNA ligase Nucleotide fragment 
ligation 
Thermo Scientific, Dreieich 
Pfu DNA polymerase DNA amplification Promega, Mannheim 
RedTaq® polymerase DNA amplification Sigma, Steinheim 
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Other enzymes Function Company 
Diaphorase from 
Clostridium klyveri 
Enzyme assay, reduction of resazurin Sigma, St. Louis, MO, USA 
DNaseI DNA digestion Roche, Mannheim 
Lysozyme Cell lysis Sigma, Steinheim 
 
2.4.5 Oligonucleotides 
Primers for cloning of PvGluPho and PvG6PD 
OPvGPN 5'-atatGGATCCGATTGCCAGGCGCTGGCGAA-3' 
OPvGPC 5'-atatGTCGACTCAGTTGATGTCCAACAAGTCGT-3' 
PvG6PDs 5'-CGGGATCCCTGAATAGGAGGGAATGCCTA-3' 
PvG6PDas 5'-atatGTCGACTCAGTTGATGTCCAACAAGTCGT-3' 
 
Primers for site-directed mutagenesis 
PfGluPhoS899Es 5'-CTGAGTTTGTTAGAAAAGAGTCTTTTTATGAAGACGATT-3' 
PfGluPhoS899Eas 5'-AATCGTCTTCATAAAAAGACTCTTTTCTAACAAACTCAG-3' 
PfGluPhoS900Es 5'-CTGAGTTTGTTAGAAAATCCGAATTTTATGAAGACGATT-3' 
PfGluPhoS900Eas 5'-AATCGTCTTCATAAAATTCGGATTTTCTAACAAACTCAG-3' 
PfGluPhoS315Ys 5'-AAAATTATACAAAATATATTGAAGAAATTTATG-3' 
PfGluPhoS315Yas 5'-CATAAATTTCTTCAATATATTTTGTATAATTTT-3' 
PfGluPhoL395Fs 5'-ATAGTTATATATTTCAAACGATGTTTATTATG-3' 
PfGluPhoL395Fas 5'-CATAATAAACATCGTTTGAAATATATAACTAT-3' 
PfGluPhoF507Ls 5'-TCATCAAATTATAATTTGCCATATGTTATAAA-3' 
PfGluPhoF507Las 5'-TTTATAACATATGGCAAATTATAATTTGATGA-3' 
Pf6PGDW104Ls 5'-GCGGCAACGAATTGTATATCAACTCT-3' 
Pf6PGDW104Las 5'-AGAGTTGATATACAATTCGTTGCCGC-3' 
Pf6PGDC281Ss 5'-TGCCCGACGATGTCTGCTGCGTTAGAT-3' 
Pf6PGDC281Sas 5'-ATCTAACGCAGCAGACATCGTCGGGCT-3' 
 
2.5 Buffers and Solutions 
2.5.1 Stock solutions 
Solution Concentration Solved in Storage 
APS 10% (w/v) ddH2O -20 °C 
Carbenicillin 50 mg∙mL-1 50% (v/v) Ethanol -20 °C 
Chloramphenicol 35 mg∙mL-1 100% Ethanol -20 °C 
Cystatin 40 µM ddH2O -20 °C 
IPTG 1 M ddH2O, sterile filtrated -20 °C 
Kanamycin 25 mg∙mL-1 ddH2O, sterile filtrated -20 °C 
Pepstatin A 300 µM DMSO -20 °C 
PMSF 100 mM DMSO -20 °C 
SDS 10% (w/v) ddH2O -20 °C 
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2.5.2 Buffers for chemocompetent E. coli cells 
Buffer Composition 
TFB1 buffer for chemocompetence 100 mM 
50 mM 
30 mM 
10 mM 
15% 
pH 5.8 
Rubidium chloride 
Manganese chloride 
Potassium acetate 
Calcium chloride 
Glycerol 
TFB2 buffer for chemocompetence 10 mM 
10 mM 
75 mM 
pH 8.0 
MOPS 
Rubidium chloride 
Calcium chloride 
 
2.5.3 Medium for bacterial cell culture 
Medium Composition 
Lysogeny broth (LB) 10 g Tryptone 
 5 g Yeast extract 
 10 g Sodium chloride 
 Adjusted to 1 L with dH2O and autoclaved before use 
Terrific Broth (TB) 12 g Tryptone 
 24 g Yeast extract 
 9.4 g Dipotassium phosphate 
 2.2 g Monopotassium phosphate 
 4 mL Glycerol 
 Adjusted to 1 L with dH2O and autoclaved before use 
2xYT 16 g Tryptone 
 10 g Yeast extract 
 5 g Sodium chloride 
 Adjusted to 1 L with dH2O and autoclaved before use 
Agar plates 10 g Tryptone 
 5 g Yeast extract 
 10 g Sodium chloride 
 15 g Agar 
 Adjusted to 1 L with dH2O and autoclaved before use 
 Respective antibiotics are added after autoclaving at 50-60 °C 
 
2.5.4 Buffers for protein purification 
Buffer Composition 
Lysis buffer for: 
− PfGluPho wt and mutants 
− PfG6PD 
− Pf6PGD wt and mutants 
− h6PGD 
500 mM 
50 mM 
pH 7.8 
Sodium chloride 
Tris 
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Elution buffer (Ni-NTA) for: 
− PfGluPho wt and mutants 
− PfG6PD 
− Pf6PGD wt and mutants 
− h6PGD 
500 mM 
50 mM 
10-500 mM 
pH 7.8 
Sodium chloride 
Tris 
Imidazole 
Elution buffer (Talon) for: 
− PfG6PD 
500 mM 
50 mM 
10-200 mM 
pH 7.8 
Sodium chloride 
Tris 
Imidazole 
 
2.5.5 Buffers for electrophoresis 
Buffer Composition 
DNA sample buffer (6x) 0.1% 
60% 
1 mM 
pH 8.3 
Bromophenol blue 
Saccharose 
Tris 
adjusted with HCl 
Tris-Borat-EDTA (TBE) buffer (5x) 89 mM 
89 mM 
2 mM 
pH 8.3 
Tris 
Boric acid 
EDTA 
adjusted with HCl 
Electrophoresis buffer 192 mM 
25 mM 
0.1% (w/v) 
pH 8.3 
Glycine 
Tris 
SDS 
adjusted with HCl 
SDS sample buffer (4x) 250 mM 
8% (w/v) 
40% (v/v) 
0.03% (w/v) 
(200 mM 
Tris-HCl, pH 6.8 
SDS 
Glycerol 
Bromophenol blue 
DTT) 
SDS sample buffer (1x) 62.5 mM 
2% (w/v) 
25% (v/v) 
0.01% (w/v) 
(50 mM 
Tris-HCl, pH 6.8 
SDS 
Glycerol 
Bromophenol blue 
DTT) 
Coomassie staining solution 160 mg 
ad 1 L 
3 mL  
Coomassie Brilliant Blue R 250 
ddH2O, 2 h stirring 
HCl, fuming, 37% 
Separating gel buffer 1.5 M 
pH 8.8 
Tris 
Sample gel buffer 0.5 M 
pH 6.8 
Tris 
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2.5.6 Gels 
Gel Composition 
Agarose gel 0.7% Agarose in TBE buffer 
SDS-PAGE separating gel (12%) 5.1 mL ddH2O 
3.75 mL Separating gel buffer 
 6 mL Acrylamide/bisacrylamide (30%) 
 0.15 mL SDS (10%) 
 75 µL APS (10%) 
 7.5 µL TEMED 
SDS-PAGE sample gel (4%) 3.05 mL ddH2O 
 1.25 mL Sample gel buffer 
 0.65 mL Acrylamide/bisacrylamide (30%) 
 0.05 mL SDS (10%) 
 25 µL APS (10%) 
 5 µL TEMED 
 
2.5.7 Buffers for semi-dry Western blotting 
Buffer Composition 
Anode buffer I 300 mM Tris 
Anode buffer II 25 mM Tris 
Cathode buffer 40 mM 6-Aminohexanoic acid 
Western blot transfer buffer 25 mM 
192 mM 
10% (v/v) 
pH 8.3 
Tris 
Glycine 
Ethanol 
Tris-buffered saline (TBS) 10 mM Tris 
 0.9% Sodium chloride 
 pH 7.4 adjusted with HCl 
TBS with Tween 20 (TBST) 0.05% (v/v) Tween 20 in TBS buffer 
Ponceau S solution 2% Ponceau S 
 3% TCA 
Ponceau S destaining 
solution 
1% Acetic acid 
Blocking buffer 5% (w/v) Milk powder in TBST buffer 
Luminol mixture 1.25 mM Luminol 
 0.0093% (v/v) Hydrogen peroxide 
 100 mM Tris-HCl 
 pH 8.6  
Coumaric acid 0.11% Coumaric acid in DMSO 
Chemiluminescence mixture 1 mL Luminol mixture 
 10 µL Coumaric acid 
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2.5.8 Assay buffers 
Buffer Composition 
Enzyme activity buffer 100 mM 
10 mM 
0.5 mM 
pH 8.0 
Tris-HCl 
Magnesium chloride 
EDTA 
GSNO buffer 50 mM 
1 mM 
0.2 mM 
pH 7.4 
Tris 
EDTA 
Neocuproine 
Blocking buffer 8 M 
50 mM 
1 mM 
0.1 mM 
pH 8.0 
Urea 
Tris 
EDTA 
Neocuproine 
Labeling buffer 4 M 
50 mM 
1 mM 
0.01 mM 
pH 8.0 
Urea 
Tris 
EDTA 
Neocuproine 
 
2.6 Protein crystallization 
To crystallize the proteins, the purification buffers were exchange via size exclusion 
chromatography to the buffers stated below. 
Buffer Composition 
Crystallization buffer for: 
− Pf6PGD wt and mutants 
300 mM 
50 mM 
pH 7.8 
Sodium chloride 
Tris 
 
Crystallization buffer for: 
− PfGluPho 
− PfG6PD 
150 mM 
50 mM 
pH 7.8 
Lithium citrate 
Tris 
 
 
To find conditions of protein crystallization, commercially available crystallization screens 
were used. 
Screen Company 
Additive Screen HT HR2-138 Hampton Research, Aliso Viejo, CA, USA 
JBScreen Classic HTS I Jena Bioscience, Jena 
JBScreen Classic HTS II Jena Bioscience, Jena 
JBScreen Wizard 1 HTS Jena Bioscience, Jena 
JBScreen Wizard 2 HTS Jena Bioscience, Jena 
JCSG Core I Suite (NeXtal Tubes) Qiagen, Hilden 
JCSG Core II Suite (NeXtal Tubes) Qiagen, Hilden 
JCSG Core III Suite (NeXtal Tubes) Qiagen, Hilden 
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JCSG Core IV Suite (NeXtal Tubes) Qiagen, Hilden 
MemStart + MemSys HT-96 Molecular Dimensions Limited, Sufflok, UK 
MPD Suite (PrNeXtal DWBlock) Qiagen, Hilden 
XP Screen Jena Bioscience, Jena 
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3 Methods 
The work was performed using the following recombinantly produced enzymes: 
− From Plasmodium falciparum: PfGluPho wt (PlasmoDB accession number 
PF3D7_1453800; Jortzik et al., 2011), PfGluPhoS315Y, PfGluPhoL395F, PfGluPhoF507L (plasmids 
kindly provided by the working group of Prof. Becker), PfGluPhoS899E, and PfGluPhoS900E 
(plasmids generated within this thesis), PfG6PD (Jortzik et al., 2011), and Pf6PGD wt 
(PF3D7_1454700, plasmid generated within my master thesis, Haeussler, 2015), 
Pf6PGDC281S and Pf6PGDW104L (plasmids generated within this thesis) 
− From Plasmodium vivax: PvGluPho and PvG6PD as the C-terminal part PvGluPho 
(PVX_117790; plasmids kindly provided by the working group of Prof. Becker) 
− From Homo sapiens: the homologs hG6PD (Jortzik et al., 2011) and h6PGD (plasmid 
generated within this thesis) 
3.1 Molecular biological methods 
3.1.1 Plasmid preparation 
Plasmid DNA from E. coli cells was purified using the QIAprep Spin Miniprep Kit (Qiagen, 
Hilden) or the PureYield Plasmid Miniprep System (Promega, Mannheim) following the 
instructions of the manufacturer. In brief, the pellet of up to 3 mL overnight culture of E. coli 
cells containing the plasmid of interest was lysed, neutralized, and transferred to the kit’s 
column. After washing, the plasmid DNA was eluted from the silica membrane column. 
3.1.2 Determining DNA concentration 
The DNA concentration of a sample was determined spectrophotometrically at a wavelength 
of 260 nm using the BioPhotometer with UV cuvettes or the BioSpectrometer basic (both 
Eppendorf, Hamburg). To evaluate the purity of the sample, the ratio of absorbance at 260 nm 
and at 280 nm was calculated. A ratio of approximately 1.8 was defined as pure. 
3.1.3 Agarose gel electrophoresis 
To analyze DNA mixtures, agarose gel electrophoresis was performed. This technique 
separates DNA fragments, e. g. polymerase chain reaction (PCR) products or restricted 
plasmid DNA, by their size. The DNA sample was mixed 5:1 with DNA-Dye NonTox and loaded 
on a 0.7% agarose gel. The DNA fragments were separated electrophoretically in 1x TBE 
running buffer by applying 100 V for approximately 45 min. The 1 kb DNA ladder GeneRuler 
was used to estimate the size of the DNA bands. The DNA bands were afterwards visualized 
with LED light in the gel documentation chamber FAS Digi Gel Imaging System (Nippon 
Genetics, Düren). 
3.1.4 Molecular cloning 
The DNA plasmids used for heterologous overexpression of PfGluPho, PfG6PD, and hG6PD 
were produced previously as described in Jortzik et al., 2011. The coding sequences for the 
N-terminally 6xHis-tagged proteins Pf6PGD and h6PGD were ordered as codon-optimized 
synthetic genes from Eurofins/MWG (Ebersberg). They were subcloned into the expression 
vector pQE30 using the restriction sites BamHI and HindIII and verified via sequencing. The 
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gene of PvGluPho containing no introns was amplified via PCR using a vivax EcoR DNA-library 
– obtained from the Malaria Research and Reference Reagent Resource Center (MR4) – as a 
template using the primers listed in 2.4.5, introducing the restriction sites for BamHI and SalI. 
This construct was cloned into the cloning vector pBluescript SK (+) and verified via 
sequencing. For heterologous overexpression, the PvGluPho gene was subcloned into the 
expression vectors pQE30 and pET28a using the same restriction sites. The G6PD part of 
PvGluPho (aa 310-927) was amplified via PCR (bp 930-2,784) using primers listed in 2.4.5 and 
cloned into the expression vector pQE30 for heterologous overexpression as described below. 
Restriction digestion 
The vector containing the gene of interest and the desired target vector (pQE30 or pET28a) 
were cleaved with the respective restriction enzymes for 1 h at 37 °C. The DNA fragments 
were purified using the QIAquick PCR Purification Kit (Qiagen, Hilden) following the 
instructions of the manufacturer. The size of the obtained DNA fragments was analyzed by 
agarose gel electrophoresis (3.1.3). 
Ligation 
The DNA fragments were ligated with T4-DNA ligase for 5-10 min at 37 °C. Afterwards, 5 µL of 
the ligation mixture was transformed into competent E. coli cells (KRX). The transformed 
E. coli cells were plated onto an agar plate containing the respective antibiotics (carbenicillin 
in case of pQE30, kanamycin in case of pET28a). The remaining ligation mixture was stored 
overnight at 4 °C. In case the transformation was not successful, it was repeated using the 
overnight ligation. 
Verifying the insert 
To check the correct insertion of the gene of interest into the desired vector, the plasmids 
from several bacterial colonies after transformation were prepared as described in 3.1.1. 
Afterwards, the plasmids were digested using the same restriction enzymes as used for cloning 
for 5 min at 37 °C and the size of the fragments were analyzed using agarose gel 
electrophoresis (3.1.3). Plasmids containing the inserts of the correct sizes were used for 
further procedures. 
3.1.5 Site-directed mutagenesis 
Prior to this thesis, the following PfGluPho mutants were generated by the working group of 
Prof. Becker: PfGluPhoS315Y, PfGluPhoL395F, and PfGluPhoF507L. The PfGluPho mutants 
PfGluPhoS899E and PfGluPhoS900E, as well as the Pf6PGD mutants Pf6PGDW104L and Pf6PGDC281S 
were generated within this thesis via site-directed mutagenesis using PCR. 
Briefly, PfGluPho wt and Pf6PGD wt, both in pQE30, were used as templates, the 
oligonucleotide primers (2.4.5) containing the desired mutated codons were added in order 
to insert the mutations with the Pfu DNA polymerase (Table 2). The PCR reaction products 
were purified using the QIAquick PCR Purification Kit (Qiagen, Hilden) following the 
manufacturer’s instructions. Dpnl digested methylated, non-mutated template plasmids for 
1 h at 37 °C before they were transformed into E. coli KRX cells. Insertion of the correct 
mutation was confirmed by sequencing in an in-house facility. 
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Table 2. Site-directed mutagenesis of PfGluPho and Pf6PGD using PCR 
Reaction mixture 
Template DNA ad 100 ng 
Forward primer ad 400 nM 
Reverse primer ad 400 nM 
dNTP mixture ad 200 µM 
10x Pfu buffer 5 µL 
Pfu DNA polymerase 1 µL 
Sterile H2O ad 50 µL 
  
 Pf6PGDC281S Pf6PGDW104L PfGluPhoS899E PfGluPhoS900E 
Denaturation 95 °C for 90 sec 95 °C for 90 sec 94 °C for 90 sec  94 °C for 90 sec  
Cycles 18 18 24 24 
Denaturation 95 °C for 30 sec 95 °C for 30 sec 94 °C for 30 sec 94 °C for 30 sec 
Annealing 75 °C for 30 sec 69 °C for 30 sec 55 °C for 60 sec 65 °C for 60 sec 
Elongation 68 °C for 90 sec 68 °C for 90 sec 68 °C for 9 min 68 °C for 9 min 
Final elongation 68 °C for 90 sec 68 °C for 90 sec 68 °C for 9 min 68 °C for 9 min 
 
3.2 Microbiological methods 
For the work with E. coli, autoclaved medium containing the appropriate antibiotics was used 
exclusively. The work was performed in a sterile environment close to a flame, and only 
autoclaved or sterilized instruments were used. After the experiments, any medium and 
instruments that were in contact with E. coli cells were autoclaved or incubated with 70% 
ethanol. 
3.2.1 Preparation of competent E. coli cells 
Competent E. coli cells have the ability to take up plasmid DNA from the environment. This 
competence is used for molecular cloning or recombinant protein production. The glycerol 
stocks of the respective cell lines were stored at -80 °C. A sample of the stock was streaked 
onto an agar plate containing the appropriate antibiotics and incubated overnight at 37 °C. A 
single colony was transferred to 10 mL LB medium containing the appropriate antibiotics, and 
the cells were allowed to grow overnight at 37 °C under constant shaking at 180 rpm. 1 mL of 
this culture was transferred to 100 mL LB medium with antibiotics, and the optical density 
measured at a 600 nm wavelength (OD600) was monitored until 0.7 was reached. The culture 
was cooled on ice for 5 min, followed by a centrifugation step at 3,000 rpm and 4 °C for 5 min. 
The supernatant was completely discarded, and the cells were resuspended in a total volume 
of 30 mL cold TFB1 buffer. The cells were incubated on ice for 90 min, followed by a second 
centrifugation step at 2,000 rpm and 4 °C for 5 min. The supernatant was discarded and the 
cells were resuspended in 2 mL cold TFB2 buffer. Aliquots of 125 µL were frozen in liquid 
nitrogen for 1 min and stored at -80 °C until transformation. 
3.2.2 Transformation of competent E. coli cells 
Chemically competent E. coli cells were transformed in order to insert the desired plasmid 
DNA into the cells. An overview of the vectors and E. coli cell lines used for the different 
proteins is given in Table 3. First, a 100-125 µL E. coli cell suspension was thawed on ice and 
then incubated with plasmid DNA for 30 min. A heat shock for 90 sec at 42 °C was performed, 
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forcing the cells to internalize the plasmid. Afterwards, the cells were allowed to rest for 2 min 
on ice prior to adding 400 µL LB medium, followed by incubation for 1 h at 37 °C under 
constant shaking (180 rpm). After incubation, the cells were plated onto LB agar plates 
containing the appropriate antibiotics and incubated overnight at 37 °C. If no colony was 
visible, the transformation was repeated and E. coli cell density was increased before the cells 
were streaked onto the plate. For this, the cell suspension was centrifuged for 2 min at 
13,400 rpm, 300 µL of the supernatant was discarded, and the pellet was resuspended and 
transferred completely to the plate. Plates containing colonies were stored at 4 °C for up to 
four weeks. 
Table 3. Vectors, E. coli cell lines and antibiotics used for transformation 
C: carbenicillin, K: kanamycin, Cam: chloramphenicol. 
 Vector E. coli cell line Antibiotics 
h6PGD pQE30 M15 C, K 
Pf6PGD pQE30 M15 C, K 
PfG6PD pQE30 M15 C, K 
PfGluPho pQE30 M15, pRAREII C, K, Cam 
PvG6PD pQE30 M15, pRAREII C, K, Cam 
PvGluPho pQE30 Various Various 
PvGluPho pET28a Various Various 
 
3.2.3 Heterologous overexpression in E. coli cells 
The exact conditions of heterologous overexpression for each protein used in this thesis are 
given in Table 4. In order to recombinantly produce the protein of interest, a single colony of 
E. coli cells containing the corresponding plasmid DNA was inoculated into 3 mL LB medium 
and grown at 37 °C. To ensure consistent cell growth behavior, all incubation steps were 
performed under constant shaking at 180 rpm. After 8 h, 3 mL were transferred to 50-100 mL 
of LB or TB medium, and the cells were allowed to grow overnight at 37 °C. Using this culture, 
1 L of LB or TB medium was inoculated to an OD600 of 0.1, and the cells were grown at 37 °C. 
As soon as an OD600 of 0.6-0.8 was reached, cells were induced with 1 mM IPTG. Heterologous 
overexpression was allowed for 4 h at 37 °C or for 20 h at room temperature (RT, 22 °C). Cells 
were harvested via centrifugation (15 min, 8,000 rpm, 4 °C), resuspended in 500 mM NaCl, 
50 mM Tris, pH 7.8 with the addition of protease inhibitors (100 µM PMFS, 150 nM pepstatin 
A, 40 nM cystatin), and stored at -20 °C until lysis. 
Table 4. Conditions of heterologous overexpression for recombinant proteins 
Different conditions of heterologous overexpression were tested for each protein. Shown here are the conditions 
that resulted in the highest yield of active protein. C: carbenicillin, K: kanamycin, Cam: chloramphenicol. hG6PD 
was heterologously overexpressed as described in Jortzik et al., 2011. 
 E. coli cells Antibiotics Medium Temperature [°C] Duration [h] 
h6PGD M15 C, K LB 37 4 
Pf6PGD M15 C, K LB 22 20 
PfG6PD M15 C, K TB 22 20 
PfGluPho M15, pRAREII C, K, Cam TB 22 20 
PvG6PD M15, pRAREII C, K, Cam LB, TB 37 4 
PvGluPho Various Various LB, TB, 2xYT 16-37 4-20 
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3.3 Protein biochemical methods 
To preserve the integrity of the proteins, all steps were performed at 4 °C if not stated 
otherwise. 
3.3.1 Purification of recombinant protein by affinity chromatography 
In this thesis, affinity chromatography using the hexahistidly-tag (6xHis-tag) of the proteins 
was the first step of purification. E. coli cell pellets were thawed, DNaseI and 16 mg lysozyme 
were added to each liter of E. coli culture, and the suspension was stirred for 2-16 h, 
depending on the solubility of the protein. If this prolonged lysis was not enough to overcome 
limited solubility, the cell suspension was adjusted to a higher volume. The exact conditions 
of purification for each protein used in this thesis are given in Table 5. To further increase the 
efficiency of lysis, the cells were manually sonicated three times for 30 sec each at 70% 
maximum power. The cell debris was centrifuged for 30 min at 18,000 rpm, and the 
supernatant containing the recombinant protein was applied to Ni-NTA or Talon column that 
had been equilibrated with 500 mM NaCl, 50 mM Tris, pH 7.8. The supernatant was allowed 
to run slowly through the column, while the recombinant protein bound to the column via its 
6xHis-tag. To remove nonspecifically bound proteins, the column was washed with the buffer 
stated above before the protein was eluted with increasing concentrations of imidazole (up 
to 500 mM for Ni-NTA, up to 200 mM for Talon). The different fractions were analyzed using 
SDS-PAGE (3.3.2). 
Table 5. Conditions of purification for recombinant proteins 
Different conditions of purification were tested for each protein. Shown here are the conditions that resulted in 
the highest yield of active protein. The human homolog hG6PD was purified as described in Jortzik et al., 2011. 
 Duration 
of lysis [h] 
Volume of lysis [mL 
per L E. coli culture] 
Column 
material 
Imidazole concentration 
for elution [mM] 
h6PGD 16 20-40 Ni-NTA 75 
Pf6PGD 2 20-30 Ni-NTA 75 
PfG6PD 16 50-70 Talon 25 
PfGluPho 16 50 Ni-NTA 50 
PvG6PD 16 50-70 Ni-NTA 40 
PvGluPho Various Various Ni-NTA Various 
 
3.3.2 Gel electrophoresis 
Denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates 
proteins depending on their molecular weight and was used in this thesis to control the purity 
of protein samples and before protein immunoblotting. SDS denatures and coats the proteins, 
giving them a negative charge proportional to their molecular weight. The reduction of 
disulfide bonds via DTT fully unfolds the three-dimensional structure of the proteins. Within 
an electric field, the proteins migrate through the gel towards the positively charged anode, 
thereby separating them by size (Laemmli, 1970). 
SDS sample buffer was added to each protein sample; for the exact compositions, see Table 
6. The samples were boiled for 5 min at 95 °C and applied to a 12% polyacrylamide gel (5 µL 
of pellet, flow-through, and washing fraction; 18 µL of elution fractions, entire sample of final 
purity and analysis of S-glutathionylation, 2 µL of the 1:10 diluted sample for analysis for 
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S-nitrosation). Upon applying 200 V for approximately 40 min, the proteins migrated through 
the gel. As soon as the smallest proteins reached the lower end of the gel, the gel was washed 
with water three times and followed by staining with Coomassie Brilliant Blue. The efficiency 
of washing and staining was enhanced by briefly heating the gel in a microwave (40 sec, 
700 W). After staining, excessive Coomassie was removed by washing the gel with water. For 
Western blot analysis, the gel was not washed and stained but directly used to blot the 
proteins to the membrane. 
Table 6. Sample preparation for SDS-PAGE 
SB: sample buffer. All SB included DTT, except for the SB used for the identification of S-glutathionylation. 
 Protein sample Protein amount SB Volume of SB 
Protein purification Pellet Small amount pellet 4x 5 µL 
Flow-through 3 µL 4x 5 µL 
Washing 3 µL 4x 5 µl 
Elution 20 µL 4x 5 µL 
Final purity Ad 7.5 µg protein 1x Equal to volume of 
protein sample 
S-glutathionylation Identification Ad 2.5 µg protein 1x Equal to volume of 
protein sample 
Reversibility Ad 2.5 µg protein 1x Equal to volume of 
protein sample 
S-nitrosation 
 
Initial sample 
 
 
1:10 dilution 
60-200 µg protein 
 
 
2 µL of the initial 
sample 
4x 
 
 
1x 
¼ of the blocking 
buffer volume used 
for resuspension 
18 µL 
 
3.3.3 Size exclusion chromatography 
In this thesis, size exclusion chromatography was performed for three different reasons: to 
improve the purity of a protein, to study the oligomerization behavior, and to simultaneously 
change the buffer in case a different buffer was used for crystallization than for purification. 
Size exclusion chromatography separates the proteins according to their molecular weight in 
their native form by using a separation column. The smaller the proteins, the better they can 
infiltrate the porous matrix of the separation column; therefore, larger proteins elute from 
the column first. 
The experiments were performed with a HiLoad 16/600 Superdex 200 prep grade column 
connected to an ÄKTA/Unicorn FPLC system (GE Healthcare, Freiburg). Prior to the 
experiments, the column was calibrated with a size exclusion calibration kit (GE Healthcare, 
Freiburg) and equilibrated with the appropriate buffer. If applicable, the sample was 
incubated with 5 mM DTT, 1-5 mM H2O2, or 100 µM NADPH and centrifuged for 15 min at 
13,400 rpm in order to remove potential solid particles. Afterwards, the sample was applied 
to the column and eluted at a flow rate of 1 mL·min-1. Eluting proteins were detected 
spectrophotometrically at 280 nm, fractions of 2 mL were collected, peak areas and kAV 
values were evaluated using the Unicorn 4.11 and 7.1 software. The final purity of the protein 
was controlled by SDS-PAGE (3.3.2). 
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3.3.4 Determination of protein concentration 
Protein concentration was determined in two different ways. The first was the Bradford assay. 
A standard curve was created containing 0-20 µg·mL-1 BSA in 500 µL water, before 125 µL of 
Bradford reagent (Bio-Rad, Munich) was added. After exactly 15 min, absorption was 
measured spectrophotometrically at 595 nm. The samples were treated in the same way, and 
concentration was calculated based on the standard curve. 
The second way was by measuring the absorbance of the protein solution at 260 and 280 nm 
using the Eppendorf BioSpectrometer basic. The concentration was calculated using the 
molecular weight and the extinction coefficient of the proteins. 
Table 7. Molecular weights and extinction coefficients of proteins 
Molecular weights including the 6xHis-tag and extinction coefficients were calculated using the online tool of 
JustBio (www.justbio.com). Concentration of hG6PD was only determined using the Bradford assay. 
 Molecular weight [kDa] Extinction coefficient [M-1cm-1] 
h6PGD 54.4 62,700 
Pf6PGD wt 54.0 65,520 
Pf6PGDC281S 54.0 65,460 
Pf6PGDW104L 53.9 59,830 
PfG6PD 67.9 60,200 
PfGluPho wt, PfGluPhoL395F, 
PfGluPhoS899E, PfGluPhoS900E 
108.3 111,630 
PfGluPhoF507L 108.2 111,630 
PfGluPhoS315Y 108.3 112,910 
PvG6PD 71.8 57,590 
PvGluPho 109.5 91,740 
 
3.3.5 Protein immunoblotting 
Western blot analysis was used to identify either 6xHis-tagged proteins or post-translationally 
modified proteins using specific antibodies (see Table 8). 
First, an SDS-PAGE gel was run (chapter 3.3.2), and the proteins were transferred to a 
polyvinylidene difluoride (PVDF) or nitrocellulose membrane. Before use, the PVDF membrane 
was activated by soaking in 100% methanol. For the transfer, filter papers, gel, and membrane 
were soaked in buffer (three papers in anode buffer I, two papers and the membrane in anode 
buffer II, five papers and the gel in the cathode buffer). The five filter papers (cathode buffer) 
were placed quickly and without air bubbles onto the graphite cathode plate, followed by the 
gel, membrane, two filter papers (anode buffer II) and three filter papers (anode buffer I). The 
proteins were transferred from the gel to the membrane by applying 13 V for 30 min. 
Alternatively, twelve filter papers, the gel, and the membrane were soaked in Western blot 
transfer buffer. Six papers were placed at the anodic bottom of the transfer cassette, followed 
by the membrane, the gel, and the remaining six filter papers. The proteins were transferred 
by applying 25 V and 1 A for 30 min. To control blotting efficiency, the membrane was stained 
in Ponceau S for 30 sec and destained with 1% acetic acid until the bands were visible. 
Afterwards, the membrane was completely destained by washing it several times in TBST. To 
prevent non-specific binding of the antibodies to unoccupied protein binding sites, the 
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membrane was blocked with 5% (w/v) non-fat milk in TBST for 1 h at 22 °C or overnight at 
4 °C. The membrane was washed three times for 5 min in TBST before the primary antibody 
was applied (for the antibody dilutions, see Table 8). After incubation with the primary 
antibody for 1 h at 22 °C, the membrane was washed again in TBST as described above, and 
the secondary antibody was applied for 1 h at 22 °C, followed by a final washing step in TBST. 
The secondary antibody coupled to a horseradish peroxidase enabled visualization of the 
proteins labeled by antibodies. Therefore, the membrane was incubated for 1 min with the 
chemiluminescence mixture, and chemiluminescence was detected with either an X-ray film 
or the Intas ECL ChemoStar Imager connected to ChemoStar TS software. If applicable, the 
antibodies were removed afterwards by incubating the membrane in Restore Plus Western 
Blot Stripping Buffer for 7 min. 
Table 8. Antibodies used for Western blot analysis 
Identification of… Primary antibody Secondary antibody 
… 6xHis-tag 1:1,000 Anti-mouse, 1:20,000 
… S-glutathionylation 1:250 Anti-mouse, 1:10,000 
… S-nitrosation 1:1,000 Anti-mouse, 1:10,000 
 
3.3.6 Enzyme assays 
In this thesis, the G6PD activities of full-length PfGluPho, PfG6PD and PvG6PD, the activity of 
Pf6PGD, and the activities of the human homologs hG6PD and h6PGD were examined. The 
enzymes catalyze the following reactions: 
           G6PD 
Glucose 6-phosphate + NADP+ → 6-phosphoglucono-δ-lactone + NADPH + H+ 
         6PGD 
6-Phosphogluconate + NADP+ → ribulose 5-phosphate + CO2 + NADPH + H+ 
The activity of the enzymes was determined spectrophotometrically by measuring the 
absorption of the initial reduction of the cofactor NADP+ to NADPH at 340 nm according to 
Beutler, 1984. All enzymatic measurements were carried out at 25 °C. Briefly, the reaction 
mixture contained the cofactor NADP+ and varying concentrations of enzyme (around 
5-50 nM) in the assay buffer described in 2.5.8. The exact cofactor and substrate 
concentrations used for each enzyme are described in Table 9. 
Table 9. Cofactor/substrate concentrations used for G6PD/6PGD enzyme activity assays 
The concentrations given are considered saturated. * According to Jortzik et al., 2011; N/A: not applicable. 
 Cofactor NADP+ [µM] Substrate G6P [µM] Substrate 6PG [µM] 
h6PGD 200 N/A 400 
hG6PD* 200 200 N/A 
Pf6PGD mutants 50 N/A 200 
Pf6PGD wt 100 N/A 200 
PfGluPho mutants 200 200 N/A 
PfGluPho wt* 200 200 N/A 
PvG6PD 200 800 N/A 
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The reaction was started by adding the appropriate substrate. The KM for NADP+ was 
determined by titrating NADP+ at the saturating concentrations of the corresponding 
substrate, the KM for the substrate was determined vice versa by titrating the substrate at the 
saturating concentration of NADP+. All measurements were performed using the Evolution 
300 spectrophotometer (Thermo Scientific, Dreieich) at a final assay volume of 500 µL. For 
evaluations, only linear signal increase was considered. Specific activities were calculated 
using Microsoft Excel; KM and Vmax were analyzed using GraphPad Prism 5. 
3.3.7 Protein S-glutathionylation 
Potential protein S-glutathionylation of the plasmodial enzymes was studied via Western blot 
analysis and enzyme activity measurements. 
Western blot analysis 
Purified enzymes were reduced with 5 mM DTT for 30 min. Afterwards, DTT was removed 
using ZebaTM Spin Desalting Columns according to the instructions of the manufacturer. Each 
protein was adjusted to a final concentration of 2 mg·mL-1 and incubated with 0, 2, 6, or 
10 mM GSSG for 10 min at 37 °C, followed by desalting as described above. To identify 
S-glutathionylated proteins, samples were prepared for SDS-PAGE with 1x sample buffer 
without DTT (see Table 6). Sample buffer with DTT was used to study the reversibility of the 
modification. Western blot analysis was performed as described in 3.3.5 using a monoclonal 
anti-glutathione antibody (Virogen, Watertown, MA, USA; diluted 1:250 in 5% (w/v) non-fat 
milk in TBST) and a horseradish peroxidase-conjugated goat anti-mouse antibody (Dianova, 
Hamburg; diluted 1:10,000 in 5% (w/v) non-fat milk in TBST). 
Enzyme activity 
To investigate the time and concentration-dependent impact of S-glutathionylation on 
enzyme activity, prereduced enzyme was incubated with 0-10 mM GSSG at 37 °C for 15 min. 
The activity was determined as described in 3.3.6. To study the reversibility of the 
modification, S-glutathionylated protein was incubated with 5 mM DTT for up to 1 h at 4 °C 
before the activity was determined. 
3.3.8 Protein S-nitrosation 
Potential protein S-nitrosation on PfGluPho/PfG6PD, PvG6PD, and Pf6PGD was studied via 
Western blot analysis, MALDI-TOF MS, and enzyme activity measurements. The 
physiologically relevant small molecular weight S-nitrosothiol GSNO served as an NO donor, 
which is able to release NO and transnitrosate proteins (Broniowska et al., 2013; Hess et al., 
2005). 
Biotin-switch assay and Western blot analysis 
Since no antibody for directly detecting S-nitrosation is available, the biotin-switch assay was 
performed for S-nitrosated proteins as described in Wang et al., 2014, enabling the detection 
of S-nitrosated thiol groups via Western blot analysis using an anti-biotin antibody. 0.6-
0.8 mg·mL-1 prereduced enzyme was incubated with 0 or 1 mM GSNO in GSNO buffer (chapter 
2.5.8) for 1 h at 22 °C in the dark. The reaction was stopped by adding 100% ice-cold acetone, 
followed by protein precipitation for 30 min at -20 °C. After centrifugation of the samples at 
8,000 g and 4 °C for 5 min, the supernatant was discarded and the pellets were washed three 
times with 70% ice-cold acetone, each time followed by centrifugation (first 8,000 g, followed 
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by 5,000 g, 4 °C, 5 min). Residual free cysteine thiols were blocked by resuspending the pellets 
in blocking buffer (chapter 2.5.8) containing 200 mM IAA, followed by incubation in the dark 
for 45 min at 50 °C. The reaction was stopped by adding 100% ice-cold acetone, followed by 
protein precipitation and washing of the pellets with 70% ice-cold acetone as described above. 
To switch S-nitrosated thiols to biotinylated thiols, the pellets were dissolved in labeling buffer 
(chapter 2.5.8) containing 20 mM sodium ascorbate and 0.2 mM iodoacetyl-PEG2-biotin and 
incubated for 1 h in the dark at 25 °C. Samples without sodium ascorbate served as a negative 
control. The reaction was again stopped by adding 100% ice-cold acetone, followed by protein 
precipitation and washing of the pellets with 70% ice-cold acetone as described above. The 
final pellets were resuspended in blocking buffer and applied to SDS-PAGE. Western blot 
analysis was performed as described in 3.3.5, using the monoclonal anti-biotin antibody (33): 
sc-101339 (Santa Cruz, Dallas, TX, USA; diluted 1:1,000 in 5% (w/v) non-fat milk in TBST) and 
a horseradish peroxidase-conjugated goat anti-mouse antibody (Dianova, Hamburg; diluted 
1:10,000 in 5% (w/v) non-fat milk in TBST). 
MALDI-TOF MS 
To identify the cysteine residues of Pf6PGD that had been affected by S-nitrosation, matrix-
assisted laser desorption/ionization time-of-flight-mass spectrometry (MALDI-TOF MS) was 
used. After incubating the reduced protein with varying concentrations GSNO, excess GSNO 
was removed via desalting as described above, and residual free thiols were blocked with 
20 mM NEM. The MALDI-TOF MS analyses were performed in two different facilities (Core 
Facility of Mass Spectrometry and Elemental Analysis, Philipps University Marburg; Protein 
Analytics, Justus Liebig University Giessen). 
Enzyme activity 
The enzymes were reduced and desalted as described in 3.3.7. Afterwards, the proteins were 
incubated with 0-1,000 µM GSNO in GSNO buffer for up to 180 min at RT in the dark. The 
effect of S-nitrosation on enzyme activity and the potential reversibility of the effect were 
determined as described in 3.3.6 and 3.3.7. 
3.3.9 Stability tests of PfGluPho and PfG6PD 
Despite numerous trials, it was not yet been possible to crystallize PfGluPho or the C-terminal 
part PfG6PD. This might be due to weak protein stability at RT in the buffer used so far 
(500 mM NaCl, 50 mM Tris, pH 7.8). Therefore, differential scanning fluorimetry (DSF) was 
performed in order to find additives or alternative buffer ingredients that would increase the 
stability of the enzyme and therefore improve the possibility of protein crystallization. Within 
this thesis, the effects of promising additives/buffer ingredients on protein stability during 
storage at RT were tested on both PfGluPho and PfG6PD. 
PfGluPho and PfG6PD were heterologously overexpressed and purified as described above 
(3.2-3.3). The purified enzymes were highly concentrated using Vivaspin 30,000 tubes in order 
to ensure that the remaining buffer was kept to a minimum. Afterwards, the proteins were 
diluted into stock solutions of promising chemicals found via DSF (100-300 mM sodium 
chloride, 50 mM bicine, pH 9.0, 50 mM Hepes, pH 6.0, 1 mM GSH/GSSG, 2 mM Gly-Gly-Gly, 
2 mM NADP+, 2 mM G6P, 100 mM calcium chloride, 100 mM sodium bromide, 100 mM 
ammonium sulfate, 50-500 mM lithium citrate, 50-500 mM sodium citrate, 1 mM betaine, 
1 mM xylitol, and different combinations). Protein concentration was determined 
immediately as described in 3.3.4. The proteins were then stored in the dark at RT, and 
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concentration was determined on a regular basis as described in 3.3.4. Before each 
measurement, the samples were centrifuged for 5 min at 13,400 rpm to remove potentially 
degraded protein. 
3.4 Structural biology methods 
Detailed characterization of a protein is largely facilitated by the knowledge of its three-
dimensional structure (Chayen and Saridakis, 2008). This may enable statements about the 
enzyme mechanism or – especially in the case of cocrystallization with a substrate or cofactor 
– give insights into the binding sites of the enzyme. Moreover, knowing the structure of an 
enzyme makes rational drug design possible. Improving a compound based on the structure 
of the target protein largely enhances the chance of a significant and specific effect on the 
target (Chen et al., 2012). 
3.4.1 Protein crystallization using the vapor diffusion technique 
The first step in elucidating the three-dimensional structure of a protein is to crystallize it. This 
step can be very challenging since proteins are highly colloidal with respect to their 
physiochemical properties, size, and conformational stability, making them sensitive to any 
change in the environmental conditions (Gavira, 2016). It is therefore necessary to find 
chemical, biochemical, and physical conditions that allow transition of the protein in solution 
to crystalline material (McPherson and Gavira, 2014). This first-order phase transition is called 
nucleation, which is followed by growth of the crystal. An essential premise of nucleation is 
the generation of protein in a supersaturated phase, meaning that the protein concentration 
in solution is higher than its actual solubility limit. The saturation state depends on the 
concentration of both the protein and precipitant, as illustrated in the phase diagram of Figure 
7. If both concentrations are low, the protein is in a stable, undersaturated phase where no 
nucleation is possible. Increasing one or even both concentrations shifts the protein to 
supersaturation, a non-equilibrium condition. In the labile phase, both nucleation and crystal 
growth can occur, whereas in the metastable phase only the growth of already existing crystals 
is possible. The highest level of supersaturation is reached in the precipitation phase. Under 
this condition, nucleation and crystal growth are unlikely. There are several ways to generate 
a supersaturated state, e.g., adding or removing salt, altering the temperature, adding ligands 
or polymers, etc. (Chayen and Saridakis, 2008; Holcomb et al., 2017; McPherson and Gavira, 
2014). 
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Figure 7. Phase diagram for protein crystallization 
The phase diagram shows the influence of protein concentration and precipitant concentration on the saturation 
state of a protein. The precipitant may be a salt or a polymer. The premise of crystallization is supersaturation of 
the protein. If both protein and precipitant concentrations are low, the protein is in a stable, undersaturated 
state. Increasing protein or precipitant concentration transitions it to the metastable, labile, or precipitation 
phase (Chayen and Saridakis, 2008; Holcomb et al., 2017; McPherson and Gavira, 2014). The figure was taken 
from McPherson and Gavira, 2014. 
There are several techniques to reach the supersaturation state such as microbatch 
crystallization and dialysis. In this thesis, the vapor diffusion technique was used, which is 
based on vapor diffusion between a drop containing precipitant and protein in a concentration 
below the solubility limit and the reservoir containing the precipitant solution. Diffusion slowly 
increases the concentration of the protein, promotes supersaturation, and may thereby 
enable nucleation. There are two variants to the vapor diffusion technique: the sitting drop 
and the hanging drop approach. The difference between these is the position of the 
protein/precipitant mixture as shown in Figure 8. In the sitting drop approach, it sits in a well 
in the middle of or next to the reservoir solution, while in the hanging drop approach it hangs 
over the reservoir solution from an inverted cover slide (Chayen and Saridakis, 2008; Holcomb 
et al., 2017; McPherson and Gavira, 2014). 
 
Figure 8. Protein crystallization using the vapor diffusion technique 
Vapor diffusion can be performed in two different approaches: the sitting drop (a) and the hanging drop (a) 
technique. Diffusion between the protein solution and the reservoir solution results in an adjustment of the 
concentrations and may allow protein crystal formation. This figure was modified from Caffrey and Cherezov, 
2009. 
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3.4.2 Screening the crystallization condition 
Finding a condition that allows protein crystal formation is mainly empirical (McPherson and 
Gavira, 2014). Commercially available crystallization screens (see 2.6) can be used as a starting 
point. They are based on conditions that previously resulted in successful protein 
crystallization (Chayen and Saridakis, 2008). Additionally, screens designed in the laboratory 
of Prof. Becker consisting of common precipitants were used in this thesis. The screenings 
were performed using the Honeybee crystallization robot 961 in 96-well two-drop trays. The 
robot pipetted drops comprising 200 nL reservoir solution and 200 nL protein solution into the 
trays next to the reservoir with 100 µL reservoir solution. A drop comprising 200 nL reservoir 
solution and 200 nL buffer was placed into the second tray to enable differentiation between 
salt and protein crystals. In some screenings, this control drop was replaced by the screening 
of a second condition, e. g., another protein concentration or a cocrystallization trial. This 
enabled the screening of 192 different conditions in one plate. The plates were afterwards 
sealed with clear adhesive tape, stored at RT if not stated otherwise, and controlled for 
crystals or crystal-like precipitation on a regular basis using a stereomicroscope. 
3.4.3 Additives 
An additive is defined as any chemical substance or small molecular weight compound that is 
added to the crystallization trial described above (3.4.2). A rational approach is the use of 
additives that bind to the protein for physiological reasons, e. g. substrates, cofactors, or 
inhibitors. However, other classes of substances may also be used (Holcomb et al., 2017; 
McPherson and Gavira, 2014). The use of additives may facilitate or promote nucleation and 
crystal growth by enhancing protein solubility or structural rigidity (Holcomb et al., 2017). 
In this thesis, substrates, cofactors, products, and inhibitors were used as additives (Table 10). 
The molar concentration of the additive in the drop was at least 2.5-fold higher than the 
protein concentration in order to enable binding of one additive molecule to each protein 
molecule. Furthermore, we used the Additive Screen HT HR2-138 from Hampton Research 
(Aliso Viejo, CA, USA). The procedure for using this Additive Screen was almost the same as 
the one described in 3.4.2, except that 90 µL of a promising reservoir solution was mixed with 
10 µL of the additive solution. This mixture was used to prepare the 200 nL drops. 
Table 10. Physiological additives used for crystallization trials 
 Additive   Additive   Additive 
Pf6PGD 6PG 
NADP+ 
 PfG6PD G6P 
NADP+ 
 PfGluPho G6P 
NADP+ 
NADPH 
SBI-0797750 
 
3.4.4 Optimization of initial crystallization conditions 
Crystalline material yielded during an initial screen is often not suitable for X-ray diffraction 
analysis. The quality of these crystals (e.g. suitable size for X-ray diffraction analysis) may be 
improved by slightly varying the initial conditions (McPherson and Gavira, 2014). In this thesis, 
crystal quality was optimized via the vapor diffusion technique in 24-well crystallization plates 
with hanging and sitting drops. For hanging drops, 2 µL of protein solution was mixed with 
2 µL of reservoir solution in the center of a microscope cover slip. The slip was put face-down 
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onto the well containing 800 µL of reservoir solution. To seal the wells hermetically, the clefts 
around the wells were covered with silicone oil before the slips were emplaced. For the sitting 
drops, 2 µL of protein solution and 2 µL of reservoir solution were put into the middle of a 
sitting drop crystallization plate, surrounded by 800 µL of reservoir solution. The plates were 
sealed with a clear adhesive tape. These plates were then stored at 4-22 °C and controlled for 
crystals on a regular basis. 
3.4.5 Data collection and processing 
Crystals of appropriate size and quality were used for X-ray diffraction analysis. The resulting 
diffraction pattern was then used to calculate the three-dimensional protein structure. 
Dr. Karin Fritz-Wolf processed the data on crystals obtained within this thesis at the Max 
Planck Institute for Medical Research (MPI), Heidelberg. Prior to data collection, the crystals 
were transferred to a cryoprotection buffer containing glycerol or ethylene glycol in addition 
to the actual crystallization buffer and were stored in liquid nitrogen. Diffraction data was 
collected at X10SA (detector: Pilatus) of the Swiss Light Source, Villigen, Switzerland. 
Diffraction data were collected at 100 K and processed with XDS (Kabsch, 2010). 
3.5 Methods for characterization of “small molecule” inhibitors 
3.5.1 IC50 determination 
One important characteristic parameter of a compound is its median inhibitory concentration 
(IC50). It indicates the compound concentration at which, e.g., the activity of an enzyme is 
reduced to 50% of its initial value (Cheng and Prusoff, 1973). 
If not stated otherwise, the IC50 determinations in this thesis were based on the enzyme assay 
described in 3.3.6 in the presence of different compound concentrations. For the assessment 
of the compounds, following enzyme concentrations were used: 5-10 nM PfGluPho, 1-6 nM 
PvG6PD, 2 nM Pf6PGD, 1-2 nM hG6PD, and 1 nM h6PGD. All measurements were performed 
in 96-well plates, half area (Greiner Bio-One, Frickenhausen), using the Tecan Infinite M200 
plate reader (Tecan, Maennedorf, Switzerland) at a minimum assay volume of 75 µL. First, the 
compounds were dissolved ad 10 mM in 100% DMSO and afterwards diluted in enzyme 
activity buffer to different concentrations around the expected IC50. The final concentration 
of DMSO was not allowed to exceed 1%. The compound dilution series was added to a mixture 
of enzyme and NADP+ in enzyme activity buffer. In case of substrate saturation, the 
concentrations given in Table 9 were used. However, to enable the identification of 
competitive inhibitors, the cofactor and substrate were usually added in concentrations close 
to the KM of the enzyme, given in Table 11. The reaction was started by adding the appropriate 
substrate. A negative control containing no compound was defined as 0% inhibition, a positive 
control containing no substrate as 100% inhibition. The increase in NADPH was monitored by 
measuring either absorption at 340 nm or fluorescence at an excitation wavelength of 340 nm 
and an emission wavelength of 460 nm (ex340/em460). For evaluations, only the initial linear 
increase of absorption/fluorescence was considered. The IC50 values were calculated using 
GraphPad Prism 5. 
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Table 11. Cofactor/substrate concentrations close to KM used for IC50 determinations 
* Determined in Jortzik et al., 2011. ƚ Depending on the individual KM of the enzyme batch used. N/A: not 
applicable. 
 Cofactor NADP+ [µM] Substrate G6P [µM] Substrate 6PG [µM] 
h6PGD 4.5 N/A 26 
hG6PD* 19 125 N/A 
Pf6PGD 9 N/A 11 
PfGluPho* 10 15 N/A 
PvG6PD 15 70-85ƚ N/A 
 
3.5.2 Determination of the mechanism of inhibition 
To further characterize a compound, its most likely mechanism of inhibition (MOI) was 
determined by using the assay described above (3.5.1) with one modification. To determine 
the MOI against NADP+, the cofactor was titrated at different compound concentrations 
around IC50, while the substrate was kept in saturation (Table 9). Vice versa, to determine the 
MOI against the substrate, it was titrated at fixed concentrations of NADP+ in saturation. The 
initial linear slope was used to plot the Michealis-Menten curves and the Lineweaver-Burk 
plots and to calculate KM and Vmax using GraphPad Prism 5. The most likely MOI was evaluated 
using the decision criteria listed in Table 12. 
Table 12. Decision criteria for determining the mechanism of inhibition 
(Cornish-Bowden, 2004) 
Mechanism of inhibition 
Increase of inhibitor concentration 
KM Vmax Lineweaver-Burk plots 
Competitive ↑ ↔ Intersection at the ordinate 
Non-competitive ↔ ↓ Intersection at the abscissa 
Uncompetitive ↓ ↓ Parallel lines 
Mixed type Mixed characteristics 
 
3.5.3 Reversibility of inhibition 
Besides the MOI, a second important characteristic of a compound is the potential reversibility 
of its inhibition. To test this, the enzymes were incubated with high inhibitor concentrations. 
The activity of this incubation mixture was determined in order to ensure that the compound 
concentration was high enough to completely inhibit the enzyme. Afterwards, the 
enzyme/inhibitor mixture was diluted to a compound concentration below IC50 and incubated 
for 10 min on ice to allow potential dissociation of the inhibitor from the protein. For 
comparison, controls containing either no inhibitor or inhibitor in the concentration remaining 
after dilution were prepared in parallel. To start the reaction, substrate and cofactor were 
added either in saturation (Table 9) or at concentrations close to KM (Table 11). The activity 
measurements were performed based on the assay described in 3.3.6 using the Tecan Infinite 
M200 plate reader (Tecan, Maennedorf, Switzerland) in 96-well plates, half area (Greiner Bio-
One, Frickenhausen), with a final assay volume of 50-80 µL. The activity of the control without 
any inhibitor was defined as 100%. If the activity of the sample after dilution was significantly 
below the activity of the controls, inhibition was considered irreversible; however, if the 
activity of the sample was equal to the controls, inhibition was considered reversible. 
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3.5.4 Testing compounds in high-throughput screening assay format 
Within this thesis, many compounds were tested in a high-throughput screening assay format 
at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA, USA using the assays 
described below. 
3.5.4.1 Diaphorase-coupled assay 
For the first test of new compounds, the assay described in 3.3.6 was coupled to the enzyme 
diaphorase, which uses NADPH to reduce resazurin to the highly fluorescent resorufin. For 
each molecule of converted G6P, one molecule of resorufin is generated, which allows the 
determination of G6PD activity by measuring fluorescence of resorufin (Figure 9). The actual 
fluorescence wavelengths of resorufin are ex530/em590; however, due to available filter 
combinations for the plate reader, ex530/em580 were used. This shift to higher wavelengths 
(the fluorescence of NADPH itself is ex340/em460) increases the sensitivity of the assay. 
Moreover, it avoids interference with the fluorescence of the compounds themselves, which 
is very common in the UV range (Preuss et al., 2012a). 
 
Figure 9. Diaphorase-coupled screening assay 
PfGluPho converts glucose 6-phosphate to 6-phosphoglucono-δ-lactone. The thereby generated NADPH is used 
by diaphorase to reduce resazurin to resorufin. The fluorescence of resorufin can be measured at ex530/em590 
(Preuss et al., 2012a). 
The assays for PfGluPho and hG6PD described in Preuss et al., 2012a and Preuss et al., 2013 
were used with slight modifications. The same assay was used for PvG6PD, appropriate 
concentrations were determined by titration of each component. Exact assay concentrations 
are given in Table 13. Varying volumes of compound dissolved in 100% DMSO were 
transferred to columns 5-34 of a 1,536-well plate using the Echo Liquid Handler (Labcyte, San 
Jose, CA, USA). Columns 1-4 served as positive controls without substrate; columns 35-38 
served as negative controls without compound. Additional DMSO was added to all wells in 
order to equilibrate the DMSO concentration across the plate. A volume of 2.5 μL of enzyme 
mix (Table 13) was added to all wells using the Multidrop Combi Reagent Dispenser (Thermo 
Fisher Scientific, Waltham, MA, USA). To start the reaction, 2.5 μL of substrate mix (Table 13) 
was added to columns 5-34 using the Combi. Substrate mix without G6P was added to columns 
1-4 for positive control. The plate was centrifuged at 1,500 rpm for 1 min and incubated in the 
dark for 2 hours. Fluorescence of resorufin was then detected at ex530/em580 using a Viewlux 
plate reader (PerkinElmer, Waltham, MA, USA). IC50 values were calculated using CBIS 
(Chemical and Biological Information Systems, www.cheminnovation.com). 
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Table 13. Concentrations used for the diaphorase-coupled assay 
The final assay concentrations are given. 
  PfGluPho PvG6PD hG6PD 
Highest compound concentration [µM] 4 4 79 
Enzyme mix 
Tris, pH 7.5 [mM] 50 50 50 
Tween 20 [%] 0.005 0.005 0.005 
BSA [mg∙mL-1] 1 1 1 
Enzyme [μg∙mL-1] 0.075 0.15 0.15 
Substrate mix 
Tris, pH 7.5 [mM] 50 50 50 
Tween 20 [%] 0.005 0.005 0.005 
BSA [mg∙mL-1] 1 1 1 
MgCl2 [mM] 3.3 3.3 3.3 
Diaphorase [U∙mL-1] 1 1 1 
Resazurin [µM] 25 60 140 
G6P [µM] 20 30 125 
NADP+ [µM] 4 12 6 
 
3.5.4.2 Orthogonal assay 
Determination of IC50 values 
In order to exclude an interaction with the diaphorase-coupled assay, IC50 values were 
determined using the orthogonal assay directly detecting the fluorescence of NADPH. Plates 
were prepared as described in 3.5.4.1. For hG6PD, 99 µM were used as the highest compound 
concentration. The enzyme mix contained 0.05 μg∙mL-1 PfGluPho, 0.025 μg∙mL-1 PvG6PD, and 
0.045 μg∙mL-1 hG6PD, respectively. The reaction was started by adding the substrate mix 
described above (Table 13) without diaphorase and resazurin. The plates were centrifuged, 
and the reaction was read kinetically using the PHERAstar multiwell plate reader (BMG 
LABTECH, Cary, NC, USA) at ex350/em460 (due to filter availability) over 45 min. The reaction 
rate was calculated by dividing the relative fluorescence units (RFU) by time. For analysis, only 
the linear signal increase was considered. CBIS was used to calculate IC50 values. 
Determination of the mechanism of inhibition 
The most potent inhibitors were mechanistically characterized as described in 3.5.2 with slight 
modifications. Varying inhibitor concentrations around IC50 were transferred to a 1,536-well 
plate using the Echo Liquid Handler. The enzyme mix containing 0.04-0.05 µg∙mL-1 PfGluPho 
was added to the plate. Enzyme and substrate mixes (without diaphorase and resazurin, Table 
13) were dispensed using the BioRAPTR Microfluidic Workstation (Beckman Coulter, Brea, CA, 
USA). After centrifuging the plate, the NADPH fluorescence increase was monitored at 
ex350/em460 (due to filter availability) with the PHERAstar multiwell plate reader. For the 
analysis, only the linear slope was considered. Based on the data, Lineweaver-Burk plots were 
created, and KM and Vmax values were calculated with GraphPad Prism 5 software. The 
mechanism of inhibition was evaluated using the criteria given in Table 12. 
3.5.5 Screening the MMV Malaria Box 
DMSO tolerance test 
The MMV Malaria Box comprises 200 drug-like and 200 probe-like compounds with known 
antimalarial activity. Until December 2015, it could be ordered free of charge from MMV 
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(Spangenberg et al., 2013). Like many others, compounds of the MMV Malaria Box are 
dissolved in 100% DMSO. High concentrations of DMSO can change the conformation of some 
proteins and thereby influence their activity (Rammler, 1967). Therefore, a DMSO tolerance 
test was performed before screening MMV Malaria Box by measuring Pf6PGD activity under 
varying DMSO concentrations (0-5%). The assay was performed as described in 3.3.6 using the 
Tecan Inﬁnite M200 plate reader (Tecan, Maennedorf, Switzerland) with a final assay volume 
of 75 µL. The initial linear slope was used to calculate the activity in comparison to the control 
without DMSO. 
Screening of the MMV Malaria Box 
The MMV Malaria Box was screened based on the assay described in 3.3.6 containing NADP+ 
and 6PG at concentrations close to the KM to allow identification of competitive inhibitors 
(Table 11). The compounds were added in a final concentration of 10 µM before the reaction 
was started. The final DMSO concentration was 1%; therefore, a negative control containing 
1% DMSO but no compound was defined as 0% inhibited. The positive control contained no 
6PG and was defined as 100% inhibited. All measurements were performed in 384-well plates 
with a final assay volume of 100 µL using the Tecan Inﬁnite M200 plate reader (Tecan, 
Maennedorf, Switzerland). Microsoft Excel was used to calculate the activity of the enzyme 
compared to the controls. This determination was repeated four times. For all compounds 
that showed an inhibition of ≥ 50% in at least three of the four determinations, IC50 values 
were determined as described in 3.5.1 applying substrate and cofactor at KM concentrations 
(Table 11). 
3.5.6 Characterization of compounds in P. falciparum cell culture 
Cultivation of Plasmodium falciparum parasites 
P. falciparum 3D7 and NF54-attB parasites were grown in continuous culture as described by 
Trager and Jensen, 1976 with slight modiﬁcations (Akoachere et al., 2005). Parasites were 
maintained at 1-10% parasitemia and 3.3% hematocrit in an RPMI 1640 culture medium 
supplemented with A+ erythrocytes (purchased from the blood bank of the University Hospital 
Giessen and Marburg, UKGM), 0.5% (w/v) lipid-rich-bovine serum albumin (Albumax), 9 mM 
(0.16%) glucose, 0.2 mM hypoxanthine, 2.1 mM L-glutamine, 25 mM Hepes, and 22 µg∙mL-1 
gentamicin. All incubations were carried out at 37 °C in 3% O2, 3% CO2, and 94% N2. Parasites 
were synchronized in culture to ring stages as a starting population by treating them with 5% 
(w/v) sorbitol (Lambros and Vanderberg, 1979). P. falciparum trophozoites were enriched via 
magnetic separation (Paul et al., 1981). Cell lysates were obtained via saponin lysis (Sturm et 
al., 2009). Parasitemia was counted using Giemsa-stained blood smears (Rahbari et al., 2017). 
In vitro activity of compounds against Plasmodium falciparum parasites 
To investigate the effect of the compound SBI-0797750 on asexual blood stage parasites, its 
activity against the P. falciparum 3D7 strain was determined using the [3H]-hypoxanthine 
incorporation assay (Desjardins et al., 1979; Kasozi et al., 2013) and against P. falciparum 3D7 
and NF-54-attB parasites using the SYBR Green I-based fluorescence assay (Ekland et al., 2011; 
Rahbari et al., 2017). Stock solutions of the inhibitors were dissolved in DMSO. For the [3H]-
hypoxanthine incorporation assay, serial double dilutions of the inhibitor (100 µL) were 
prepared in hypoxanthine-free medium in 96-well microtiter plates. Synchronized ring-stage 
parasites in hypoxanthine-free complete medium (100 µL) were added to each well (0.15-
0.20% parasitemia and 1.25% final hematocrit). After 44 h incubation at 37 °C in a gaseous 
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mixture (3% O2, 3% CO2, and 94% N2), 50 µL of [3H]-hypoxanthine (final concentration of 
0.5 µCi/well) were added per well, and the plate was further incubated for 24 h. After a total 
incubation of 68 h, the plates were frozen at -80 °C for at least 24 h. To measure the effect of 
the compound, the plates were then thawed, and each well was harvested on a glass fiber 
filter (Perkin-Elmer, Rodgau-Jügesheim) and dried. Radioactivity from each well was measured 
in counts per minute (Desjardins et al., 1979; Kasozi et al., 2013). For the SYBR Green-I assay, 
serial double dilutions of the inhibitor (50 µL) in complete medium were performed in 96-well 
microtiter plates, half area (µClear bottom). Synchronized ring-stage parasites in complete 
medium (50 µL) were added to each well (0.15% parasitemia and 1.25% final hematocrit) and 
incubated for 44 h (3D7) or 48 h (NF-54-attB) at 37 °C. Afterwards, 20 μL of 5x SYBR Green in 
lysis buffer (20 mM Tris-HCl, 5 mM EDTA, 0.16% (w/v) saponin, and 1.6% (v/v) Triton X-100) 
were added to each well and incubated for 24 h at RT in the dark. Fluorescence was measured 
using the CLARIOstar plate reader at ex494/em530. The IC50 values were determined by curve-
fitting the percentage of growth inhibition (in relation to controls) against the log of drug 
concentration with a variable slope sigmoidal function (Microsoft Excel) (Ekland et al., 2011; 
Rahbari et al., 2017). Infected RBCs were used as a positive control, uninfected RBCs as a 
negative control (Rahbari, 2017). 
A potential impact of combinations of SBI-0797750 with chloroquine, methylene blue, or 
artemisinin on asexual blood stage P. falciparum 3D7 parasites was investigated using the 
[3H]-hypoxanthine incorporation assay as described above (Desjardins et al., 1979; Fivelman 
et al., 2004). The resulting IC50 values allowed the detection of potential combination effects. 
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4 Results 
4.1 GluPho and G6PD from Plasmodium falciparum 
Bifunctional PfGluPho catalyzes the first two steps of the oxidative PPP in Plasmodium; the 
C-terminal part – PfG6PD – comprises amino acid residues 339-911 (Jortzik et al., 2011). 
4.1.1 Heterologous overexpression and purification of PfGluPho and PfG6PD 
Recombinant PfGluPho wt and PfG6PD were produced as described in Jortzik et al., 2011 using 
a pQE30 expression vector and E. coli M15 cells, for PfGluPho containing pRAREII. 
Representative gels of the PfGluPho purification are shown in Figure 10a, b. For the affinity 
chromatography of PfG6PD, Talon was used as an alternative column material within this 
thesis, resulting in high purity of the protein (Figure 10c, d). The yield of pure and active 
proteins varied from 0.3 to 3 mg per liter E. coli cell culture. The proteins were stored at 4 °C 
for up to five days, long-term storage conditions were -80 °C and 50% glycerol. 
 
Figure 10. Purification of PfGluPho wt and PfG6PD 
(a) PfGluPho was purified via affinity chromatography using Ni-NTA as column material. Purest fractions (75-
500 mM imidazole) were pooled and applied to size exclusion chromatography. (b) To control the final purity of 
PfGluPho, 7.5 µg of protein were applied to a 12% SDS-PAGE gel. (c) PfG6PD was purified via affinity 
chromatography using Talon as column material. Purest fractions (25-200 mM imidazole) were pooled and 
applied to size exclusion chromatography. (d) To control the final purity of PfG6PD, 7.5 µg of protein were applied 
to a 12% SDS-PAGE gel. The numbers above the lanes indicate the imidazole concentration used for elution. M: 
Unstained Protein Molecular Weight Marker; P: pellet; F: flow-through. 
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4.1.2 Characterization of naturally occurring PfGluPho variants 
The naturally occurring PfGluPho variants investigated in this thesis were identified via an in 
silico analysis of the protein with the former ID: PF14_0511 (now PF3D7_1453800) in the 
malaria database PlasmoDB. Prominent single nucleotide polymorphisms resulting in an 
amino acid exchange were S315Y, L395F, and F507L. So far, it is unknown whether these 
mutations have an impact on the kinetic parameters of the enzyme. Furthermore, proteomic 
approaches identified several amino acid residues of PfGluPho to be phosphorylated in vivo, 
the phosphorylation of the C-terminally located Ser-Ser pair (S899 and S900) was reported by 
several groups (Lasonder et al., 2012; Pease et al., 2013; Treeck et al., 2011). To study the 
potential impact of the mentioned mutations and phosphorylations on the properties of 
PfGluPho, site-directed mutagenesis was performed. The naturally occurring 
phosphorylations were mimicked by replacement of the two serines on position 899 and 900 
by glutamic acids (Kim et al., 2015). The mutants were heterologously overexpressed and 
purified using the same protocol as for the wt enzyme (chapter 4.1.1), resulting in comparable 
yield and purity. The mutants were stored at -80 °C and 50% glycerol until kinetic 
determinations. 
Oligomerization behavior of naturally occurring PfGluPho variants 
Simultaneous to the improvement in purity, size exclusion chromatography was used to study 
the oligomerization behavior of PfGluPho variants. The reduced mutants eluted as tetramers 
with molecular masses of approximately 480 kDa from the size exclusion chromatography 
column (Figure 11b-f), indicating that the oligomerization is not primarily based on disulfide 
bonds between the subunits. Since this behavior was also observed for the wt enzyme (Figure 
11a), none of the mutations changed the oligomerization behavior of PfGluPho. Similar to full-
length PfGluPho, reduced PfG6PD eluted from size exclusion chromatography after 65 min 
(= 65 mL) in a tetrameric form with approximately 260 kDa (not shown). 
Kinetic characterization of naturally occurring PfGluPho variants 
To investigate a potential impact of the mutations on PfGluPho, the kinetic parameters were 
determined in comparison to the wt enzyme. An overview of the kinetic data is shown in Table 
14. Parts of the measurements were performed by members of Prof. Becker’s group 
(Stegmayer, 2013) and by Max Reichmann, a master student supervised by myself in the 
laboratory (Reichmann, 2018). The values for the wt enzyme determined within this thesis are 
in good accordance with values from the literature (Jortzik et al., 2011). The Vmax values of the 
mutants ranged between 4.0 and 6.0 U∙mg-1 and therefore did not majorly differ from the wt 
enzyme (5.9 ± 1.0 U∙mg-1 for G6P, 5.9 ± 0.6 U∙mg-1 for NADP+). Likewise, the KM values were 
with a range of 18.4 and 29.2 µM for G6P and of 3.7 and 6.2 µM for NADP+ comparable to the 
values of the wt (G6P: 20.3 ± 5.6 µM; NADP+: 6.1 ± 1.3 µM). 
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Figure 11. Size exclusion chromatography of PfGluPho wt and mutants 
Reduced PfGluPho wt and mutants eluted after approximately 58 mL in a tetrameric form from the size exclusion 
chromatography column. The experiment for PfGluPhoF507L (d) was stopped after 65 mL due to technical reasons. 
The PfGluPho peaks are indicated by arrows; the other peaks resulted from proteins that could not be removed 
using affinity chromatography. 
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Table 14. Kinetic characteristics of PfGluPho variants 
Values are represented as mean values ± standard deviations (SD) of at least two independent determinations, each including at least two independent measurements. 
* Values from Jortzik et al., 2011 are given for comparison. ƚ Catalytic efficiency (kcat/KM) from Jortzik et al., 2011 was calculated from mean values to allow for comparison. 
  PfGluPho wt* PfGluPho wt PfGluPhoS315Y PfGluPhoL395F PfGluPhoF507L PfGluPhoS899E PfGluPhoS900E 
Vmax [U∙mg-1] 
G6P 5.2 ± 1.6 5.9 ± 1.0 4.4 ± 1.1 4.5 ± 0.9 6.0 ± 1.4 5.6 ± 0.1 6.0 ± 1.1 
NADP+ 4.6 ± 0.8 5.9 ± 0.6 4.6 ± 1.5 4.0 ± 1.1 5.0 ± 0.3 5.2 ± 0.2 6.0 ± 0.6 
KM [μM] 
G6P 19.2 ± 3.9 20.3 ± 5.6 23.4 ± 7.1 29.2 ± 4.1 24.1 ± 4.4 24.1 ± 2.8 18.4 ± 5.1 
NADP+ 6.5 ± 2.2 6.1 ± 1.3 5.1 ± 1.0 4.0 ± 0.2 3.7 ± 0.1 6.2 ± 0.5 5.8 ± 1.5 
kcat [sec-1] 
G6P 8.6 ± 1.5 10.7 ± 1.8 7.9 ± 2.0 8.1 ± 1.6 10.9 ± 2.5 10.1 ± 0.2 10.8 ± 1.9 
NADP+ 8.2 ± 1.2 10.1 ± 0.9 8.3 ± 2.7 7.2 ± 2.0 9.1 ± 0.5 9.3 ± 0.4 10.8 ± 1.2 
Catalytic 
efficiency 
[M-1∙sec-1] 
G6P 4.4·105ƚ 
5.8∙105 
 ± 1.5∙105 
3.7∙105 
 ± 2.0∙105 
2.9∙105 
 ± 9.4∙104 
4.5∙105 
 ± 2.2∙104 
5.2∙105 
 ± 2.3∙105 
6.2∙105 
 ± 2.2∙105 
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4.1.3 Crystallization of PfGluPho and PfG6PD 
Parts of the crystallization trials were performed in collaboration with the master student Max 
Reichmann (Reichmann, 2018). 
Stability tests on PfGluPho and PfG6PD 
To enable protein crystallization, stability of the protein at the temperature used for 
crystallization trials over several days or weeks is essential (McPherson and Gavira, 2014). So 
far, the stability of PfGluPho and PfG6PD at RT – the most commonly used condition – was not 
sufficient; the protein often degraded within minutes after preparation of the drops. To 
enhance the stability, a fluorescence-based thermal shift assay screening for new buffer 
conditions or additives that enhance the stability of PfGluPho was carried out in the group of 
Prof. Becker. Within this thesis, the effects of promising buffers and chemicals (listed in 3.3.9) 
on the stability of PfGluPho and PfG6PD were tested. 
Both PfGluPho and PfG6PD were most stable in a lithium citrate/Tris buffer, pH 7.8. Down to 
75 mM lithium citrate, PfGluPho was stable for two weeks at RT (Figure 12). During this time, 
most crystals are able to grow. Higher lithium citrate concentrations enhanced the stability 
even more. However, crystallization trials showed that lithium citrate tends to build salt 
crystals; therefore, the salt concentration was kept to a minimum of 75 mM lithium citrate as 
the lowest concentration that could stabilize the enzyme for two weeks. Since the buffer 
concentration is halved after preparing the drops, the protein was prepared in the following 
buffer: 150 mM lithium citrate, 50 mM Tris, pH 7.8. Buffer exchange prior to crystallization 
was performed via size exclusion chromatography as described in chapter 3.3.3. 
 
Figure 12. Stability of PfGluPho in lithium citrate buffer 
The stability of PfGluPho at room temperature was tested under various concentrations of lithium citrate with 
50 mM Tris, pH 7.8. One representative of two independent determinations is shown. 
Crystallization of PfG6PD 
Using the newly identified buffer (150 mM lithium citrate, 50 mM Tris, pH 7.8), the 
crystallization conditions of PfG6PD were screened in sitting drops by using the screens listed 
in 2.6 as well as screens designed in-house. The most promising crystals were found using 
10 mg∙mL-1 PfG6PD in 0.1 M MES, pH 5.0, 10% (w/v) PEG 6,000, final pH 6.0 (JCSG Core I Suite, 
F1, Figure 13); therefore, this condition was used for further optimization. 
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Figure 13. Initially obtained PfG6PD crystals 
During a screening for crystallization conditions, the most promising PfG6PD crystals grew in sitting drops using 
10 mg∙mL-1 PfG6PD in 0.1 M MES, pH 5.0, 10% (w/v) PEG 6,000, final pH 6.0 (JCSG Core I Suite, F1). 
Variations in pH and PEG concentrations, as well as the addition of ethylene glycol and G6P 
improved the crystal quality; the best crystals (14.4 mg∙mL-1 PfG6PD, 0.1 M MES, pH 6.0, 9% 
(v/v) PEG 6,000, 40% ethylene glycol, 2.9 mM G6P) had a resolution of 7 Å. Although this is a 
slight improvement over the crystals obtained previously (8.5 Å), it is still too low to solve the 
three-dimensional structure of the protein. Using the hanging drop approach instead of sitting 
drops improved the size of the crystals (Figure 14); however, they were unstable and therefore 
not suitable for X-ray diffraction analysis. 
 
Figure 14. Crystals obtained during optimization trials of PfG6PD crystallization 
Crystals were obtained in hanging drops at 10 mg∙mL-1 PfG6PD, 0.2 M MES, pH 6.0, 8% PEG 6,000. 
Crystallization of PfGluPho 
Screening for crystallization conditions of PfGluPho showed that most crystals were found 
when adding at least 40% MPD. The major problem during optimization trials using this 
precipitant was phase separation within the reservoir solution (Figure 15a, b). The 
microcrystals obtained were not suitable for X-ray diffraction analysis due to their limited size 
(Figure 15c). 
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Figure 15. Crystallization of PfGluPho wt using MPD 
Phase separation was observable using 11.5 mg∙mL-1 PfGluPho wt, 48% MPD, 0.1 (a) or 0.2 (b) M potassium 
citrate. (c) 11.5 mg∙mL-1 PfGluPho wt, 48% MPD, 0.15 M sodium citrate, 0.1 M Hepes, pH 7.5. 
The affinity for MPD was also observed during crystallization trials of the mutant PfGluPhoS899E 
(Figure 16). X-ray diffraction analysis revealed a disordered plate type, meaning that the 
crystal structure was disturbed and therefore not suitable for structure determination. 
 
Figure 16. Crystals of PfGluPhoS899E 
(a) 13.1 mg∙mL-1PfGluPhoS899E, 47% MPD, 0.25 M Hepes, pH 7.5, 5 mM G6P. (b) 13.1 mg∙mL-1PfGluPhoS899E, 50% 
MPD, 0.1 M ammonium dihydrogen phosphate, 0.1 M Hepes, pH 7.5. 
In summary, it was so far not possible to crystallize PfGluPho or PfG6PD in a sufficient quality. 
Further possible approaches to solve the three-dimensional structure of these enzymes will 
be discussed in 5.5.1.1. 
4.2 GluPho and G6PD from Plasmodium vivax 
4.2.1 Heterologous overexpression and purification of PvGluPho and PvG6PD 
PvGluPho 
Similar to P. falciparum, the first two steps of the oxidative PPP in P. vivax are catalyzed by the 
bifunctional enzyme PvGluPho (Mohring et al., 2014). Angeles Stegmayer first attempted to 
recombinantly produce the enzyme. However, since this turned out to be extremely 
challenging, this important enzyme was characterized in the meantime by using the C-terminal 
PvG6PD, comprising amino acids 310-927 (Stegmayer, 2013). A new attempt to produce full-
length PvGluPho was performed by a master student supervised by myself in the laboratory, 
Isabell Berneburg (data not shown here, for details see Berneburg, 2017). Different vectors 
(pQE30, pET28a) and E. coli strains (M15, BL21, KRX, XL1-Blue, SHuffle T7, SHuffle T7 Express, 
C41, C43, Lemo21) cultivated in different media (LB, TB, 2xYT) under various temperatures 
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(16-37 °C) for different durations (4-20 h) as well as co-expression with chaperones (pGRO7, 
pKEJ7, pGroRARE) and additional plasmid (pRAREII) were employed to overexpress 
recombinant PvGluPho. The expression of the enzyme as well as the result of subsequent 
purification steps were checked via Western blot analyses using an anti-6xHis-tag antibody as 
described in chapter 3.3.5. The major problem was degradation of the protein during 
overexpression. The most promising condition was overexpression of PvGluPho in E. coli 
Lemo21 cells using LB medium, 100 µM rhamnose and 400 µM IPTG at 18 °C for 4 h. Since the 
solubility of the protein tended to be low, E. coli cells were lysed under the addition of various 
detergents (Triton X-100, glycerol, n-octyl-β-D-glucopyranoside, FOScholine®12, n-decyl-β-D-
maltopyranoside, n-dodecyl-β-D-maltoside, and N,N-dimethyldodecylamine N-oxide); 
simultaneously, different buffer systems were tested (500 mM NaCl, 50 mM Tris or Hepes, pH 
7.8). Cell lysis using N,N-dimethyldodecylamine N-oxide or glycerol as detergents and Hepes 
buffer were the most promising conditions. The protein was purified via affinity 
chromatography using Ni-NTA as column material. Western blot analysis of samples after 
purification resulted in a clear band at the expected height of 110 kDa. Reduced PvGluPho 
eluted from size exclusion chromatography as a tetramer of approximately 383 kDa. The G6PD 
activity was tested using the assay described in chapter 3.3.6 for PfGluPho. Unfortunately, 
however, the protein did not show any activity (Berneburg, 2017). In summary, it has so far 
not been possible to produce active full-length PvGluPho; the following experiments were 
conducted using its C-terminal part, PvG6PD. Further conditions need to be tested to produce 
PvGluPho. 
PvG6PD 
The gene for PvG6PD in the pQE30 expression vector was transformed into competent E. coli 
M15 cells containing pRAREII, and heterologously overexpressed. The N-terminal 6xHis-tag 
was used for purification via affinity chromatography with Ni-NTA as column material (Figure 
17a). In order to improve purity, size exclusion chromatography was performed (see chapter 
3.3.3). The final purity was controlled using SDS-PAGE, loading 7.5 µg of protein onto the gel 
(Figure 17b). The yield of pure, soluble, and active protein per liter E. coli cell culture was 0.1-
0.4 mg.  
 
Figure 17. Purification of PvG6PD 
(a) PvG6PD was purified via affinity chromatography using Ni-NTA as column material. Purest fractions (40-
500 mM imidazole) were pooled and applied to size exclusion chromatography. (b) To control the final purity of 
PvG6PD, 7.5 µg of protein was applied to a 12% SDS-PAGE gel. The numbers above the lanes indicate the 
imidazole concentration used for elution. M: Unstained Protein Molecular Weight Marker; P: pellet. 
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Attempts to increase the yield were performed using a similar approach as described above 
for PvGluPho (various E. coli cells, media, temperatures, and durations for expression, 
different buffers and detergents). However, none of the tested conditions resulted in an 
increased yield (not shown; Berneburg, 2017). The protein was stored at 4 °C for up to five 
days, long-term storage conditions were -80 °C and 50% glycerol. 
Oligomerization behavior of PvG6PD 
Simultaneous to the improvement in purity, size exclusion chromatography was used to study 
the oligomerization behavior of PvG6PD. Prior to each run, the enzyme was reduced by 5 mM 
DTT. Under this condition, PvG6PD eluted as a peak of approximately 390 kDa indicating that 
the protein is presumably present as a hexamer (Figure 18). This hexameric conformation of 
the reduced enzyme indicates that oligomerization is not primarily based on intermolecular 
disulfide bonds. 
 
Figure 18. Size exclusion chromatography of PvG6PD 
Reduced PvG6PD eluted from the size exclusion chromatography column after 60 mL with a molecular mass of 
approximately 390 kDa. The PvG6PD peak is indicated by arrows; the other peaks result from proteins that could 
not be removed using affinity chromatography. 
4.2.2 Kinetic characterization of PvG6PD 
The kinetic parameters of PvG6PD were determined within my own master thesis (Haeussler, 
2015) and confirmed later (Berneburg, 2017) using the assay established for PfGluPho 
measuring the NADPH production. The specific activity of PvG6PD was determined to be 4.6 
± 0.3 U∙mg-1, with KM values of 80.2 ± 19.8 µM and 14.8 ± 2.9 µM for G6P and NADP+, 
respectively (Figure 19). Due to the high KM for G6P, standard assay conditions were slightly 
changed; 800 µM of G6P was defined as saturation for PvG6PD. An overview of the kinetic 
parameters is given in Table 15. 
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Figure 19. KM determinations for PvG6PD 
Representative Michaelis-Menten curves (mean values ± SD of three measurements) for the KM determinations 
of PvG6PD. The KM values for G6P (a) and NADP+ (b) are shown as mean values ± SD of four independent 
determinations (see also Table 15). 
Table 15. Kinetic characteristics of PvG6PD 
Values are represented as mean values ± SD of four independent determinations, each including at least three 
independent measurements. 
Vmax [U∙mg-1] KM [μM] kcat [sec-1] 
Cat. efficiency 
 [M-1∙sec-1] 
G6P NADP+ G6P NADP+ G6P NADP+ G6P 
5.6 ± 0.7 5.5 ± 0.4 80.2 ± 19.8 14.8 ± 2.9 6.7 ± 0.8 6.5 ± 0.4 8.2·104 
 
4.3 6PGD from Plasmodium falciparum 
4.3.1 Heterologous overexpression and purification of Pf6PGD and h6PGD 
The coding sequences for Pf6PGD wt and h6PGD were ordered as codon-optimized synthetic 
genes, cloned into the pQE30 expression vector using the restriction sites BamHI and HindIII, 
and transformed into competent E. coli M15 cells used for heterologous overexpression. 
Pf6PGD wt was for the first time heterologously overexpressed and purified within my master 
thesis (Haeussler, 2015) and optimized within this thesis. The proteins were purified via 
affinity chromatography using the N-terminal 6xHis-tag and Ni-NTA as a column material 
(Figure 20a, c). In order to improve the purity, size exclusion chromatography was performed 
as described in chapter 3.3.3; all enzymes eluted with a comparable pattern under all tested 
conditions (see also 4.3.4, Figure 27). The final purity was controlled using SDS-PAGE, loading 
7.5 µg of protein onto the gel (Figure 20b, d). The yield of pure, soluble, and active protein 
was up to 1 mg Pf6PGD wt and 11 mg h6PGD per liter E. coli cell culture. For short-term 
storage up to five days, Pf6PGD wt was stored at 4 °C. This condition was only used to 
investigate post-translational modifications. Long-term storage conditions of Pf6PGD and 
h6PGD were -80 °C and 50% glycerol. 
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Figure 20. Purification of Pf6PGD wt and h6PGD 
(a) Pf6PGD wt was purified via affinity chromatography using Ni-NTA as column material. Purest fractions (100-
500 mM imidazole) were pooled and applied to size exclusion chromatography. (b) To control the final purity of 
Pf6PGD wt, 7.5 µg protein were applied to a 12% SDS-PAGE gel. (c) h6PGD was purified via affinity 
chromatography using Ni-NTA as column material. Purest fractions (75-500 mM imidazole) were pooled and 
applied to size exclusion chromatography. (d) To control the final purity of h6PGD, 7.5 µg protein were applied 
to a 12% SDS-PAGE gel. The numbers above the lanes indicate the imidazole concentrations used for elution. M: 
Unstained Protein Molecular Weight Marker; P: pellet; F: flow-through. 
4.3.2 Crystallization of Pf6PGD 
Crystallization of native Pf6PGD wt 
To find an initial condition that enables crystallization of native Pf6PGD wt, a screening was 
performed within my master thesis with a protein concentration of 6 mg∙mL-1, using screens 
listed in 2.6 and screens designed in-house for PEG, MPD, and ammonium sulfate (Haeussler, 
2015). Crystals grew under two main conditions containing either (I) lithium nitrate and PEG 
3,350 or (II) sodium citrate, pH 5.6, PEG 4,000, glycerol, and ammonium acetate or ammonium 
sulfate. The initial conditions were optimized by varying the precipitant concentrations and 
using a higher protein concentration (10 mg∙mL-1) in 24-well plates using the hanging drop 
approach. Crystals suitable for X-ray diffraction analysis grew under 25% (v/v) PEG 4,000, 15% 
glycerol, 0.085 M sodium citrate, pH 5.6, and 0.17 M ammonium acetate (Figure 21) 
(Haeussler et al., 2018). 
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Figure 21. Crystals of native Pf6PGD wt 
Crystals of native Pf6PGD wt, grown in hanging drops. 10 mg∙mL-1 Pf6PGD wt, 25% (v/v) PEG 4,000, 15% glycerol, 
0.085 M sodium citrate, pH 5.6, and 0.17 M ammonium acetate. 
Crystallization of Pf6PGD wt in complex with 6PG and NADP+ 
First, cocrystallization with substrate and cofactor was attempted under the conditions that 
were successful for native Pf6PGD wt; however, the obtained crystals did not show sufficient 
X-ray diffraction patterns. Therefore, new screenings were performed yielding crystals that 
were immediately suitable for X-ray diffraction analysis, or after a small variation of the 
conditions. The crystals in complex with 6PG were grown in sitting drops at 7.6 mg∙mL-1 
Pf6PGD wt, 24% (w/v) PEG 1,500, 20% glycerol (JCSG Core II Suite, E11, Figure 22a), and 5 mM 
6PG, the crystals in complex with NADP+ at 15.4 mg∙mL-1 protein, 25% MME550, 0.1 M Hepes, 
pH 4.6, and 5 mM NADP+ (Figure 22b) (Haeussler et al., 2018). 
 
Figure 22. Crystals of Pf6PGD wt in complex with 6PG and NADP+ 
(a) 7.6 mg∙mL-1 Pf6PGD wt, 24% (w/v) PEG 1,500, 20% glycerol (JCSG Core II Suite, E11), and 5 mM 6PG. (b) 
15.4 mg∙mL-1 protein, 25% MME550, 0.1 M Hepes, pH 4.6, and 5 mM NADP+. 
4.3.3 Structure of Pf6PGD 
Dr. Anton Meinhart, Dr. Ilme Schlichting, and Dr. Miroslaw Tarnawski collected diffraction data 
of the crystals at X10SA (detector: Pilatus) of the Swiss Light Source at the Paul Scherrer 
Institute in Villigen, Switzerland. Data processing using the XDS program package (Kabsch, 
2010) was performed by Dr. Karin Fritz-Wolf at MPI Heidelberg. The structures were solved 
with the molecular replacement method. Coordinates and measured reflection amplitudes 
are accessible in the RCSB PDB Protein Data Bank under the PDB codes 6FQX (apo-Pf6PGD), 
6FQY (in complex with NADP+), and 6FQZ (in complex with 6PG). The enzyme complexed with 
6PG diffracted to the highest resolution of 1.9 Å, while native Pf6PGD wt and complexed with 
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NADP+ had a resolution of 2.8 and 2.9 Å, respectively. In one monomer of the NADP+ 
complexed structure, residues 1-67, 85-92, and 129-133 were only weakly defined; however, 
the corresponding region of the other monomer was well defined. Moreover, a short surface 
loop comprising residues 306-314 showed weak electron density. Apart from that, all 
structures were well defined. The enzyme complexed with 6PG showed significant density for 
6PG in each subunit in the difference electron density map. For the bound NADP+, however, 
only the adenine moiety and the three phosphate groups were well defined; the rest of NADP+ 
was not visible (see 4.3.3.3) (Haeussler et al., 2018). 
4.3.3.1 Overall structure of Pf6PGD 
The structure revealed that Pf6PGD is a functional homodimer that contains 468 amino acids 
per subunit. Subunits A and B of the homodimer each contain two domains, one with the 6PG 
and the other one with the NADP+ binding site, and a C-terminal tail of domain 2. Domain 1 is 
the smaller domain; it comprises residues 1-176 and is a βαβ domain, composed of a mixed 
parallel and anti-parallel 6-stranded β sheet. The larger domain 2 (residues 177-468) is in 
contrast mainly α-helical. The C-terminal tail comprises residues 434-468 of one subunit, and 
penetrates domain 2 of the adjacent subunit. This interaction very tightly links the two 
monomers of the dimer (Figure 23) (Haeussler et al., 2018). 
 
Figure 23. Overall structure of the Pf6PGD dimer 
The structure of the apoenzyme is shown. In subunit A, domain 1 and domain 2 are colored amber and brown, 
respectively, in subunit B light-yellow and yellow. All parts of subunit B are marked with ‘. The important residues 
C281, W104, and W265 are shown as ball and stick models (Haeussler et al., 2018). 
With this overall structure, Pf6PGD shares major similarities with other members of the highly 
conserved 6PGD family, e.g. from humans (2JKV (to be published)), Lactococcus lactis 
(Sundaramoorthy et al., 2007), or Geobacillus stearothermophilus (Cameron et al., 2009). 
Apart from the similarities to the 6PGD family, there are also interactions between 
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Plasmodium-specific residues; in two of our three structures (apo and NADP+ complex), the 
Plasmodium-specific cysteine residues C281 and C281′ link the subunits, forming a disulfide 
bridge between them. Cysteine C281 is not only present in P. falciparum 6PGD, but in all five 
human pathogenic species (shown in the amino acids alignment in Appendix 2). Furthermore, 
the Plasmodium-specific W104 in domain 1 interacts with the strictly conserved residue W265 
in domain 2. An alignment of 6PGDs from different species highlighting important residues is 
given in Figure 24 (also see chapters below). To investigate whether these interactions play a 
role in the mechanism of Pf6PGD, the mutants Pf6PGDC281S and Pf6PGDW104L were created by 
using site-directed mutagenesis as described in chapter 3.1.5. For heterologous 
overexpression and purification of Pf6PGD mutants, the same protocol was used as for the wt 
enzyme, resulting in comparable yield and purity (chapter 4.3.1). For oligomerization behavior 
and kinetic characterization of the mutant enzymes, see chapters 4.3.4 and 4.3.5, respectively 
(Haeussler et al., 2018). 
 Pf   ---MCDIGLIGLAVMGQNLSLNISSKGFKIGVYNRTYERTEETMKRAKEE--NLVVYGYK 55 
 Tb   --MSMDVGVVGLGVMGANLALNIAEKGFKVAVFNRTYSKSEEFMKANASAPFAGNLKAFE 58 
 Gs   HMAKHQIGVIGLAVMGKNLALNIESKGYSVAVYNRLREKTDEFLQ-EA-K--GKNIVGTY 56 
 Sc   --MSADFGLIGLAVMGQNLILNAADHGFTVCAYNRTQSKVDHFLANEA-K--GKSIIGAT 55 
 Oa   -MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEA-K--GTKVLGAH 56 
 Hs   -MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEA-K--GTKVVGAQ 56 
           :..::**.*** ** **  .:*: : .:**i .: :. :           : .   
 
 Pf   TVEELINNLKKPRKVILLIKAGPAVDENISNILKHFEKGDIIIDGGNEWYINSERRIKLC 115 
 Tb   TMEAFAASLKKPRKALILVQAGAATDSTTEQLKKVFEKGDILVDTGNAHFKDQGRRAQQL 118 
 Gs   SIEEFVNALEKPRKILLMVKAGAPTDATIEQLKPHLEKGDIVIDGGNTYFKDTQRRNKEL 116 
 Sc   SIEDFISKLKRPRKVMLLVKAGAPVDALINQIVPLLEKGDIIIDGGNSHFPDSNRRYEEL 115 
 Oa   SLEEMVSKLKKPRRIILLVKAGQAVDNFIEKLVPLLDIGDIIIDGGNSEYRDTMRRCRDL 116 
 Hs   SLKEMVSKLKKPRRIILLVKAGQAVDDFIEKLVPLLDTGDIIIDGGNSEYRDTTRRCRDL 116 
      ::: :   *::**: :::::** ..*   .::   :: ***::* **  : :  ** .   
 
 Pf   KEKDVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDCVKEILEKCSAQ-VGNSPCVTYIGP 174 
 Tb   EAAGLRFLGMGISGGEEGARKGPAFFPGGTLSVWEEIRPIVEAAAAKADDGRPCVTMNGS 178 
 Gs   AELGIHFIGTGVSGGEEGALKGPSIMPGGQKEAHELVRPIFEAIAAK-VDGEPCTTYIGP 175 
 Sc   KKKGILFVGSGVSGGEEGARYGPSLMPGGSEEAWPHIKNIFQSISAK-SDGEPCCEWVGP 174 
 Oa   KDKGILFVGSGVSGGEDGARYGPSLMPGGNKEAWPHIKAIFQGIAAKVGTGEPCCDWVGD 176 
 Hs   KAKGILFVGSGVSGGEEGARYGPSLMPGGNKEAWPHIKTIFQGIAAKVGTGEPCCDWVGD 176 
         .: ::. *:**** **  * :::***   .   :: *.:  :*:   . **    *  
 
 Pf   GSSGNYVKMVHNGIEYGDMQLISESYVIMKHILKYDNQKLSEVFNKWNE-GILNSYLIEI 233 
 Tb   GGAGSCVKMYHNSGEYAILQIWGEVFDILR-AMGLNNDEVAAVLEDWKSKNFLKSYMLDI 237 
 Gs   DGAGHYVKMVHNGIEYGDMQLIAEAYFLLKHVLGMDAAELHEVFADWNK-GELNSYLIEI 234 
 Sc   AGAGHYVKMVHNGIEYGDMQLICEAYDIMKRLGGFTDKEISDVFAKWNN-GVLDSFLVEI 233 
 Oa   DGAGHFVKMVHNGIEYGDMQLICEAYHLMKDVLGLGHKEMAKAFEEWNK-TELDSFLIEI 235 
 Hs   EGAGHFVKMVHNGIEYGDMQLICEAYHLMKDVLGMAQDEMAQAFEDWNK-TELDSFLIEI 235 
       .:*  *** **. **. :*:  * : :::        ::  .: .*:.   *.*::::* 
 
 Pf   TANILAKKDDLTNNYLVDMILDIAGAKGTGKWTMLEATERGIPCPTMCAALDARNISVFK 293 
 Tb   SIAAA-RAKDKDGSYLTEHVMDRIGSKGTGLWSAQEALEIGVPAPSLNMAVVSRQFTMYK 296 
 Gs   TADIFTKIDEETGKPLVDVILDKAGQKGTGKWTSQNALDLGVPLPIITESVFARFLSAMK 294 
 Sc   TRDIL-KFDDVDGKPLVEKIMDTAGQKGTGKWTAINALDLGMPVTLIGEAVFARCLSALK 292 
 Oa   TASIL-KFQDADGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLK 294 
 Hs   TANIL-KFQDTDGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLK 294 
      :     : .:  .. *   : *  * **** *:  .* : *:*   :i :: :* ::  * 
 
 Pf   ELRTKAESNFNKDNILIDPNEDLNDF----ENDLLNALYCCKIISYTQGLFLLKQVSEEM 349 
 Tb   TERQANASNAPGITQSPGYTLKNKSPSGPEIKQLYDSVCIAIISCYAQMFQCLREMDKVH 356 
 Gs   DERVKASKVLAGPAVKP-FEGDRAHF----IEAVRRALYMSKICSYAQGFAQMKAASEEY 349 
 Sc   NERIRASKVLPGPEVPKDAVKDREQF----VDDLEQALYASKIISYAQGFMLIREAAATY 348 
 Oa   DERIQASKKLKGPQNIP-FEGDKKSF----LEDIRKALYASKIISYAQGFMLLRQAATEF 349 
 Hs   DERIQASKKLKGPQKFQ-FDGDKKSF----LEDIRKALYASKIISYAQGFMLLRQAATEF 349 
        *    .             .         . :  ::  . * .*:* :  ::       
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 Pf   NWKLNLGEIARIWRGGCIIRAVFLDRIANAYKNNEKLELLFLDNEFSDDIKNKLPSLRKI 409 
 Tb   NFGLNLPATIATFRAGCILQGYLLKPMTEAFEKNPNISNLMCA--FQTEIRAGLQNYRDM 414 
 Gs   NWNLRYGDIAMIFRGGCIIRAQFLQKIKEAYDRDPALSNLLLDSYFKDIVERYQDALREI 409 
 Sc   GWKLNNPAIALMWRGGCIIRSVFLGQITKAYREEPDLENLLFNKFFADAVTKAQSGWRKS 408 
 Oa   GWTLNYGGIALMWRGGCIIRSVFLGKIKDAFDRNPGLQNLLLDDFFKSAVENCQDSWRRA 409 
 Hs   GWTLNYGGIALMWRGGCIIRSVFLGKIKDAFDRNPELQNLLLDDFFKSAVENCQDSWRRA 409 
      .: *.       :*.***::. :*  : .*: .:  :. *:    *   :       *   
 
 Pf   VLM-ATKYSIPIPAFSASLAYFQMVTSQ-NLPLNLVQAQRDYFGSHTYRRTDRE------ 461 
 Tb   VALITSKLEVSIPVLSASLNYVTAMFTPTLKYGQLVSLQRDVFGRHGYERVDKDGR---- 470 
 Gs   VAT-AAMRGIPVPGSASALAYYDSYRTA-VLPANLIQAQRDYFGAHTYERVDKE------ 461 
 Sc   IAL-ATTYGIPTPAFSTALSFYDGYRSE-RLPANLLQAQRDYFGAHTFRVLPECASDNLP 466 
 Oa   IST-GVQAGIPMPCFTTALSFYDGYRHA-MLPANLIQAQRDYFGAHTYELLAKP------ 461 
 Hs   VST-GVQAGIPMPCFTTALSFYDGYRHE-MLPASLIQAQRDYFGAHTYELLAKP------ 461 
      :        :  *  :::* :            .*:. *** ** * :.   .        
 
 Pf   --GNYHTLW-------------- 468 
 Tb   ----ESFQWPELQ---------- 479 
 Gs   --GIFHTEWLK------------ 470 
 Sc   VDKDIHINWTGHGGNVSSSTYQA 489 
 Oa   -GQFIHTNWTGHGGSVSSSSYNA 483 
 Hs   -GQFIHTNWTGHGGTVSSSSYNA 483 
              *               
Figure 24. Amino acid alignment of 6PGDs from different species 
Residue C281 (green) forming a disulfide bridge with C281 of the second subunit, W104 interacting with W265 
(magenta), and R36 (yellow) involved in NADP+ binding are specific for Plasmodium. In contrast, all residues 
involved in 6PG binding are conserved (cyan), other residues involved in NADP+ binding (gray) and the flexible 
loop (boxes) are similar in most species. Pf: Plasmodium falciparum (UniProtKB - Q8IKT2); Tb: Trypanosoma 
brucei (UniProtKB - P31072); Gs: Geobacillus stearothermophilus (UniProtKB - I3NI58); Sc: Saccharomyces 
cerevisiae (UniProtKB - P38720); Oa: Ovis aries (UniProtKB - P00349); Hs: Homo sapiens (UniProtKB - P52209). * 
Identical residues, : very similar residues, . similar residues. 
4.3.3.2 Substrate binding site of Pf6PGD 
The binding site for 6PG is located in a pocket of domain 2, but residues from domain 1 and 
the C-terminal tail are also involved in binding the substrate (Figure 25a). The carboxyl-group 
of 6PG is hydrogen bonded by S128 and G129 (both from domain 1), the gluconate moiety 
interacts with N102 (domain 1), K182, H185, N186, E189, (domain 2) and H453’ of the adjacent 
subunit (C-terminal tail). The oxygens of the phosphate group are hydrogen bonded with 
R287, Y190 (domain 2), and R447’ (C-term), respectively. A flexible loop comprising residues 
255-262 borders one site of the substrate binding pocket; the sidechain of K260 stacks against 
the substrate. This lysine is conserved in many species (Figure 24) (Haeussler et al., 2018). 
In the native structure, one molecule of PEG is located in the binding pocket in a position 
similar to the binding of 6PG; however, the binding is mainly hydrophobic. Interestingly, 
superimposition of the apo-Pf6PGD structure and in complex with 6PG shows that the flexible 
loop (residues 255-262) bordering the 6PG binding site has a more open conformation in the 
apoenzyme structure (Figure 25b); therefore, the substrate binding pocket seems to be more 
easily accessible in the apo and NADP+ structures and less accessible in the 6PG complex. Also 
K260, which interacts with 6PG once it is bound, adopts a different conformation with an open 
active site loop (Haeussler et al., 2018). 
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Figure 25. Substrate binding site of Pf6PGD 
(a) 6PG as seen in the Pf6PGD structure complexed with substrate. The flexible active site loop comprises amino 
acids 255-262 (magenta). Hydrogen bonds between 6PG and the enzyme are shown by tiny black spirals. (b) In 
apo-Pf6PGD, the substrate binding site is occupied by a PEG molecule. Superimposition of apo-Pf6PGD (green) 
and the structure in complex with 6PG (gray) shows that the active site loop adopts an open conformation 
without 6PG bound, and a closed conformation with 6PG bound (colored blue and magenta, respectively) 
(Haeussler et al., 2018). 
4.3.3.3 Cofactor binding site of Pf6PGD 
 
Figure 26. Cofactor binding site of Pf6PGD 
NADP+ is covered by a composite omit map at 2.9 Å resolution. Structures in complex with NADP+ (amber) and 
6PG (gray) are superimposed; residues with different conformations in the two structures are labeled twice. 
Hydrogen bonds are indicated by tiny black spirals (Haeussler et al., 2018). 
The binding site for NADP+ is located in a cleft of domain 1 and is highly conserved within the 
6PGD family (Figure 26). As mentioned above (4.3.3), NADP+ is only partially defined by 
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electron density; only the adenine moiety and the three phosphate groups were visible, but 
not the ribose and the nicotinamide moiety, implying flexibility of the molecule. The 
phosphate groups showed a different conformation in the two subunits. Amino acids A10-
M12, N31, R32, T33, and R36 form the binding pocket on one side, and residues A79, L73, I74, 
and K75 on the other side. One phosphate of NADP+ interacts with R32, whose guanidinium 
group stacks against the adenine (see also 4.3.5). Superimposition of Pf6PGD in complex with 
6PG and in complex with NADP+ shows that R32 and R36 adopt a different conformation upon 
ligand binding (Figure 26). While most of the pocket residues are strictly conserved, R36 is 
replaced by a lysine in mammals and bacteria (Figure 24) (Haeussler et al., 2018). 
4.3.4 Oligomerization behavior of Pf6PGD, mutants and h6PGD 
The oligomerization behavior of native, reduced, and oxidized Pf6PGD wt, as well as in the 
presence of the product NADPH, was studied using size exclusion chromatography. Under all 
conditions tested, Pf6PGD wt eluted after 79 mL, corresponding to a molecular mass of 
approximately 78 kDa (Figure 27a-d). The theoretical mass of the Pf6PGD dimer is with 
108 kDa larger than 78 kDa; however, it is clearly larger than a monomeric enzyme with 
54 kDa. Proteins tend to elute from size exclusion chromatography with a smaller than 
theoretical mass; therefore, the presence of a Pf6PGD dimer is most likely. Recombinant 
h6PGD eluted after 78 mL as a dimer with a molecular mass of 84 kDa (Figure 27g) (Haeussler 
et al., 2018). 
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Figure 27. Size exclusion chromatography of Pf6PGD and h6PGD 
Pf6PGD wt eluted from the size exclusion chromatography column after approximately 79 mL as a dimer of 
78 kDa under all conditions tested (native (a), reduced (b), oxidized (c), and in the presence of NADPH (d)). 
Similarly, mutants Pf6PGDC281S (e) and Pf6PGDW104L (f) eluted after 79 mL as 78 kDa dimers, and h6PGD after 
78 mL as an 84 kDa dimer (g). The additional peaks resulted from proteins that could not be removed using 
affinity chromatography. 
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4.3.5 Kinetic characterization of Pf6PGD wt, mutants, and h6PGD 
The reduction of NADP+ to NADPH was measured to determine the kinetic parameters of the 
enzymes. Pf6PGD wt showed a specific activity of 8.0 ± 1.8 U∙mg-1 and KM values of 11.3 ± 
2.7 µM for 6PG and 9.0 ± 4.2 µM for NADP+. The kcat values were determined to be 7.1 ± 
2.5 sec-1 for 6PG and 7.6 ± 2.2 sec-1 for NADP+ (Table 16). Representative Michaelis-Menten 
curves are shown in Figure 28. The crystal structure of Pf6PGD wt revealed two interactions 
that can only be found in Plasmodium: a disulfide bridge between the Plasmodium-specific 
cysteines C281 of the two monomers and an interaction between the Plasmodium-specific 
W104 and the highly conserved W265 (4.3.3.1). In order to investigate a potential impact upon 
catalysis, site-directed mutagenesis was performed, creating the mutants Pf6PGDC281S and 
Pf6PGDW104L. All kinetic parameters of the mutants – especially the KM for 6PG of Pf6PGDW104L 
– were slightly lower than those of the wt enzyme (Table 16). The interaction of W104 and 
W265 most likely supports the rearrangement of the initially only partially bound NADP+ by 
linking the cofactor domain with the substrate binding pocket domain. This interaction is 
disturbed in Pf6PGDW104L, resulting in decreased kinetic parameters (Haeussler et al., 2018). 
The mechanistic reason for the slightly decreased kinetic parameters of Pf6PGDC281S is so far 
unclear. 
Table 16. Kinetic characteristics of Pf6PGD wt, Pf6PGDC281S, Pf6PGDW104L, and h6PGD 
Each value is a mean value ± SD from at least three independent determinations. 
 Pf6PGD wt Pf6PGDC281S Pf6PGDW104L h6PGD 
Specific activity [U∙mg-1] 8.0 ± 1.8 5.0 ± 0.4 5.8 ± 0.9 22.1 ± 1.2 
KM 6PG [µM] 11.3 ± 2.7 8.4 ± 1.8 5.8 ± 0.8 33.7 ± 7.1 
KM NADP+ [µM] 9.0 ± 4.2 4.7 ± 1.0 4.8 ± 0.8 6.9 ± 2.0 
kcat 6PG [sec-1] 7.1 ± 2.5 5.0 ± 0.6 5.2 ± 0.3 22.2 ± 0.3 
kcat NADP+ [sec-1] 7.6 ± 2.2 4.8 ± 0.6 5.7 ± 0.6 21.4 ± 0.8 
 
One aim of this thesis was to find inhibitors for Pf6PGD. The human homolog h6PGD was used 
to test the identified inhibitors for selectivity. Prior to inhibitor testing, the recombinant 
h6PGD was shown to have a higher specific activity than the plasmodial enzyme (22.1 ± 1.2 
U∙mg-1) and KM values of 33.7 ± 7.1 µM for 6PG and 6.9 ± 2.0 µM for NADP+. Notably, the kcat 
values 21.4 ± 0.8 sec-1 for NADP+ and 22.2 ± 0.3 sec-1 for 6PG were substantially higher than 
the corresponding values for Plasmodium (Table 16) (Haeussler et al., 2018). 
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Figure 28. KM determinations for 6PG and NADP+ of 6PGD 
Representative Michaelis-Menten curves (mean values ± SD of three measurements) for the KM determinations 
for 6PG and NADP+ of Pf6PGD wt (a, b), Pf6PGDC281S (c, d), Pf6PGDW104L (e, f), and h6PGD (g, h). The KM values are 
shown as mean values ± SD of three independent determinations (see also Table 16). 
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Test of NAD+ as an alternative cofactor 
NAD+ was tested as an alternative cofactor for Pf6PGD wt and h6PGD. For Plasmodium, the 
measurements revealed an activity of 8.0 U∙mg-1 using 100 µM NADP+ (Table 16), but was 
below the detection limit of the spectrophotometer of 0.001 ΔA∙min-1 using 100 µM NAD+. 
The highest NAD+ concentration tested was 2.5 mM, resulting in a Pf6PGD activity between 
0.0 and 1.1 U∙mg-1, depending on the batch of enzyme. Therefore, it was concluded that 
Pf6PGD is specific for NADP+. Similarly, h6PGD did not show any activity at the tested NAD+ 
concentrations (0.05-2.5 mM). Structural analysis revealed for Plasmodium that the specificity 
is most likely due to the interaction of the negatively charged phosphates from NADP+ with 
the positively charged arginine residues R32 and R36 (Figure 26). In NAD+, this negative charge 
is missing and prevents NAD+ from binding to Pf6PGD (Haeussler et al., 2018). 
Mechanistic considerations 
Because it was possible to crystallize Pf6PGD in complex with 6PG and with NADP+, it can be 
assumed that substrate and cofactor can bind independently from each other. This 
observation was confirmed enzymatically using the assay described in chapter 3.3.6. Thereby, 
NADP+ and 6PG were titrated at different fixed concentrations of the substrate/cofactor, and 
the relationship between initial enzyme velocity and substrate concentrations was analyzed 
in Lineweaver-Burk plots. The intersections left of the ordinates point towards a sequential 
mechanism (Figure 29), meaning that both substrate and cofactor have to bind before the 
product formation can be initiated (Haeussler et al., 2018). 
 
Figure 29. Sequential enzyme mechanism of Pf6PGD 
The substrate 6PG (a) and the cofactor NADP+ (b) were titrated at different fixed concentrations of the 
cofactor/substrate. The Lineweaver-Burk plots intersect left of the ordinate, pointing towards a sequential 
enzyme mechanism (Haeussler et al., 2018). 
4.3.6 Crystallization trials of Pf6PGD mutants 
To investigate potential impacts of the mutations on Pf6PGD structure, the mutants were 
crystallized under similar conditions as found for native wt enzyme (Figure 30). However, the 
stability of the crystals was very low, therefore it was not possible to assemble them for X-ray 
diffraction analysis. Further crystallization trials need to be performed to elucidate potential 
impacts of the mutations on the overall structure of Pf6PGD. 
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Figure 30. Crystals of Pf6PGDW104L and Pf6PGDC281S 
Pf6PGD mutants were crystallized at 4 °C using the sitting drop approach. (a) 15 mg∙mL-1 Pf6PGDW104L, 24% (v/v) 
PEG 3,350, 0.2 M ammonium sulfate, 4 mM 6PG. (b) 8.3 mg∙mL-1 Pf6PGDC281S, 30% (v/v) PEG 4,000, 0.1 M sodium 
citrate, pH 5.6, 0.05 M ammonium sulfate, 4 mM 6PG. 
4.4 Post-translational modification of cysteines 
The two PTMs, protein S-glutathionylation and S-nitrosation, are – amongst other functions – 
important regulators of enzyme activity (Belcastro et al., 2017; Jortzik et al., 2012). Therefore, 
the effects of these two modifications on enzymes of the oxidative PPP from P. falciparum and 
P. vivax were studied within this thesis. 
4.4.1 S-glutathionylation 
4.4.1.1 S-glutathionylation studies on PfGluPho, PfG6PD, and PvG6PD 
PfGluPho and the G6PD parts of P. falciparum and P. vivax GluPho were reduced and 
afterwards incubated with 0-10 mM GSSG, followed by removal of unbound glutathione via 
desalting. Potential S-glutathionylation of the enzymes was visualized with Western blot 
analysis using an anti-glutathione antibody. As shown in Figure 31, neither PfGluPho nor the 
two G6PDs showed a signal at concentrations up to 6 mM GSSG. At 10 mM GSSG, the proteins 
precipitated visibly during sample preparation; therefore, it was not possible to apply 
sufficient amounts of the protein to Western blot analysis, resulting in a lack of protein bands 
in the Ponceau stains (right side of Figure 31). The result indicates that none of the three 
enzymes are prone to regulation via S-glutathionylation under the tested conditions. 
In contrast to this finding, it has been stated previously that the G6PD activity of PfGluPho is 
redox-regulated via S-glutathionylation (Jortzik et al., 2011). Therefore, it was tested whether 
such a feigned redox-regulation can be observed for PvG6PD as well. Prereduced PvG6PD was 
incubated with 0-10 mM GSSG for 15 min at 37 °C before the activity was measured using the 
assay described in chapter 3.3.6. Indeed, PvG6PD activity decreased dramatically at very high 
GSSG concentrations (Figure 32a), as shown before for PfGluPho (Figure 32b). However, since 
Western blot analysis clearly showed that none of the three tested enzymes were 
S-glutathionylated, and Ponceau staining showed a lack of protein bands at 10 mM GSSG 
(Figure 31), the loss of activity is likely based on a loss of conformation rather than redox-
regulation. This is further supported by the fact that adding DTT could not restore the activity 
of the samples (data not shown). 
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Figure 31. Western blot analysis of S-glutathionylation of PfGluPho, PfG6PD, and PvG6PD 
Prereduced enzymes were incubated with 0-10 mM GSSG for 10 min at 37 °C; potential S-glutathionylation was 
detected via Western blot analysis using an anti-glutathione antibody. The reversibility of potential 
S-glutathionylation was studied by reducing SDS-PAGE with DTT. Samples of S-glutathionylated PfPrx1a were 
prepared in parallel as a positive control. PfPrx1a exists in a dimeric form without DTT, while adding DTT shifts 
the conformation to a monomeric form. Ponceau staining of the membrane used for Western blotting served as 
a loading control. Representative blots from at least two independent experiments are shown. Pos. ctrl.: positive 
control. 
 
Figure 32. Activity of S-glutathionylated PvG6PD and PfGluPho 
(a) Reduced PvG6PD was incubated with different concentrations of GSSG (0-10 mM) for 15 min, activity of the 
sample incubated with 0 mM GSSG was defined as 100%. Values shown are mean values ± SD from three 
determinations. (b) Activity of PfGluPho after incubation with different GSSG concentrations. Panel (b) was taken 
from Jortzik et al., 2011 for comparison. 
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4.4.1.2 S-glutathionylation studies of Pf6PGD 
Western blot analysis 
Pf6PGD wt was reduced, S-glutathionylated, and afterwards subjected to Western blot 
analysis as described above (4.4.1.1). Figure 33a indicates that GSSG does not 
S-glutathionylate Pf6PGD under the tested conditions. To ensure application of comparable 
protein quantities to each lane, the anti-glutathione antibody was removed from the 
membrane, and 6xHis-tagged proteins were detected using an anti-6xHis-tag antibody. As 
shown in Figure 33b, all lanes contained the same amounts of Pf6PGD except for the sample 
treated with 10 mM GSSG, most likely caused by precipitation of the protein in the presence 
of high GSSG concentration (see kinetic analysis below) (Haeussler et al., 2018). 
 
Figure 33. Western blot analysis of S-glutathionylation of Pf6PGD 
(a) S-glutathionylated protein was detected using an anti-glutathione antibody. Reducing SDS-PAGE was used to 
study the reversibility of the modification. S-glutathionylated PfPrx1a served as a positive control. (b) After 
chemiluminescence detection, the anti-glutathione antibody was removed from the membrane used in panel 
(a), and the His-tagged proteins were detected using an anti-6xHis-tag antibody. Pos. ctrl.: positive control 
(Haeussler et al., 2018). 
Impacts of S-glutathionylation on Pf6PGD activity 
To fully exclude a regulation of Pf6PGD by S-glutathionylation, the reduced enzyme was 
incubated with different GSSG concentrations, followed by activity determination. Incubation 
of reduced Pf6PGD wt with up to 8 mM GSSG had no impact on enzyme activity (Figure 34); 
in contrast, 10 mM GSSG resulted in an immediate and complete loss of Pf6PGD activity. This 
observation is in accordance with the likely precipitation of the protein observed in the anti-
6xHis-tag Western blot (Figure 33b). Recovery of the activity by adding 5 mM DTT was not 
successful, indicating that high GSSG levels led to an irreversible change in Pf6PGD 
conformation (Haeussler et al., 2018). 
 
Figure 34. Activity of S-glutathionylated Pf6PGD 
Reduced Pf6PGD wt was incubated with different concentrations of GSSG (0-10 mM) for 15 min; activity of the 
sample incubated with 0 mM GSSG was defined as 100%. Values shown are mean values ± SD from two 
independent determinations, each including three measurements. 
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4.4.2 S-nitrosation 
S-nitrosation is considered an important mediator of redox regulation (Jortzik et al., 2012). In 
2014, our group performed a large-scale proteomic analysis to identify targets of protein 
S-nitrosation in P. falciparum parasite lysate after treatment with S-nitrosoglutathione 
(GSNO). Interestingly, PfGluPho and Pf6PGD were found to be likely targets of S-nitrosation 
(Wang et al., 2014); therefore, one aim of this thesis was to confirm the accessibility of these 
enzymes, including the P. vivax homolog to S-nitrosation, and to study the potential functional 
effects of this important post-translational modification. As an NO donor, we used the 
physiologically relevant nitrosating agent GSNO. This small-molecular-weight S-nitrosothiol is 
able to release NO and transnitrosate proteins (Broniowska et al., 2013; Hess et al., 2005). 
4.4.2.1 S-nitrosation studies on PfGluPho, PfG6PD, and PvG6PD 
To study the susceptibility of PfGluPho, PfG6PD, and PvG6PD to S-nitrosation, reduced 
enzymes were incubated with 1 mM GSNO and subjected to the biotin-switch assay followed 
by Western blot analysis using an anti-biotin antibody. Samples without GSNO and/or without 
sodium ascorbate were prepared in parallel as controls. As shown in Figure 35a, samples 
treated with 1 mM GSNO and sodium ascorbate resulted in a prominent signal for all three 
enzymes, indicating that they are targets of S-nitrosation. 
To elucidate whether the modification has an impact on the activity of PfGluPho, PfG6PD, and 
PvG6PD, the enzymes were incubated with different GSNO concentrations, and the activity 
was measured at various time points. As shown in Figure 35b, the impact was with a maximal 
inhibition of only 20-25% marginal. Since there is no major difference in Western blot and 
kinetic analyses between PfGluPho and PfG6PD, it can be assumed that at least some of the 
S-nitrosation sites of PfGluPho are located in the G6PD part. After 3 h, 5 mM DTT was added 
to the samples incubated with 1,000 µM GSNO to study the reversibility of the modification; 
the enzymes did not regain full activity (PfGluPho: 91.3 ± 9.5%, PfG6PD: 81.7 ± 9.6%, PvG6PD: 
79.2 ± 6.5%), indicating that they are not extensively regulated via S-nitrosation. 
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Figure 35. Analysis of S-nitrosation of PfGluPho, PfG6PD, and PvG6PD 
(a) Reduced enzymes were incubated with 1 mM GSNO for 1 h at 22 °C in the dark and subjected to the biotin-
switch assay. Controls without sodium ascorbate and/or GSNO were prepared in parallel. S-nitrosated proteins 
were detected indirectly with Western blot analysis using an anti-biotin antibody. Coomassie staining of the 
samples served as a loading control. Representative blots from at least two independent experiments are shown. 
(b) To study the impact of S-nitrosation on enzyme activity, reduced enzymes were incubated with different 
concentrations of GSNO for 180 min at 22 °C in the dark. Activity of the samples was measured at different time 
points. Activity of the sample with 0 µM GSNO was defined as 100%. Values shown are mean values ± SD from 
at least three independent determinations. 
4.4.2.2 S-nitrosation studies on Pf6PGD 
Western blot analysis 
To test the susceptibility of Pf6PGD to S-nitrosation, samples were prepared as described 
above (chapter 4.4.2.1). The sample treated with 1 mM GSNO and sodium ascorbate resulted 
in a prominent signal (Figure 36a). As a loading control, the anti-biotin antibody was removed 
and an anti-6xHis-tag Western blot was performed, showing that – especially for the controls 
treated without GSNO – Pf6PGD was indeed applied to each lane (Figure 36b) (Haeussler et 
al., 2018). 
81 
 Results 
 
Figure 36. Western blot analysis of S-nitrosation on Pf6PGD 
(a) S-nitrosated protein was indirectly detected after a biotin-switch assay by using an anti-biotin antibody. 
Samples without sodium ascorbate were prepared in parallel as a control. (b) As a loading control after 
chemiluminescence detection, the anti-biotin antibody was removed from the membrane used in panel (a); 
afterwards, 6xHis-tagged proteins were detected using an anti-6xHis-tag antibody (Haeussler et al., 2018). 
Impacts of S-nitrosation on Pf6PGD activity 
To investigate the impact of S-nitrosation on Pf6PGD activity, enzyme activity was determined 
after incubation with different GSNO concentrations. The downregulation of Pf6PGD activity 
increased with increasing GSNO concentrations and longer incubation periods. The maximal 
inhibition of approximately 65% was reached after incubation with 1,000 µM GSNO for 90 min 
(Figure 37). Upon removal of the S-nitrosation caused by the highest GSNO concentration via 
reduction with 5 mM DTT, Pf6PGD wt regained 100% activity (99.4 ± 3.3%), showing the full 
reversibility and potential redox-regulatory function of the modification (Haeussler et al., 
2018). 
 
Figure 37. Time and concentration-dependent inhibition of Pf6PGD via S-nitrosation 
Reduced Pf6PGD wt was incubated with different concentrations of GSNO (0-1,000 µM) for up to 180 min. 
Activity of each sample was measured directly after adding GSNO and at different time points. Activity of the 
sample with 0 µM GSNO was defined as 100%. Values shown are mean values ± SD from three independent 
determinations (Haeussler et al., 2018). 
MALDI-TOF MS analysis of S-nitrosated Pf6PGD 
Since S-nitrosation results in a time and concentration-dependent inhibition of Pf6PGD, there 
was the hypothesis that the modification of specific cysteine residues close to the binding sites 
might be involved in the regulation of this enzyme. Numerous samples treated with different 
GSNO concentrations were prepared, and modified cysteine residues were identified via 
MALDI-TOF MS. Surprisingly, all eleven cysteines of Pf6PGD seemed to be accessible to 
S-nitrosation; no specific modification pattern could be determined (Haeussler et al., 2018). 
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Crystallization trials of S-nitrosated Pf6PGD 
Since MALDI-TOF MS did not reveal a specific pattern of S-nitrosation sites, Pf6PGD was 
crystallized after S-nitrosation with 1 mM GSNO to structurally identify the binding sites. 
Before crystallization it was ensured that the activity of the enzyme was indeed 
downregulated. Crystals were obtained under the same conditions as in complex with 6PG 
(JCSG Core II Suite, E11: 24% (w/v) PEG 1,500, 20% glycerol, Figure 38). However, the 
resolution of 3.2 Å was not sufficient, a resolution of at least 2.5 Å would be necessary to 
identify NO-modified cysteine residues; therefore, further experiments need to be conducted 
to identify residues that are responsible for regulation. 
 
Figure 38. Crystals of S-nitrosated Pf6PGD wt 
S-nitrosated Pf6PGD wt crystallized in sitting drops at 8.4 mg∙mL-1 protein, 24% (w/v) PEG 1,500, and 20% glycerol 
(JCSG Core II Suite, E11). 
4.5 Assessment of enzyme inhibitors 
The electron donor NADPH is of essential importance to maintain the cellular redox balance 
of Plasmodium parasites (summarized in chapter 1.2.3). Enzymes of the oxidative PPP as the 
main source of NADPH are therefore considered promising targets for the development of 
antimalarial drugs, as already proven for PfGluPho (Allen et al., 2015). One aim of this thesis 
was to characterize the effect of different compounds on PfGluPho, Pf6PGD, and PvG6PD. 
4.5.1 Ellagic acid 
Ellagic acid (EA) is a phenolic lactone that was identified to be an active component of 
traditional West African medicine to treat malaria (Soh et al., 2009). The structures of EA and 
its two derivatives flavellagic acid (FEA) and coruleoellagic acid (CEA) are shown in Figure 39 
(Sturm et al., 2009). 
 
Figure 39. Structures of ellagic acid and its derivatives flavellagic acid and coruleoellagic acid 
The figure was modified from Sturm et al., 2009. 
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Similar to PfGluPho with an IC50 of 77 ± 22 nM (Allen et al., 2015), EA inhibits PvG6PD with an 
IC50 of 32.5 ± 13.4 nM (Figure 40a) as determined within my master thesis. Moreover, FEA and 
CEA inhibit PvG6PD in the same range, with IC50 values of 37.2 ± 5.8 nM and 44.4 ± 1.9 nM, 
respectively (Figure 40b, c; Haeussler, 2015). 
 
Figure 40. IC50 values of ellagic acid, flavellagic acid, and coruleoellagic acid for PvG6PD 
The IC50 values of ellagic acid (a), flavellagic acid (b), and coruleoellagic acid (c) for PvG6PD were determined 
under substrate saturation. Given are mean values ± SD of at least four measurements. 
The mode of inhibition of PvG6PD by EA was determined to be a mixed type inhibition against 
both G6P and NADP+ (Figure 41). This is identical with the type of inhibition determined for 
PfGluPho (Allen et al., 2015). 
 
Figure 41. Mode of inhibition of PvG6PD by ellagic acid 
The Lineweaver-Burk plots for titration of G6P (a) or NADP+ (b) show that high ellagic acid concentrations result 
in low Vmax values and increased KM values. This indicates that ellagic acid acts as a mixed-type inhibitor of PvG6PD 
with respect to both G6P and NADP+. Representative graphs from four independent determinations are shown. 
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Reversibility of the PfGluPho inhibition by EA 
Within this thesis, the reversibility of the inhibition of PfGluPho by EA was tested. The enzyme 
was incubated with a high EA concentration (10 µM), and afterwards diluted to a 
concentration of 10 nM, which is below IC50. The activity of the undiluted sample was 
0.0 U·mg-1, showing that 10 µM EA completely inhibited PfGluPho. The activity of the diluted 
sample was 1.3 ± 0.2 U·mg-1. Control samples containing either no EA or 10 nM EA (the 
concentration remaining after dilution) were prepared in parallel. The control without EA had 
an activity of 1.4 ± 0.1 U·mg-1, the control containing EA had 1.3 ± 0.2 U·mg-1, the identical 
activity as the sample incubated with a high EA concentration. This clearly shows that the 
inhibition of PfGluPho by EA is fully reversible (Allen et al., 2015). The generally low PfGluPho 
activity might be caused by an activity loss during the incubation period. 
4.5.2 ML304 
ML304 was identified as a selective inhibitor for PfGluPho via a high-throughput screening of 
the MLSMR chemical library, the structure is shown in Figure 42. With an IC50 of 190 nM for 
PfGluPho and 80 µM for hG6PD, its effect is highly selective for Plasmodium (Maloney et al., 
2012). 
 
Figure 42. Structure of ML304 
(Maloney et al., 2012) 
This promising compound was therefore tested on PvG6PD. Under conditions of substrate 
saturation, ML304 inhibited PvG6PD with an IC50 of 15.3 ± 0.9 µM. Application of substrate 
and cofactor in concentrations close to the KM values of PvG6PD resulted in a lower IC50 of 2.6 
± 0.8 µM (Figure 43). 
 
Figure 43. IC50 determination of ML304 for PvG6PD 
The IC50 of ML304 for PvG6PD was determined under substrate saturation (red) and under substrate 
concentrations close to KM values (blue). The IC50 is clearly shifted to a lower compound concentration when the 
substrates are added at KM concentrations. Representative determinations (mean values ± SD) including four 
(red) and eight (blue) measurements are shown. 
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This change in IC50 depending on the substrate concentration was confirmed by mode of 
inhibition studies, which showed that ML304 acts as a competitive inhibitor towards G6P for 
both PvG6PD and PfGluPho (Ki = 0.7 ± 0.3 µM for PvG6PD) and as a mixed type inhibitor 
towards NADP+ for PvG6PD (Ki = 16.3 ± 8.8 µM), while it acts as a non-competitive inhibitor 
for PfGluPho (Figure 44). 
 
Figure 44. Mode of inhibition of PvG6PD and PfGluPho by ML304 
(a, c) Most likely, ML304 acts as a competitive inhibitor with respect to G6P for both enzymes. The higher the 
concentration of ML304, the higher the KM values of both enzymes for G6P were, while Vmax stayed constant. (b) 
With respect to NADP+, ML304 acts as a mixed type inhibitor on PvG6PD (d) and as a non-competitive inhibitor 
on PfGluPho. 
4.5.3 The novel ML304 derivative SBI-0797750 
To further improve the efficiency of compound ML304 (4.5.2), the structure-activity-
relationship was analyzed at the Sanford Burnham Prebys Medical Discovery Institute (SBP), 
La Jolla, CA, USA. Within this thesis, 85 novel compound formulations derived from these 
analyses were tested against PfGluPho, PvG6PD, and hG6PD in high-throughput screening 
assay format. The structures of the compounds are not shown due to ongoing patenting 
processes. 
4.5.3.1 Adjustment of the diaphorase-coupled assay to PvG6PD 
For PfGluPho and hG6PD, the diaphorase-coupled assay was used as described in Preuss et 
al., 2012a and Preuss et al., 2013 with minor modifications. Within this thesis, the same assay 
was used for PvG6PD for the first time; therefore, the assay concentrations had to be adjusted 
to the P. vivax enzyme. 
Determination of appropriate G6P and NADP+ concentrations for PvG6PD 
For the assessment of the compounds, substrate and cofactor were added in concentrations 
close to KM to allow the identification of competitive inhibitors. Prior to compound 
characterization, the KM values were redetermined in high-throughput screening assay format 
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(final assay volume of up to 8 µL; the minimum final assay volume used elsewhere in this thesis 
was 75 µL). The KM for NADP+ was in good accordance with the previously determined value, 
while the KM for G6P, 30 µM, was notably lower (Table 15, Figure 45); therefore, 30 µM G6P 
and 12 µM NADP+ were used for compound characterization on PvG6PD at SBP. 
 
Figure 45. KM determination for PvG6PD in high-throughput screening assay format 
The KM values for G6P (a) and NADP+ (b) of PvG6PD were determined in high-throughput screening assay format 
by using the orthogonal assay, measuring the fluorescence of NADPH. Michealis-Menten curves (mean values ± 
SD) of one determination each including eight measurements, are shown. RFU: relative fluorescence units. 
Determination of appropriate resazurin and diaphorase concentrations for PvG6PD 
To find the optimal resazurin concentration, PvG6PD activity was determined using the 
diaphorase-coupled assay with different resazurin concentrations. As observed in Preuss et 
al., 2012a, very high resazurin concentrations led to a decrease in fluorescence signal. The 
highest activity was reached by adding 60 µM resazurin (Figure 46a). Since this concentration 
is higher than the substrate concentrations used in the assay (30 µM G6P, 12 µM NADP+), it 
was ensured that resazurin was not limiting the reaction; therefore, 60 µM were used for the 
assessment of compounds on PvG6PD. Similarly, the activity was determined by adding 
varying diaphorase concentrations. Since there were no major differences in activity between 
the diaphorase concentrations (Figure 46b), 1 U·mL-1 was used as in the assays for PfGluPho 
and hG6PD. 
 
Figure 46. Determination of resazurin and diaphorase concentrations used in high-throughput assay format 
for PvG6PD 
PvG6PD activity was determined using the diaphorase-coupled assay with varying resazurin (a) and diaphorase 
(b) concentrations. Mean values ± SD of one representative determination, each including eight measurements, 
are shown. RFU: relative fluorescence units. 
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Determination of an appropriate PvG6PD concentration 
To find a PvG6PD concentration resulting in a linear signal increase for 2 h, activity was 
determined using different PvG6PD concentrations. At the same time, the signal increase 
should be as high as possible in order to ensure a good range for later enzyme inhibition. 
Therefore, a PvG6PD concentration of 0.15 µg·mL-1 was chosen (Figure 47). 
 
Figure 47. Determination of PvG6PD concentration used in high-throughput assay format 
PvG6PD activity was measured using the diaphorase-coupled assay. Mean values ± SD of one representative 
determination including eight measurements are shown. RFU: relative fluorescence units. 
4.5.3.2 IC50 determination on PfGluPho, PvG6PD, and hG6PD 
First, the IC50 values were determined by using the diaphorase-coupled assay, measuring the 
fluorescence of the product resorufin at ex530/em590. SBI-0797750 turned out to be the most 
promising compound, with an IC50 of 5.2 ± 1.4 nM for PfGluPho and 26.5 ± 7.3 nM for PvG6PD; 
the human homolog hG6PD was not inhibited at 79 µM SBI-0797750 as the highest 
concentration tested. For the seven most promising compounds, false positive results due to 
interactions with the diaphorase-coupled assay were excluded by measuring the IC50 values 
using the orthogonal assay directly detecting the fluorescence of NADPH. The orthogonal 
assay resulted in comparable IC50 values (Table 17), for SBI-0797750 of 6.7 ± 1.8 nM and 31.0 
± 3.1 for PfGluPho and PvG6PD, respectively (Figure 48a, b). The inhibition of hG6PD at 99 µM 
as the highest concentration tested was below 50% (Figure 48c). This difference clearly shows 
that the inhibition of SBI-0797750 is highly selective for the plasmodial enzymes. 
Table 17. IC50 values of the most promising novel compound formulations 
IC50 values were determined using the orthogonal assay. Values given are mean values ± SD from two 
determinations, each including two measurements. 
 PfGluPho [nM] PvG6PD [nM] hG6PD [nM] 
SBI-0786225 102.6 ± 18.5 195.6 ± 23.9 > 99,000 
SBI-0796683 10.1 ± 1.4 41.4 ± 3.6 > 99,000 
SBI-0797749 18.4 ± 2.2 100.7 ± 10.5 > 99,000 
SBI-0797750 6.7 ± 1.8 31.0 ± 3.1 > 99,000 
SBI-0797751 24.1 ± 2.1 142.6 ± 12.2 > 99,000 
SBI-0798044 16.0 ± 2.7 66.3 ± 6.0 > 99,000 
SBI-0799057 16.2 ± 1.7 72.2 ± 8.1 > 99,000 
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Figure 48. IC50 determination for SBI-0797750 on PfGluPho, PvG6PD, and hG6PD 
The IC50 values of SBI-0797750 for PfGluPho (a), PvG6PD (b), and hG6PD (c) were determined by using the 
orthogonal assay measuring the fluorescence of NADPH. Representative measurements are shown. IC50 values 
given are mean values ± SD from two determinations, each including two measurements. 
Although SBI-0797750 was optimized to inhibit PfGluPho, its effect was tested on Pf6PGD. As 
expected, no inhibition could be detected at the highest tested concentration of 100 µM (data 
not shown). 
4.5.3.3 Mechanism of inhibition of SBI-0797750 
The most likely mechanism of inhibition was determined by titrating G6P or NADP+ at different 
concentrations of SBI-0797750. The higher the concentration of the compound, the more 
increased the KM value for G6P, while Vmax stayed nearly constant (Figure 49a). This indicates 
that SBI-0797750 competes with G6P for the substrate binding site. Similarly, increasing 
compound concentrations led to increasing KM values for NADP+; however, Vmax decreased 
(Figure 49b), suggesting a mixed type inhibition of SBI-0797750 against NADP+. The most likely 
mechanism of inhibition was also determined for the other six compounds listed in Table 17, 
all resulting in a competitive inhibition with respect to G6P and a mixed type inhibition with 
respect to NADP+. 
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Figure 49. Mechanism of inhibition of SBI-0797750 against PfGluPho 
(a) Varying compound concentrations were titrated against G6P. SBI-0797750 acts as a competitive inhibitor 
against PfGluPho since the KM value for G6P increased with increasing compound concentrations while Vmax 
stayed constant. (b) Titration of NADP+ against different compound concentrations. The KM value for NADP+ was 
increasing while Vmax was decreasing, indicating a mixed-type inhibition. RFU: relative fluorescence units. 
4.5.3.4 Reversibility of the PfGluPho inhibition by SBI-0797750 
To test whether the inhibition of PfGluPho by SBI-0797750 is reversible, the enzyme was 
incubated with a high compound concentration (1.65 µM). Afterwards, the sample was 
diluted to a final SBI-0797750 concentration below IC50 (3.3 nM) and incubated again to allow 
the compound to dissociate before the activity was measured. Controls containing either 
3.3 nM SBI-0797750 or none were prepared in parallel. The control containing 3.3 nM SBI-
0797750 was included for comparison since this concentration is expected to still cause 
inhibition (IC50: 6.7 ± 1.8 nM). The activity of the control without SBI-0797750 was defined as 
100%, the control containing 3.3 nM SBI-0797750 had an activity of 77.2 ± 1.6%, and the 
diluted sample had an almost identical activity with 79.2 ± 1.5%. Measuring the undiluted 
sample containing 1.65 µM SBI-0797750 had 2.4 ± 0.3% activity (Figure 50), indicating that the 
enzyme was inhibited before dilution. The small remaining activity might be due to the 
competition of the compound with G6P, which was added in saturation (see above, Figure 
49a). Adding substrate and cofactor at KM concentrations indeed resulted in an activity of only 
0.3 ± 0.2%. This data clearly indicates that inhibition of PfGluPho by SBI-0797750 is fully 
reversible. 
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Figure 50. Reversibility of the PfGluPho inhibition by SBI-0797750 
The reversibility of the PfGluPho inhibition by SBI-0797750 was determined by incubating the enzyme with a high 
compound concentration (1,650 nM), followed by dilution. The diluted sample had the same activity as a control 
containing the same final compound concentration (3.3 nM), while the undiluted sample was completely 
inhibited. Mean values ± SD from three independent determinations, each including two measurements, are 
shown. 
4.5.3.5 In vitro activity of SBI-0797750 against P. falciparum 
The effect of SBI-0797750 on the growth of blood stage P. falciparum 3D7 parasites was tested 
using the [3H]-incorporation assay, resulting in a growth inhibition of the parasites with an IC50 
of 64.6 ± 9.6 nM. Measurements using the SYBR Green assay resulted in an even lower IC50 of 
22.5 ± 2.2 nM, while the growth of P. falciparum NF54-attB parasites was inhibited with an 
IC50 of 83.8 ± 17.3 nM. To test for synergistic effects with known antimalarial drugs, SBI-
0797750 was simultaneously applied to P. falciparum 3D7 with either chloroquine, methylene 
blue, or artemisinin. However, these drug combinations did not result in synergistic 
improvement of the compound efficiency, but rather in antagonism (data not shown). 
4.5.4 Discovery of a novel series of G6PD inhibitors 
In order to identify potential novel inhibitors of plasmodial G6PD, several libraries of the 
Helmholtz Center for Infection Research in Brunswick, Germany, were screened prior to this 
thesis against PfGluPho. Based on this screening, Prof. Dr. Dieter E. Kaufmann and Dr. Viktor 
Zapol'skii developed a compound library (Figure 51). The compounds were tested on 
PfGluPho, PvG6PD, and – to test for selectivity – on hG6PD. Parts of the IC50 values were 
determined by Dr. Esther Jortzik and Isabell Berneburg (Berneburg, 2017). An overview of the 
IC50 values is given in Table 18. 
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Figure 51. Compound library developed by Prof. Dr. Kaufmann and Dr. Zapol'skii 
 
Table 18. IC50 values of novel compounds on PfGluPho, PvG6PD, and hG6PD 
Values are presented as mean values ± SD of at least two independent determinations, each including at least 
two independent measurements. For hG6PD, only one enzyme batch was used. N. d.: not determined due to low 
solubility/reproducibility. 
 PfGluPho [µM] PvG6PD [µM] hG6PD [µM] 
2 (vz1731) 11.7 ± 9.9 2.1 ± 0.1 91.7 ± 35.0 
4 (vz1732) 0.9 ± 0.2 0.2 ± 0.0 34.7 ± 21.0 
8 (vz0882) 18.1 ± 10.4 12.8 ± 7.8 n. d. 
10 (vz1204) n. d. 23.5 ± 3.7 > 100 
13 (vz0288) 29.6 ± 23.2 23.3 ± 7.8 > 100 
18 (vz0909) 23.6 ± 14.3 9.1 ± 2.8 26.0 ± 1.8 
19 (vz0914) 8.4 ± 8.4 5.6 ± 0.6 29.6 ± 5.0 
20 (vz0005) > 100 > 100 > 100 
21 (vz0527) 1.7 ± 0.3 0.2 ± 0.1 8.3 ± 2.7 
 
The two most potent compounds were 21 (vz0527) and 4 (vz1732), with IC50 values of 1.7 ± 
0.3 µM for PfGluPho and 0.2 ± 0.1 µM for PvG6PD, and 0.9 ± 0.2 µM for PfGluPho and 0.2 ± 
0.0 µM for PvG6PD, respectively. The corresponding IC50 values for hG6PD were at least five 
times higher, indicating a small selectivity for the plasmodial enzyme. Limited solubility or 
stability of the compounds caused the partially high standard deviations (e.g. 19 (vz0914): 8.4 
± 8.4 µM for PfGluPho). 
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The most potent compound for PfGluPho – compound 4 (vz1732) – was further characterized 
by determining its mode of inhibition. In contrast to the other compounds described in this 
thesis, it was found to act non-competitively against both the substrate G6P and the coenzyme 
NADP+ (Figure 52). This indicates that compound 4 (vz1732) does not compete with substrate 
or cofactor for the binding sites. 
 
Figure 52. Mechanism of inhibition of compound 4 (vz1732) against PfGluPho 
The compound shows non-competitive inhibition against both G6P (a) and NADP+ (b). The higher the 
concentration of compound 4 (vz1732), the lower the Vmax was, while the KM values for G6P and NADP+ stayed 
constant. The graphs represent two independent determinations each. 
4.5.5 Screening the MMV Malaria Box with Pf6PGD 
DMSO tolerance test of Pf6PGD 
Like many others, compounds of the MMV Malaria Box are dissolved in DMSO (Spangenberg 
et al., 2013). Since these compounds were the first to be tested on Pf6PGD, DMSO tolerance 
of the enzyme was assessed first. To do so, the activity was measured by adding 0-5% DMSO; 
activity of the samples with 0% DMSO was defined as 100% (Figure 53). Adding 1% DMSO 
resulted in an activity of 101.0 ± 2.5%; higher concentrations resulted in a higher activity of 
Pf6PGD (up to 110.0 ± 5.4% by adding 5% DMSO). Therefore, it was ensured that no more 
than 1% DMSO was added to the assay characterizing the effect of compounds on Pf6PGD 
(Haeussler et al., 2018). 
 
Figure 53. DMSO tolerance test of Pf6PGD 
The activity of Pf6PGD was measured by adding 0-5% DMSO. Activity of the sample with 0% DMSO was defined 
as 100%. Values shown are mean values ± SD of three determinations, each including two measurements. 
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Primary screening of the MMV Malaria Box 
For screening the MMV Malaria Box, substrate and cofactor were added in concentrations 
close to KM in order to minimize the risk of false negative results due to competition of the 
compounds with 6PG and NADP+ for the binding sites. The effect of 10 µM compound on 
Pf6PGD activity in comparison to a DMSO control was determined in quadruplicate. Out of the 
400 compounds, 55 inhibited Pf6PGD at the tested concentration by ≥ 50% in at least three of 
the four determinations. These compounds were cherry-picked for further characterization 
(Haeussler et al., 2018). 
IC50 determination 
To confirm and further quantify the effect of the 55 hits from the MMV Malaria Box 
compounds, the IC50 values against Pf6PGD were determined. 26 compounds could indeed be 
confirmed to inhibit the plasmodial enzyme with an IC50 below 10 µM: 10 compounds were 
even below 5 µM. Structures and IC50 values of the nine best compounds are shown in Table 
19. To test for selectivity, the effect on h6PGD was tested in parallel. MMV666125 showed a 
slightly higher preference for the plasmodial enzyme (2.6 µM on Pf6PGD vs. 4.9 µM on 
h6PGD); however, the overall effect on h6PGD was comparable to the effect on Pf6PGD. The 
two most promising compounds were MMV011895 and MMV007228, with IC50 values of 1.6 
± 0.6 µM and 1.8 ± 0.1 µM, respectively (Figure 54). These compounds can be used as starting 
points for further improvement (Haeussler et al., 2018). 
 
Figure 54. IC50 determinations for MMV011895 and MMV007228 on Pf6PGD 
The best two compounds of the MMV Malaria Box were MMV011895 (a) and MMV007228 (b). Mean values ± 
SD from three measurements are shown. 
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Table 19. Structures and IC50 values of the MMV Malaria Box compounds on Pf6PGD and h6PGD 
IC50 values of the nine most efficient MMV Malaria Box compounds against Pf6PGD and h6PGD. Structures of the 
compounds were generated using the online tool Pubchem Sketcher V2.4 
(https://pubchem.ncbi.nlm.nih.gov/edit2/index.html). Pf6PGD: mean values ± SD from three determinations, 
h6PGD: mean values from two determinations (Haeussler et al., 2018). 
 
 
 
MMV011895: 
Pf6PGD: 1.6 ± 0.6 µM 
h6PGD: 2.1 µM 
MMV007228: 
Pf6PGD: 1.8 ± 0.1 µM 
h6PGD: 2.7 µM 
MMV007273: 
Pf6PGD: 2.1 ± 0.6 µM 
h6PGD: 1.8 µM 
 
 
 
MMV007384: 
Pf6PGD: 2.5 ± 0.1 µM 
h6PGD: 2.4 µM 
MMV666125: 
Pf6PGD: 2.7 ± 0.2 µM 
h6PGD: 4.9 µM 
MMV007199: 
Pf6PGD: 2.9 ± 0.5 µM 
h6PGD: 1.3 µM 
 
 
 
MMV000720: 
Pf6PGD: 3.1 ± 2.1 µM 
h6PGD: 2.2 µM 
MMV665972: 
Pf6PGD: 4.0 ± 0.2 µM 
h6PGD: 4.3 µM 
MMV000563: 
Pf6PGD: 4.2 ± 1.0 µM 
h6PGD: 3.5 µM 
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5 Discussion 
5.1 Naturally occurring GluPho variants from Plasmodium falciparum 
Exposure to Plasmodium parasites has left marks in the human genome; one prominent 
example is hG6PD deficiency, whose worldwide distribution shows remarkable similarity to 
the distribution of malaria and leads to partial resistance against the disease (see 1.2.1.1) 
(Cappellini and Fiorelli, 2008). However, during recent years, extensive research on the 
plasmodial genome also elucidated genome-wide diversity of Plasmodium species (Kirchner 
et al., 2016; Neafsey et al., 2008; Volkman et al., 2007). One hypothesis is that these variants 
grant the parasites evolutionary benefits to deal with strong selection pressure (Haldar et al., 
2018). Interestingly, there are also naturally occurring mutations within the PfGluPho gene, 
listed in the malaria database PlasmoDB. This enzyme plays a central role in the maintenance 
of cellular redox balance and the survival of the parasites (Allen et al., 2015; Preuss et al., 
2012b); it can therefore be hypothesized that these mutations might lead to altered enzymatic 
activity and advantages in the defense against oxidative stress or altered redox regulation. To 
test this hypothesis, the naturally occurring mutants PfGluPhoL395F and PfGluPhoF507L, located 
in the G6PD domain of the PfGluPho gene, as well as PfGluPhoS315Y, located in the linker 
domain between 6PGL and G6PD, were created. Interestingly, F507 is located in an insertion 
sequence that is specific for G6PD genes of Plasmodium, differs in size and sequence between 
the species (Figure 4), and – most importantly – has been shown to be essential for G6PD 
activity in P. berghei (Clarke et al., 2003). However, none of the tested mutants showed major 
differences when compared to the wt enzyme; PfGluPho wt and all mutants eluted as 
tetramers from size exclusion chromatography, as already shown for the recombinant wt 
enzyme (Jortzik et al., 2011), and for PfGluPho isolated from parasites (Ling and Wilson, 1988; 
O'Brien et al., 1994). The kinetic parameters of the wt enzyme determined within this thesis 
were in good accordance with values from literature (Jortzik et al., 2011), and none of the 
kinetic parameters (substrate affinities, kcat values, or catalytic efficiency) of the tested 
mutants PfGluPhoL395F, PfGluPhoF507L, and PfGluPhoS315Y showed major differences to the wt 
enzyme (Table 14). 
In proteomic approaches, several amino acid residues of PfGluPho were found to be naturally 
phosphorylated. Interestingly, several groups identified S899 and S900, located at the 
C-terminal end of the PfGluPho gene, to be phosphorylated (Lasonder et al., 2012; Pease et 
al., 2013; Treeck et al., 2011). These two serines are highly conserved in and specific for 
Plasmodium (Appendix 3). Phosphorylation is known to be a central mediator of various 
cellular functions such as cell proliferation and differentiation, migration, and homeostasis; 
most importantly for this thesis, it is also a common regulator of enzyme activity (Doerig et 
al., 2015). Detecting phosphorylation via Western blot analyses or kinetic determinations, as 
used within this thesis to investigate the other two PTMs S-glutathionylation and 
S-nitrosation, has two disadvantages: (I) phosphorylation is mainly mediated via protein 
kinases (Doerig et al., 2015), making the investigation more difficult and laborious; (II) even if 
one were able to insert phosphorylation into the protein, it is unclear which amino acid 
residue would be affected. PfGluPho has several naturally occurring phosphorylation sites 
(including S327, Y329, S330, S332, S477, T492, S701, S899, and S900, PlasmoDB); within this 
thesis, the focus was on S899 and S900. Identification of modified residues, e.g., via MALDI-
TOF MS, would have been necessary. One easy possibility to directly investigate the impact of 
phosphorylation on specific residues is the insertion of phosphomimetic mutations by 
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exchanging the – in this case serines with glutamic acids (Kim et al., 2015). Similar to the other 
tested PfGluPho mutants, the phosphorylation-mimicking mutants PfGluPhoS899E and 
PfGluPhoS900E did not show any significant differences to the wt. Thus, most likely, the 
phosphorylation of serines 899 and 900 does not strongly regulate the in vivo activity of 
PfGluPho.  
This indicates that neither the studied naturally occurring mutants of PfGluPho nor the 
phosphorylation of the two C-terminally located serine residues seem to provide major kinetic 
advantages. However, the variants might influence other characteristics of the enzyme such 
as protein-protein interaction, giving them benefits over the wt enzyme. 
5.2 GluPho and G6PD from Plasmodium vivax 
PfGluPho, the key enzyme of the oxidative PPP of P. falciparum, has already been shown to 
be a promising target for the development of new antimalarial drugs (Allen et al., 2015). The 
corresponding enzyme of P. vivax – PvGluPho – also exists as a bifunctional enzyme and shows 
at the amino acid level a remarkable 71.2% identity and 79.9% similarity to PfGluPho 
(Appendix 1) (Mohring et al., 2014), indicating that it might be a drug target in P. vivax. 
Therefore, this central enzyme and its inhibition by selected small molecules were 
characterized within this thesis. 
5.2.1 Recombinant production of PvGluPho and PvG6PD 
Heterologous overexpression and purification of full-length PvGluPho is extremely 
challenging. Two master students in Prof. Becker’s group, Angeles Stegmayer and Isabell 
Berneburg, tested various conditions (I) for expression, including a variation of vectors, E. coli 
strains, media, temperatures, durations of overexpression, additional plasmids, and (II) for 
purification, including different buffers, detergents, etc.; however, none of the tested 
conditions resulted in pure, active PvGluPho. Western blot analyses using anti-6xHis-tag 
antibodies showed the presence of PvGluPho fragments of different sizes at all stages of 
protein production (Berneburg, 2017; Stegmayer, 2013). These fragments could be either 
caused by degradation of the protein or by incomplete translation of the gene. One common 
problem of protein translation of plasmodial genes in E. coli is the difference in codon usage. 
E. coli uses the codons AGG/AGA, CGA (arginine), CUA (leucine), AUA (isoleucine), and CCC 
(proline) at a total frequency of 1.8% (Kane, 1995), but in the mRNAs of PvGluPho and PvG6PD 
they have a frequency of 8.1% and 6.5%, respectively, potentially causing the poor quality of 
the synthesized protein (Kane, 1995). This can partially be overcome by using the additional 
plasmid pRAREII, which is supplying tRNAs for rare codons (Novagen, 2004); however, tRNA 
for CGA, which E. coli uses at a frequency of 0.3% and is present in the mRNAs of PvGluPho 
and PvG6PD at frequencies of 1.0% and 1.2%, respectively, is not encoded by pRAREII (Kane, 
1995; Novagen, 2004). This might explain the high number of PvGluPho fragments even when 
using pRAREII. Isabell Berneburg suggested in her master thesis that a slow, highly controlled 
expression of PvGluPho can improve that quality of the produced protein, indicated by a lower 
number of protein fragments. The best results were achieved using a low temperature and 
short expression duration in LB medium, and E. coli Lemo21 cells (Berneburg, 2017). Lemo21 
is a BL21 strain containing an additional plasmid with a gene that encodes T7 lysozyme under 
the control of a rhamnose promotor. Since T7 lysozyme is an inhibitor of the T7 RNA 
polymerase, the amount of expressed protein correlates negatively with the amount of added 
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rhamnose, thereby enabling a high control of expression (Schlegel et al., 2012). One additional 
issue was the low solubility of PvGluPho, which we attempted to overcome with detergents 
(Berneburg, 2017). However, not only detergents but also other additives such as metals, 
(charged or uncharged) amino acids, sugars, or reducing agents are in many cases able to 
increase the solubility of a protein (Leibly et al., 2012). Alternatively, larger fusion tags could 
be used that are known to increase protein solubility such as GST or maltose-binding protein 
tags. However, these large tags might also affect other protein characteristics such as 
oligomerization behavior (Gräslund et al., 2008). 
In order to still characterize this enzyme that is presumably important for the survival of 
P. vivax parasites, experiments were performed using the C-terminal part, PvG6PD. Similar to 
the full-length enzyme, heterologous overexpression was rather challenging, resulting in a 
relatively low yield of 0.1-0.4 mg of enzyme per liter E. coli cell culture by using pRAREII as an 
additional plasmid to overcome the codon bias (Novagen, 2004). Improvement of yield and 
quality of expression might be possible using genes optimized for the production within E. coli 
as host. One commonly used approach is the improvement of codon usage by encoding amino 
acids with a synonymous codon that is more frequently used in E. coli (Raab et al., 2010). If 
expression in the bacterial system remains challenging, the use of other production hosts such 
as yeast (Pichia pastoris or Saccharomyces cerevisiae), insect cells, or even mammalian cells 
might be considered (Gräslund et al., 2008). 
5.2.2 Kinetic characterization of PvG6PD 
So far, the key enzyme of the oxidative PPP from P. vivax has not been characterized. 
Comparison of the kinetic parameters of PfGluPho and PvG6PD shows that KM values are 
notably higher in P. vivax, while kcat values are lower (Table 20). While the KM for G6P of 
PfGluPho is 20.3 ± 5.6 µM, it is four-times higher in PvG6PD with 80.2 ± 19.8 µM; the KM for 
NADP+ is 2.5-times higher in PvG6PD (14.8 ± 2.9 µM vs. 6.1 ± 1.3 µM). Less obvious, but the 
kcat values are still over 1.5-times higher in P. falciparum (G6P: 10.7 ± 1.8 sec-1 for PfGluPho, 
6.7 ± 0.8 sec-1 for PvG6PD). The difference becomes even more evident in the catalytic 
efficiency for PfGluPho, 5.3·105 M-1∙sec-1, which is more than six-times higher than in P. vivax 
(8.2·104 M-1∙sec-1, see Table 20). The PPP is the major source of the electron donor NADPH for 
Plasmodium parasites and is crucial to maintain their cellular redox balance (see 1.2). 
Therefore, the P. falciparum enzyme is likely to have advantages over P. vivax when 
competing with the human G6PD for substrates. However, whether this contributes to the 
higher pathogenicity of P. falciparum over P. vivax can only be speculated and deserves to be 
studied in more detail. Notably, when comparing the KM for G6P of PfGluPho and PfG6PD 
(Table 20), it becomes evident that PfG6PD has a higher KM for G6P and a lower catalytic 
efficiency than the full-length enzyme (KM: 33.2 ± 1.2 µM for PfG6PD, 19.2 ± 3.9 µM for 
PfGluPho; catalytic efficiency: 1.9·105 M-1∙sec-1 for PfG6PD, 4.5·105 M-1∙sec-1 for PfGluPho, see 
Jortzik et al., 2011). This might be due to structural advantages of the fusion of the protein. 
The same is likely true for P. vivax, so the full-length PvGluPho might have lower KM values 
than PvG6PD. Interestingly, in hG6PD, Vmax and corresponding kcat values are notably higher 
than in the plasmodial enzymes (Table 20); however, since the KM values of hG6PD are also 
higher, this results in a comparable catalytic efficiency. This indicates that the fusion of G6PD 
with the second enzyme of the PPP, allowing for direct substrate transfer within the pathway, 
might give the Plasmodium parasites some kinetic advantage over the human homolog. 
Kinetic characterization of full-length PvGluPho remains to be conducted in future studies. 
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Table 20. Comparison of kinetic parameters from P. vivax and P. falciparum 
* Values from Jortzik et al., 2011 are shown for comparison. Catalytic efficiency (kcat/KM) was calculated from 
mean values to enable comparison to the values published in Jortzik et al., 2011. 
  
PvG6PD PfG6PD* 
PfGluPho 
wt 
PfGluPho 
wt* 
hG6PD* 
Vmax 
[U∙mg-1] 
G6P 5.6 ± 0.7 5.5 ± 0.2 5.9 ± 1.0 5.2 ± 1.6 64.4 ± 11 
NADP+ 5.5 ± 0.4 5.5 ± 0.1 5.9 ± 0.6 4.6 ± 0.8 57.7 ± 15 
KM [μM] 
G6P 80.2 ± 19.8 33.2 ± 1.2 20.3 ± 5.6 19.2 ± 3.9 116 ± 8.5 
NADP+ 14.8 ± 2.9 6.1 ± 0.7 6.1 ± 1.3 6.5 ± 2.2 17.5 ± 2.8 
kcat [sec-1] 
G6P 6.7 ± 0.8 6.3 ± 0.3 10.7 ± 1.8 8.6 ± 1.5 64.6 ± 8.9 
NADP+ 6.5 ± 0.4 6.3 ± 0.1 10.1 ± 0.9 8.2 ± 1.2 56.9 ± 15 
Catalytic 
efficiency 
[M-1∙sec-1] 
G6P 8.2·104 1.9·105 5.3·105 4.5·105 5.6·105 
 
5.2.3 Oligomerization behavior of PvG6PD 
G6PDs from most organisms exist in three different oligomerizations; as monomers such as 
Bos taurus (Ibrahim et al., 2015), dimers as in Trypanosoma brucei (Heise and Opperdoes, 
1999), or tetramers such as Sus scrofa (Cho and Joshi, 1990). The oligomerization of the human 
enzyme highly depends on the ionic strength, pH, and presence of substrates in its 
environment and exists in all three forms (Wrigley et al., 1972). Recombinant full-length 
PfGluPho has previously been shown to be present in a tetrameric form (Jortzik et al., 2011) 
which was confirmed in this thesis; furthermore, the same oligomerization was found for 
PfG6PD. Interestingly, PvG6PD showed a different behavior; it eluted in a presumably 
hexameric form from size exclusion chromatography. Such a hexameric oligomerization has 
not been previously described for G6PDs (Brenda, EC 1.1.1.49) and might actually represent 
an artificial state since PvG6PD occurs as a fusion protein with 6PGL under physiological 
conditions (Mohring et al., 2014). The oligomerization state of full-length PvGluPho is 
presumably different – based on the high sequence identity with PfGluPho (Appendix 1) likely 
tetrameric. This likely artificial oligomerization status might be one explanation for the lower 
affinity of P. vivax G6PD to its substrates compared to P. falciparum GluPho (Table 20). Due to 
the hexameric oligomerization, substrate binding sites might be less accessible than in the – 
presumably tetrameric – physiological conformation. First experiments using full-length 
PvGluPho performed by Isabell Berneburg indicated that it exists in a tetrameric form; 
however, the enzyme used for size exclusion chromatography was not active, therefore this 
oligomerization status might not be reliable (Berneburg, 2017). Further experiments with 
active full-length PvGluPho are essentially important for verifying the characteristics of this 
central enzyme of P. vivax. 
5.3 6PGD from Plasmodium falciparum 
Pf6PGD catalyzes the third step of the oxidative PPP and has not been characterized before. 
Since it contributes to the NADPH supply of the parasites in the same amounts as PfGluPho, it 
might also be important for the survival of the parasites (Haeussler et al., 2018). Therefore, 
one aim of the thesis was the structural and kinetic characterization of Pf6PGD. 
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5.3.1 Structure of Pf6PGD 
The overall structure of Pf6PGD is remarkably similar to the structure of other members of the 
6PGD family; it is active as a homodimer, each monomer consisting of one substrate and one 
cofactor binding domain and a C-terminal tail threading through the adjacent subunit as 
observed, e.g., in Homo sapiens (Hitosugi et al., 2012), Lactococcus lactis (Sundaramoorthy et 
al., 2007), and Geobacillus stearothermophilus (Cameron et al., 2009). The high similarity of 
Pf6PGD to other members of the 6PGD family is already noticeable at the primary sequence 
level (Table 21) (Haeussler et al., 2018). Further characteristics of the structure will be 
discussed in the chapters below. 
Table 21. Comparison of the amino acid sequences of 6PGDs from different species to Pf6PGD 
The table contains species from which the three-dimensional structure of 6PGD is known. UniProtKB for Pf6PGD: 
Q8IKT2; for the other species it is given in parentheses. 
 Identity to Pf6PGD Similarity to Pf6PGD 
Geobacillus stearothermophilus (I3NI58) 49.2% 65.0% 
Alicyclobacillus acidocaldarius (C8WVH6) 46.9% 65.2% 
Escherichia coli (P00350) 45.9% 63.6% 
Klebsiella pneumoniae (P41576) 45.7% 63.4% 
Lactococcus lactis (P96789) 45.6% 64.7% 
Saccharomyces cerevisiae (P38720) 44.4% 61.3% 
Homo sapiens (P52209) 43.4% 61.3% 
Ovis aries (P00349) 43.4% 61.3% 
Dyadobacter fermentans (C6VSE5) 42.7% 62.3% 
Corynebacterium glutamicum (Q8NQI2) 40.1% 60.9% 
Trypanosoma brucei (P31072) 34.6% 54.4% 
Geobacter metallireducens (Q39SD5) 21.5% 32.9% 
Pseudomonas syringae (S3MGN3) 21.1% 34.6% 
 
5.3.2 Oligomerization behavior of Pf6PGD 
As determined within this thesis, native, reduced, and oxidized Pf6PGD wt, as well h6PGD 
were present in a dimeric form. Reduced dimeric Pf6PGD indicates that dimerization is not 
primarily based on intermolecular disulfide bonds. This was further confirmed by the 
oligomerization of Pf6PGDC281S; although the Plasmodium-specific disulfide bridge between 
the cysteine residues 281 of the two subunits A and B (Figure 23) was missing, there was no 
change in the dimeric conformation of the enzyme. Therefore, this disulfide bridge is not 
essential for dimerization. This oligomerization state is in accordance with previous studies on 
the 6PGDs of various species such as those isolated from human RBCs (Pearse and Rosemeyer, 
1974b), Lactococcus lactis (Sundaramoorthy et al., 2007), Saccharomyces cerevisiae (He et al., 
2007), and Trypanosoma brucei (Phillips et al., 1998). All these structures have the C-terminal 
tail in common. As seen in our structure, the C-term of one subunit threads through the 
adjacent subunit, thereby linking the two monomers very tightly (Haeussler et al., 2018). 
However, despite this close interaction, there are additional interactions between the α-
helices located in the dimer interface. He et al., 2007 created mutants lacking the C-terminal 
tail; although less stable than the full-length enzyme, the truncated mutants were still present 
in a dimeric form yet did not show any enzymatic activity. In the structure of 
Saccharomyces cerevisiae 6PGD, they found the highly conserved residues R446 and H452 
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(Figure 24) to be involved in binding citrate molecules that were located in the 6PG binding 
site (He et al., 2007). It has been shown before that in Lactococcus lactis, the corresponding 
R447 most likely plays an important role in anchoring 6PG during its oxidative decarboxylation 
since none of the mutants R447K, R447A, R447D, or R447W showed enzyme activity (Tetaud 
et al., 1999). Similar in our Pf6PGD structure in complex with 6PG, R447 and H453 located on 
the C-terminal tail have been shown to be involved in substrate binding (Figure 25a; Haeussler 
et al., 2018). Therefore, it can be concluded that the primary function of the C-term is not an 
involvement in dimerization but in the enzyme mechanism. To test this hypothesis, a 
truncated version of Pf6PGD could be generated, missing the C-terminal amino acids 434-468. 
The oligomerization behavior of Pf6PGD wt has also been tested in the presence of its product 
NADPH. For T. brucei, a dimer-tetramer equilibrium has been described, with NADPH shifting 
it more towards the tetrameric form (Hanau et al., 2013). However, in Plasmodium there was 
no difference compared to other conditions tested (Figure 27), indicating that there is no 
dimer-tetramer equilibrium (Haeussler et al., 2018). 
5.3.3 Kinetic parameters of Pf6PGD 
Within this thesis, Pf6PGD was kinetically characterized. All kinetic parameters of Pf6PGD 
were in a similar range as the corresponding parameters of the enzyme preceding the pathway 
– PfGluPho (Table 14, Table 16, see also Jortzik et al., 2011). The kinetic parameters of the 
enzyme from various organisms with known three-dimensional 6PGD structures are in a very 
broad range of 1-118 µM for the KM for NADP+ and of 3.5-153 µM for 6PG (Table 22). 
Table 22. Comparison of kinetic parameters of 6PGDs from different species 
All values are given from species with known three-dimensional structures. N. d.: not defined. 
Organism 
Specific activity 
[U∙mg-1] 
KM NADP+ 
[µM] 
KM 6PG 
[µM] 
Reference 
Plasmodium 
falciparum 
8.0 ± 1.9 9.0 ± 4.2 11.3 ± 2.7 This thesis 
Trypanosoma brucei 3.2 1 3.5 Hanau et al., 1996 
Trypanosoma cruzi 32 5.9 ± 0.2 22.2 ± 0.4 
Esteve and Cazzulo, 
2004 
Homo sapiens 
10 30 20 
Pearse and 
Rosemeyer, 1974a 
22.1 ± 1.2 6.9 ± 2.0 33.7 ± 7.1 This thesis 
Ovis aries 
18.8 ± 0.9 6.76 ± 1.6 16.1 ± 1.3 Dyson et al., 1973 
n. d. 2.9 22.7 Topham et al., 1986 
Corynebacterium 
glutamicum 
143 17 ± 3 34 ± 13 Moritz et al., 2000 
Geobacillus 
stearothermophilus 
87 25 20 
Veronese et al., 
1974 
Saccharomyces 
cerevisiae 
34.9 ± 0.6 25 ± 1 153 ± 4 Rendina et al., 1984 
n. d. 35 ± 6 50 ± 9 He et al., 2007 
Escherichia coli 24.35 ± 0.30 49 ± 7 93 ± 1 Chen et al., 2010 
Klebsiella pneumoniae 12.92 ± 0.34 118 ± 23 107 ± 4 Chen et al., 2010 
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Various methodologies (see references in Table 22) such as different enzyme sources (e.g. 
recombinant enzyme, isolated from cell culture or tissue), assay buffers (e.g. Tris buffer, 
triethanolamine buffer, different pH values), or temperatures (20-43 °C) might partially 
explain this variation. However, the KM values of the parasites P. falciparum and trypanosomes 
are noticeably lower than the values of most other organisms (P. falciparum: 9.0 µM for 
NADP+, 11.3 µM for 6PG; trypanosomes: 1-5.9 µM for NADP+, 3.5-22.2 µM for 6PG; Hanau et 
al., 1996; Esteve and Cazzulo, 2004). The glucose metabolism plays an essential role in malaria 
infections (Preuss et al., 2012b). In malaria-infected red blood cells, glucose metabolism in 
total and the PPP in particular have been shown to be increased (Atamna et al., 1994). The 
comparably low KM values in Plasmodium and T. brucei and cruzi show the high affinity of the 
enzymes for their substrates, underscoring the central role of the PPP and therefore of 6PGD 
during parasitic infection. In trypanosomes, 6PGD has already been validated as a promising 
target for the development of new drugs against the parasitic disease African trypanosomiasis 
(Hanau et al., 2004). This – together with the fact that PfGluPho as the other NADPH-producing 
enzyme of the PPP is essential for the parasites (Allen et al., 2015) – suggests that Pf6PGD is a 
promising target for new antimalarial drugs (Haeussler et al., 2018). 
One aim of this thesis was to find an initial set of inhibitors for Pf6PGD. To enable selectivity 
testing of identified compounds, the corresponding human enzyme – h6PGD – was 
recombinantly produced and kinetically characterized in parallel. Notably, the specific activity 
determined in this thesis was 22.1 ± 1.2 U∙mg-1, significantly higher than the value published 
for h6PGD isolated from RBCs (10 U∙mg-1, Pearse and Rosemeyer, 1974a). While the KM value 
of recombinant h6PGD for 6PG was close to the value in the literature (33.7 ± 7.1, 20 µM in 
Pearse and Rosemeyer, 1974a), the KM for NADP+ was notably lower in this thesis (6.9 ± 
2.0 µM, 30 µM in Pearse and Rosemeyer, 1974a). The different protein sources and 
consequently different purification procedures might explain these discrepancies; purification 
of recombinant h6PGD performed within this thesis took a maximum of two days, while 
purification of h6PGD from RBCs takes about three weeks (Pearse and Rosemeyer, 1974a). 
During this time, the enzyme is likely to lose activity. Moreover, the assay buffer conditions 
for determining the kinetic parameters were slightly different; in Pearse and Rosemeyer, 
1974a, the assay buffer had a pH of 9.0, while the buffer used in this thesis had a pH of 8.0. 
The activity of an enzyme depends on the pH in its environment. With increasing pH, the 
activity increases until it reaches a maximum (pH optimum); as soon as this pH is surpassed, 
the activity decreases again (Bisswanger, 2017). The cytosolic pH in human cells is around 7.0-
7.4 (Bright et al., 1987; Dechant et al., 2010; Llopis et al., 1998; Poburko et al., 2011). 
Therefore, it can be assumed that the pH optimum of h6PGD – located in the cytosol – is 
around 7, and the pH used in this thesis, 8.0, is closer to the optimum as 9.0 used in the 
literature. However, further enzymatic studies need to be conducted in order to determine 
the exact pH optimum. 
NAD+ as an alternative cofactor 
The 6PGD activity of T. brucei has been shown to be specific for NADP+, and NAD+ does not act 
as a cofactor (Hanau et al., 1996). Since the kinetic behavior of Pf6PGD seems to be similar to 
the behavior of Tb6PGD (both low KM values, similar mechanism, see 5.3.4), NAD+ was tested 
within this thesis as an alternative cofactor. The activity of both Pf6PGD and h6PGD was 
indeed found to be specific for NADP+. The interaction of the negatively charged phosphate 
groups of NADP+ with the positively charged arginine residues R32 and R36 can structurally 
explain the specificity in P. falciparum (Figure 26) (Haeussler et al., 2018). A negatively charged 
102 
 Discussion 
residue, e.g. aspartate, was previously shown to prefer NAD+ as a cofactor, while positively 
charged residues such as arginine prefer NADP+ binding (Chen et al., 2010; Zhang et al., 2014). 
R32 is conserved amongst different species, while R36 is specific for Plasmodium and is 
replaced in H. sapiens and T. brucei by a lysine. However, lysine is also positively charged and 
able to interact with the phosphate groups of NADP+. In two NAD+-specific 6PGDs from 
Haloferax volcanii (Pickl and Schönheit, 2015) and Bacillus subtilis (Zamboni et al., 2004), the 
positively charged residues are replaced with uncharged amino acids leucine and alanine, or 
the negatively charged tyrosine and leucine, respectively (Figure 55). 
 
      Pf   --MCDIGLIGLAVMGQNLSLNISSKGFKIGVYNRTYERTEETMKRAKEE--NLVVYGYKT 56 
      Tb   -MSMDVGVVGLGVMGANLALNIAEKGFKVAVFNRTYSKSEEFMKANASAPFAGNLKAFET 59 
      Hs   MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANE-AK--GTKVVGAQS 57 
      Hv   ---MQLGVIGLGRMGRIVVDRVLDAGHEVVAFDLSAEAVAAAA--------DAGAEPADS 49 
      Bs   -MFNSIGVIGLGVMGSNIALNMANKGENVAVYNYTRDLTDQ-LIQK-LD--GQSLSPYYE 55 
               .:.::**. **  :  .: . *  : .::O: .O  
Figure 55. Amino acid alignment of NADP+- and NAD+- specific 6PGDs 
Relevant residues involved in the specific cofactor binding are marked in yellow. Pf, Tb, and Hs are specific for 
NADP+, while Hv and Bs are specific for NAD+. Pf: Plasmodium falciparum (UniProtKB - Q8IKT2); Tb: Trypanosoma 
brucei (UniProtKB - P31072); Hs: Homo sapiens (UniProtKB - P52209); Hv: Haloferax volcanii (UniProtKB – 
D4GST8); Bs: Bacillus subtilis (UniProtKB - P12013). * Identical residues, : very similar residues, . similar residues. 
5.3.4 Mechanistic considerations of Pf6PGD 
Flexible loop rearranges upon substrate binding 
Attempts to cocrystallize Pf6PGD with NADP+ but without the substrate resulted in only 
partially bound NADP+; the adenine moiety and the three phosphate groups were visible, 
while the catalytically important nicotinamide moiety was not defined by electron density, 
most likely due to flexibility. The active site loop (amino acids 255-262, bordering the 6PG 
binding site, Figure 25a) adopted an open conformation as seen in our apo structure. As soon 
as 6PG binds, the active site loop adopts a closed conformation (Figure 56a). This movement 
of the active site loop is also visible in structures of other species. As long as the substrate 
binding pocket is empty or filled solely with solvent molecules such as PEG (seen in our apo-
Pf6PGD, Figure 25b) or H2O, the active site loop is in an open conformation, also seen, e.g., in 
Klebsiella pneumoniae (2ZYG (Chen et al., 2010)). In h6PGD, the inhibitor 3-phosphoglycerate 
forces the active site loop into the open conformation (4GWG (Hitosugi et al., 2012)). The 12 
additional C-terminal amino acids of h6PGD are disordered with an open active site loop but 
cover the active site of h6PGD as soon as the loop adopts its closed conformation (Figure 56b). 
The closed conformation is adopted as soon as the substrate pocket is occupied by a ligand or 
at least an anion such as sulfate (1PGO (Adams et al., 1994), 1PGJ (Phillips et al., 1998), 2JKV 
(to be published), 2PGD (Adams et al., 1991), 2W90 (Cameron et al., 2009)), phosphate (1PGN 
(Adams et al., 1994)), or citrate (2P4Q (He et al., 2007)) interacting with the positively charged 
R447′ and with loop residues (Haeussler et al., 2018).  
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Figure 56. Active site loop in plasmodial and human 6PGD 
(a) Superimposition of apo-Pf6PGD structure (green), and in complex with 6PG (gray); the active site loop (255-
262) is colored blue and magenta, respectively, and changes its conformation upon substrate binding. (b) 
Superimposition of the human apo-structure (light blue, 4GWG (Hitosugi et al., 2012)) and in complex with 
NADPH (magenta, 2JKV (to be published)). The active site loop is colored yellow and red, respectively. Sulfate 
and a Cl ion occupy the substrate binding site of the NADPH complex structure, resulting in a closed conformation 
of the active site loop (red) and a ordered long C-terminus (red) (Haeussler et al., 2018). 
6PG and NADP+ can bind independently from each other 
The substrate 6PG alone binds in the catalytically relevant position. Without 6PG and 
therefore with an open active site loop (Figure 56a), NADP+ is bound in a flexible waiting 
position; adenosine is fixed, while nicotinamide and the second ribose are flexible and 
therefore not in the conformation required for catalysis. However, this indicates that 6PG and 
NADP+ can bind independently from each other. Enzymatic analysis supported this 
consideration since Lineweaver-Burk plots of substrate/cofactor titrations intersected left of 
the ordinates. This points towards a sequential enzyme mechanism, meaning both substrate 
and cofactor have to bind before product formation can be initiated (Figure 29) (Haeussler et 
al., 2018). This is in accordance with mechanistic characterizations of the 6PGDs of other 
species such as sheep (Price and Cook, 1996), Trypanosoma brucei (Hanau et al., 1996), 
Saccharomyces cerevisiae (He et al., 2007), and Corynebacterium glutamicum (Moritz et al., 
2000). In the case of a ping-pong mechanism, meaning that the product is released before all 
substrates are bound, parallel lines would have been expected in the Lineweaver-Burk plots 
(Bisswanger, 2017). The crystal structures in complex with either NADP+ or 6PG suggest that 
Pf6PGD follows a random-order sequential mechanism which would be in accordance with 
the mechanism found for T. brucei (Hanau et al., 1996). 
Interestingly, amongst the numerous 6PGD crystal structures from different species, there is 
no structure with solely bound NADP+, but there are structures in complex with the products 
NADPH and ribulose 5-phosphate (2IYP from Lactococcus lactis (Sundaramoorthy et al., 
2007)), with the product NADPH, chloride, and sulfate (2JKV from Homo sapiens (to be 
published)), or with NADPH and sulfate (1PGO from Ovis aries (Adams et al., 1994)). Although 
the binding pocket is highly conserved, the conformation of the NADPH varies amongst the 
structures. Additionally, the cofactor binding domain adopts slightly different orientations in 
104 
 Discussion 
all compared structures, while there are almost no differences seen for the substrate binding 
domain and the C-terminal tail, including the substrate binding site. The substrate 6PG is 
bound very similarly in all structures, independent of the presence of the cofactor (Haeussler 
et al., 2018). These findings support our binding considerations. 
Interaction between W265 and W104 is catalytically important 
The strictly conserved W265 is in direct proximity to the active site loop and interacts with the 
non-conserved W104. This interaction links the cofactor binding domain with the substrate 
binding domain (Figure 23). It is therefore likely important for the communication between 
the two domains and for helping force NADP+ into the catalytically relevant binding position. 
Site-directed mutagenesis of the Plasmodium-specific W104 was performed in order to 
investigate a potential impact on the mechanism; all kinetic parameters of Pf6PGDW104L, 
especially the KM value for 6PG, were decreased compared to the wt enzyme (Table 16), 
supporting the hypothesis that replacing the tryptophan side chain with leucine disturbs their 
linkage between domain 1 and domain 2 and therewith the catalysis (Haeussler et al., 2018). 
A second interaction specific for Plasmodium is a disulfide bridge between the cysteine 
residues 281 of the two subunits (Figure 23). This disulfide formation was prevented by 
creating the mutant Pf6PGDC281S. Similar to Pf6PGDW104L, the kinetic parameters of Pf6PGDC281S 
were decreased compared to the wt (Table 16). Size exclusion chromatography showed that 
the disulfide bridge was not necessary for maintaining the dimeric conformation of the 
enzyme (Figure 27e); moreover, it is not in close proximity to the binding sites; therefore, the 
mechanistic reasons for the decreased kinetic parameters are so far unclear. The disulfide 
bridge was only visible in the apo-structure and the structure in complex with NADP+, but not 
in complex with 6PG. Whether the interaction was missing due to mechanistic reasons or 
radiation damage was unclear (Haeussler et al., 2018). Further experiments, e.g. further 
crystallization trials to detect potential changes in the overall structure need to be performed 
to elucidate the cause of the changed kinetic parameters in Pf6PGDC281S. 
5.4 Post-translational cysteine modifications 
The importance of post-translational modifications of reactive cysteine residues in the 
regulation of different protein properties has gained more and more attention (Belcastro et 
al., 2017; Jortzik et al., 2012). Therefore, the effect of two important PTMs – 
S-glutathionylation and S-nitrosation – was studied on enzymes of the PPP of P. falciparum 
and P. vivax. 
5.4.1 S-glutathionylation 
S-glutathionylation has multiple functions in various metabolic pathways. It can regulate not 
only protein folding and stability but also the activity of enzymes; moreover, it serves as a 
storage form of reduced glutathione during episodes of oxidative stress, and prevents 
irreversible oxidation of proteins (Becker et al., 2003; Dalle-Donne et al., 2009). Currently, 
there is no information on S-glutathionylation of G6PDs or 6PGDs in the dbGSH database of 
cysteine S-glutathionylation (http://csb.cse.yzu.edu.tw/dbGSH/). In 2011, Jortzik et al. 
showed that S-glutathionylation does not regulate hG6PD activity, while it does inhibit 
PfGluPho’s G6PD activity. A large proteomic approach was performed to reveal targets of 
protein S-glutathionylation in Plasmodium parasites. However, neither PfGluPho nor Pf6PGD 
could be detected to be part of the plasmodial glutathionylome (Kehr et al., 2011). Together 
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with PvG6PD, this could be confirmed within this thesis; neither PfGluPho, PfG6PD and 
PvG6PD, nor Pf6PGD were prone to S-glutathionylation under the tested conditions. 
Incubation with very high GSSG concentrations led to precipitation of all four tested enzymes 
(Figure 31, Figure 33). Therefore, the previous hypothesis that the G6PD activity of PfGluPho 
decreases after incubation with high GSSG concentrations (Jortzik et al., 2011) is rather an 
artefact due to protein precipitation than specific redox-regulation. In this thesis, S-
glutathionylated proteins were detected via Western blot analyses using an anti-glutathione 
antibody. In Jortzik et al., 2011, several cysteine residues of PfGluPho were detected to be 
S-glutathionylated via MALDI-TOF-MS of samples incubated with 10 mM GSSG; however, this 
might be an artefact since this very high GSSG concentration leads to protein precipitation 
(Figure 31, Figure 33), potentially giving access to cysteine residues that are not accessible in 
native protein conformation. 
The cytosol where the oxidative PPP of Plasmodium is located (Allen et al., 2015) is highly 
reducing, with a redox potential of -314 mV (Kasozi et al., 2013). The level of total glutathione 
in unstressed Plasmodium parasites is approximately 2 mM, almost all of it being present as 
GSH (Becker et al., 2003); however, even 2 mM GSSG did not have a major impact on the G6PD 
activity in P. falciparum and P. vivax (Figure 32). This further supports the finding that 
S-glutathionylation most likely does not play a major role in the regulation of the oxidative 
PPP of Plasmodium. S-glutathionylation has been shown to inhibit several enzymes of 
glycolysis; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is most often considered to 
be inhibited in various organisms (Barinova et al., 2017; Hildebrandt et al., 2015; Kehr et al., 
2011; Zaffagnini et al., 2013). Under oxidative stress, inhibition of glycolysis forces more 
glucose into the PPP in order to ensure sufficient NADPH production (Ralser et al., 2007; 
Shenton and Grant, 2003). Since the PPP is the major source of NADPH for Plasmodium (1.2.3), 
it is reasonable that S-glutathionylation does not inhibit its enzymes under oxidative stress. To 
fully exclude S-glutathionylation, however, other possibilities for S-glutathionylation 
formation could be tested, e.g. interaction of oxidized proteins with GSH (chapter 1.3.1) 
5.4.2 S-nitrosation 
Protein S-nitrosation mediates both physiological and pathophysiological effects of NO, 
influencing protein conformation, stability, activity, protein-protein interactions, and cellular 
signal transduction processes (Belcastro et al., 2017; Hess et al., 2005; Jortzik et al., 2012). 
During their complex life cycle, malaria parasites have to deal with NO from different sources 
(Ferrari et al., 2011; Jeney et al., 2014; Peterson et al., 2007b). A large-scale proteomic analysis 
identified 319 potential targets for S-nitrosation in P. falciparum, many of them located in 
glycolysis. Interestingly, also PfGluPho and Pf6PGD were identified as targets of S-nitrosation 
(Wang et al., 2014). This could be confirmed within this thesis together with PfG6PD and 
PvG6PD (Figure 35, Figure 36). 
GSNO as a nitrosative agent 
Within this thesis, S-nitrosation was studied by incubating reduced enzymes with the naturally 
occurring S-nitrosoglutathione (GSNO), followed by indirect detection of the modification 
using the biotin-switch assay (Broniowska et al., 2013; Forrester et al., 2009a). Reactions 
between reduced glutathione and nitrous acid can synthesize GSNO, which is able to transfer 
its nitroso group to thiols of other proteins, resulting in S-nitrosation. However, GSNO is also 
able to react with thiols by forming a disulfide bridge, resulting in S-glutathionylation instead 
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of S-nitrosation (Broniowska et al., 2013). The indirect detection using the biotin-switch assay 
is based on replacement of the actual modification by biotin. It has been stated before that 
ascorbate, used to transform SNOs to free thiols, does not reduce S-glutathionylated cysteines 
(Forrester et al., 2009a). Therefore, S-glutathionylation caused by GSNO should in theory not 
result in a signal using the biotin-switch assay. Moreover, none of the enzymes tested within 
this thesis were prone to S-glutathionylation upon incubation with GSSG (see results in 
chapter 4.4.1), therefore it is unlikely that GSNO causes S-glutathionylation in these enzymes. 
To fully exclude false negative detection of S-nitrosation, experiments could be repeated using 
S-nitrosocysteine instead of GSNO as a nitrosation agent (Grossi and Montevecchi, 2002; 
Peterson et al., 2007a). Alternatively, potential S-glutathionylation of the enzymes by GSNO 
could be excluded by Western blot analysis using an anti-glutathione antibody. 
S-nitrosation of G6PD 
So far, S-nitrosation of G6PDs in other organisms has not been extensively studied; to our 
knowledge, there is no information in the literature about S-nitrosation in Homo sapiens and 
Plasmodium (dbSNO, database of cysteine S-nitrosation, http://dbSNO.mbc.nctu.edu.tw). In 
a proteomic approach performed in E. coli (K12), G6PD cysteine residue 10 was identified to 
be S-nitrosated; however, the impact of the modification has not been studied (Forrester et 
al., 2009b). The C10 found in E. coli G6PD is not conserved; however, there are cysteines in 
close proximity (C315 and C323 of full-length PvGluPho, C346 of PfGluPho) which might be 
targeted by S-nitrosation. In Western blot and kinetic analyses, PfGluPho, PfG6PD, and 
PvG6PD showed the same results (Figure 35). Therefore, it can be concluded that at least some 
of the S-nitrosation sites of PfGluPho are located in its N-terminal G6PD part. 
S-nitrosation of 6PGD 
Within this thesis, Pf6PGD was found to be reversibly inhibited upon S-nitrosation. To test the 
reversibility, 5 mM DTT was added to the modified enzyme. Under physiological conditions, 
PfTrx1 – the major cytosolic Trx – might be able to denitrosate Pf6PGD (Wang et al., 2014). 
This needs to be verified. 
For 6PGD of other species, S-nitrosation has been identified in metabolomic/proteomic 
studies on mice (Bruegger et al., 2018; Kohr et al., 2011; Qu et al., 2014), and interestingly on 
recombinant h6PGD. Similar to the findings in this thesis, GSNO downregulated h6PGD activity 
with an IC50 of 556 µM. Using site-directed mutagenesis, cysteine residues 30, 113, 170, 171, 
199, 289, 366, 402, and 422 were tested for their susceptibility to S-nitrosation (Bruegger et 
al., 2018). Of these nine residues, only two (170 and 366) are present in Pf6PGD. The authors 
suggest that S-nitrosation of C366 is responsible for the inhibition of h6PGD upon GSNO 
treatment. The residue C366 is located between the two subunits of the dimer and is within 
hydrogen-bonding distance of the hydroxyl side chains of S129 and S140 (3.3 and 3.6 Å, 
respectively, Figure 57a). The interaction between the cysteine and the two serines might be 
important for the structural orientation and rigidity of the subunits. S-nitrosation of C366 
might disturb this interaction, leading to changes in structural orientations and thereby 
changes in activity (Bruegger et al., 2018). However, in P. falciparum, the distances between 
C366 and S128 as well as between C366 and S139 seen in our Pf6PGD structures are longer: 
5.1 and 4.9 Å, respectively (Figure 57b). Movement of the cysteine side chain would shorten 
the distances to 3.5 Å to S128 and 2.8 Å to S139, which would then in theory enable hydrogen 
bonding. However, even in case the cysteine side chain moves, the angles between the side 
chains would still not be favorable to form hydrogen bonds, additional movement of the serine 
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side chains would be necessary. The orientation of the side chains shown in Figure 57b has 
been observed in all three Pf6PGD structures (apo, in complex with NADP+, in complex with 
6PG); movement of all three side chains is possible, however unlikely. A disturbed interaction 
between the cysteine and the serines most likely does not explain the decreased activity upon 
S-nitrosation in Pf6PGD. One hypothesis is that S-nitrosation of C366, which is in close 
proximity to the 6PG binding site, might slightly change the overall conformation of the 
binding pocket and thereby prevent binding of 6PG. This hypothesis needs to be tested, e.g., 
by using site-directed mutagenesis or crystallization of S-nitrosated protein. Moreover, it has 
to be considered that Pf6PGD has nine cysteine residues that are not conserved in h6PGD and 
might play a role in the regulation. 
 
Figure 57. Potential hydrogen bonds of C366 in h6PGD and apo-Pf6PGD 
(a) In h6PGD (4GWK (Hitosugi et al., 2012)), hydrogen bonds between C366 and S129 or S140 are possible due 
to the short distances of 3.3 and 3.6 Å, respectively (Bruegger et al., 2018). (b) In apo-Pf6PGD (6FQX), the 
distances between C366 and S128 as well as C366 and S139 are relatively long: 5.1 and 4.9 Å, respectively. 
Therefore, the formation of hydrogen bonds is unlikely. Cysteine 366 is colored in red, the two serines 129/128 
and 140/139 in blue. The distances are indicated with the dashed lines. 
Potential explanations for S-nitrosation of the PPP in Plasmodium parasites 
Wang et al., 2014 hypothesized that under nitrosative stress, the inactivation of PfGAPDH via 
S-nitrosation serves as a signaling event that redirects the carbohydrate flux to the PPP. The 
antioxidative systems of P. falciparum can then use NADPH generated in the PPP (see 1.2.3); 
e.g. the plasmodial thioredoxin system uses NADPH to recover PfGAPDH via denitrosation 
(Wang et al., 2014). To fight against oxidative stress, it would make sense if the activity of the 
NADPH-producing PPP would increase or at least remain at the same level. For PfGluPho – 
shown to be essential for the survival of the parasites, even under physiological conditions 
(Allen et al., 2015) – downregulation of the activity upon S-nitrosation was indeed very 
moderate (Figure 35b). This is in accordance with the finding from Shenton and Grant, 2003 
that oxidative stress does not affect G6PD and 6PGD activities in Saccharomyces cerevisiae. 
However, in this thesis Pf6PGD was found to be reversibly downregulated by up to 65%. It 
might happen that this partial inhibition of Pf6PGD leads to the accumulation of substrate, 
leading to product inhibition of PfGluPho (Jortzik et al., 2011). Moreover, it has been shown 
for T. brucei that high concentrations of 6PG are toxic most likely due to inhibition of 
phosphoglucose isomerase (Hanau et al., 2004). Therefore, restriction of NADPH production 
via the PPP upon S-nitrosation might lead to severely pathophysiological conditions for the 
parasite. However, since Pf6PGD is not completely inhibited upon S-nitrosation, the remaining 
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activity might be high enough to maintain the flux through the PPP and thereby NADPH 
production, especially because 65% inhibition is only reached under very high GSNO 
concentrations. In this case, S-nitrosation of the enzymes from the PPP might be used to 
protect them from irreversible nitrosative damage (Belcastro et al., 2017). 
In addition to the downregulation of enzyme activity for signaling purposes by the parasites 
themselves, the host’s immune system might increase the nitrosative stress followed by 
enzymatic downregulation in order to fight the infection. It has been shown that the 
production of NO increases upon infection with Plasmodium and is involved in the fight against 
malaria (Akman-Anderson et al., 2007; Jaramillo et al., 2003; Jeney et al., 2014; Ong et al., 
2013; Ranjan et al., 2016). In a proteomic approach, glycolytic enzymes of P. falciparum were 
found to be extensively S-nitrosated, followed by downregulation of activity – shown, e.g., for 
PfGAPDH (Wang et al., 2014). The central role of glycolysis in Plasmodium parasites is 
underscored by the finding that there is up to a 100-fold increase in glucose uptake and 
consumption in parasitized RBCs compared to healthy cells (Roth, 1990). Since inhibition of 
glycolysis was shown to deteriorate the growth of the parasites (Davis et al., 2016; van Niekerk 
et al., 2016; van Schalkwyk et al., 2008), S-nitrosation and subsequent inactivation of these 
important enzymes might be part of the antiparasitic defense. As stated above, it has been 
shown that glycolysis inactivation redirects the carbohydrate flux to the PPP in order to 
counteract oxidative stress (Ralser et al., 2007; Shenton and Grant, 2003). However, since 
especially Pf6PGD was found to be also S-nitrosated, the host’s defense might cause this 
S-nitrosation and inhibition of Pf6PGD in order to disturb the NADPH supply of the parasites. 
In addition, there is evidence that the formation of nitroso bonds is not the end-effector 
mechanism of S-nitrosation, but an intermediate state that reacts with thiols to intra- and 
intermolecular disulfide bonds (Wolhuter and Eaton, 2017). Further research is necessary to 
find the reason for the downregulation of both – glycolysis and the PPP under nitrosative 
stress. 
5.5 Inhibition of the PPP as a mode of action in new antimalarial drugs 
Currently, the WHO recommends ACTs for the treatment of malaria (WHO, 2017b); however, 
their high failure rates endanger an effective malaria treatment (Ashley et al., 2018; WHO, 
2017b). To ensure successful treatment in the future, there is an urgent need for the 
development of new antimalarial drugs. 
A promising mechanism of action of new antimalarial drugs is to disturb the redox 
homeostasis of Plasmodium parasites in order to create a fatal dosage of oxidative stress 
(Schirmer et al., 1987). There are in principle three ways to reach this situation: (I) application 
of oxidative drugs that target, e.g., essential parasite components; (II) application of redox-
cycling drugs (see discussion for methylene blue below); and (III) inhibition of redox-active 
enzymes such as NADPH-producing enzymes that ensure the functionality of the antioxidative 
thioredoxin and glutathione systems (Nepveu and Turrini, 2013). Since the PPP is the major 
source of NADPH in Plasmodium (Preuss et al., 2012b), it is considered a promising target for 
new antimalarial drugs (Allen et al., 2015; Haeussler et al., 2018); one aim of this thesis was 
therefore to characterize the effect of potential inhibitors on the important NADPH-producing 
enzymes PfGluPho, Pf6PGD, and PvG6PD. 
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5.5.1 PfGluPho and PvG6PD as drug targets 
Attempted double crossover disruption of the PfGluPho gene showed that this enzyme is 
essential for the growth of blood stages parasites, validating it as a promising drug target 
(Allen et al., 2015). So far, it has not been possible to prove the essentiality of PvGluPho, most 
importantly due to the difficulties in maintaining P. vivax in cell culture (Thomson-Luque et 
al., 2017). However, since PfGluPho and PvGluPho share important features (bifunctional 
enzyme, central role in the metabolism, similar kinetic behavior of PfGluPho and PvG6PD in 
response to PTMs and inhibition), it can be assumed that PvGluPho also serves as a potential 
drug target. The effect of several compounds on PfGluPho and PvG6PD were characterized 
within this thesis. 
5.5.1.1 Structure-based drug design for PfGluPho 
Structure-based drug design has already been proved to be a very useful tool in any stage of 
drug development, including lead identification and lead optimization, but also in the 
prediction of the pharmacochemical behavior in absorption, distribution, metabolism, 
excretion, and toxicity (Blundell, 2017; Chen et al., 2012). Although there are already potent, 
highly selective inhibitors for PfGluPho available (see chapter 4.5.3 and discussion below), it 
is still necessary to solve the three-dimensional structure, best in the native form and in 
complex with an inhibitor. Using this approach, the mechanism of inhibition can be fully 
understood. 
Crystallization of PfGluPho and PfG6PD 
Despite numerous crystallization trials and several obtained crystals, it has not yet been 
possible to solve the three-dimensional structure of PfGluPho due to limited size, stability, or 
diffraction quality of the crystals. In contrast, the structures of G6PDs from several other 
species have been solved, including H. sapiens (5UKW (Ranzani and Cordeiro, 2017), 2BH9, 
2BHL (Kotaka et al., 2005), 1QKI (Au et al., 2000)) and T. cruzi (6D23, 6D24, 4LSM (to be 
published), 5AQ1 (Mercaldi et al., 2016)). Interestingly, the structure of Pv6PGL has also been 
solved (3E15 (to be published)). One rational approach of protein crystallization is to initially 
use the conditions of already known structures of proteins with high sequence similarities (Lu 
et al., 2012); however, due to the fusion to the bifunctional enzyme, this is not easily 
applicable to PfGluPho. 
So far, crystallization trials have been performed using the vapor diffusion technique as a 
sitting and hanging drop approach. Besides native PfGluPho/PfG6PD, cocrystallization in 
complex with inhibitor, substrate, or cofactor has been tested; however, it has not yet been 
possible to solve the three-dimensional structure of PfGluPho. The following chapter describes 
several alternative strategies to achieve protein crystallization. (I) Spontaneous formation of 
protein crystals in living cells has been reported unexpectedly often. Due to continuous 
improvement of lasers, these small, so-called in cellulo grown crystals can nowadays be used 
to solve the three-dimensional structures of the proteins. There are several physiological 
reasons for protein crystallization in living cells to appear such as storage, protection and 
stabilization of cells and proteins, or solid state catalysis (Schönherr et al., 2018). In addition, 
in cellulo crystallization has also been observed for recombinant protein during gene 
expression in, e.g., plant cells (Stöger et al., 2001), mammalian cells (Baskaran et al., 2015; 
Hasegawa et al., 2011; Tsutsui et al., 2015), and – most interestingly for this thesis – E. coli 
cells (Oeda et al., 1989). The reason for crystallization during heterologous expression is most 
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likely the locally high protein concentration that is triggering crystal nucleation. However, 
further investigations and improvements of this method are required until in cellulo 
crystallization can be used routinely (Schönherr et al., 2018). (II) One more commonly used 
approach is seeding of crystal fragments into metastable systems. The idea behind this is that 
conditions enabling nucleation might not be ideal conditions for crystal growth (see Figure 7). 
Seeding can therefore be used to separate nucleation and growth by introducing previously 
produced, pulverized crystals into new drops with lower supersaturated levels. It has been 
shown that this technique can improve the quality of the crystals obtained in the new drop 
(Bergfors, 2003; Ireton and Stoddard, 2004). (III) As described in 3.4.3, the use of additives 
such as substrates or inhibitors can improve crystal formation. The tellurium-centered 
Anderson-Evans polyoxotungstate [TeW6O24]6− (TEW) has recently been shown to act as an 
additive that is able to initiate and improve crystallization of several proteins (Bijelic et al., 
2015; Mac Sweeney et al., 2018; Molitor et al., 2017). The high negative charge of TEW leads 
to an interaction with positively charged regions of the protein; in addition, the large size of 
TEW leads to a distribution of the negative charge over a large area of the protein. This enables 
TEW to electrostatically interact with many amino acid residues, increasing the probability and 
strength of TEW-protein interactions. Using this electrostatic cross-linking of protein 
monomers, TEW is able to initiate and stabilize crystal contacts, thereby facilitating the 
formation of the crystal lattice (Bijelic and Rompel, 2017). The benefit of TEW for the 
crystallization of PfGluPho is currently tested in the working group of Prof. Becker. (VI) Besides 
crystallization trials using wt enzymes, it is a common approach to crystallize mutant proteins 
that are supposed to be, e.g., more rigid than the wt enzyme. The choice which mutants are 
reasonable to be used can be based on knowledge of the enzyme mechanism, or on mutants 
that were successfully used to solve the structure of homologous enzymes. As an example, 
crystallization of the mutant PfGluPhoD577N has been tested based on findings for G6PD from 
Leuconostoc mesenteroides (LmG6PD). In LmG6PD, H240 (corresponding H641 in PfGluPho) 
most likely accepts protons from G6P, while the carboxylate group of D177 (corresponding 
D577 in PfGluPho) stabilizes the positive charge that is generated on H240 in the transition 
state (Cosgrove et al., 1998). Use of the mutant LmG6PDD177N enabled the crystallization of 
the enzyme in complex with both G6D and NADPH; comparison to the structure of the wt 
enzyme revealed that the overall structure was not changed in LmG6PDD177N (Cosgrove et al., 
2000). Therefore, this approach was tested for the plasmodial enzyme using the mutant 
PfGluPhoD577N; however, in contrast to Leuconostoc mesenteroides, it did unfortunately not 
result in crystals that were suitable for X-ray diffraction analysis. One currently promising 
looking trial performed in the working group of Prof. Becker uses a modified version of 
PfG6PD. For the crystallization of T. cruzi G6PD, a C-terminally truncated version of the 
enzyme has been successfully used; the C-terminal end is expected to be flexible, deteriorating 
the crystal quality (Mercaldi et al., 2016). According to this approach, PfG6PD has been 
truncated by the C-terminal 27 amino acid residues. Moreover, a Rossmann-like domain starts 
at amino acid P62 in T. cruzi G6PD (Mercaldi et al., 2016), corresponding L333 in PfGluPho. 
Recombinant PfG6PD used so far started at residue 339 of full-length PfGluPho (Jortzik et al., 
2011), potentially interrupting one β-sheet and therewith impair the crystal growth and 
quality. Accordingly, recombinant PfG6PD was prolonged at the N-terminus by the sequence 
SLNKEELL ensuring that the potential β-sheet is complete. First crystallization trials using this 
modified PfG6PD resulted in crystals that are currently subjected to optimization processes. 
(V) In case these approaches are not successful, nuclear magnetic resonance (NMR) 
spectroscopy and electron microscopy – methods that are not based on crystal formation of 
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the protein –  can be used to solve the three-dimensional protein structure (Thonghin et al., 
2018; Wüthrich, 1989). 
Homology model of PfG6PD 
Since there is no crystal structure available yet, a homology model of C-terminal PfG6PD has 
been built by Alencar et al., 2018. Comparison of the amino acid sequences of PfG6PD with 
the sequences of G6PDs from H. sapiens, T. cruzi, Mycobacterium avium, and 
Leuconostoc mesenteroides showed that the residues involved in substrate binding are highly 
conserved with one exception: the negatively charged D750 in PfG6PD replaces the positively 
charged R365 in hG6PD. According to the authors, this change in size of the side chain and 
charge can be used to develop substrate analog-based inhibitors that selectively inhibit 
PfG6PD. The hypothesis was that replacing the negatively charged phosphate group of G6P 
with a short side chain ending with a basic functional group that can be protonated at 
physiological pH could implement the development of a selective inhibitor. The positive 
charge of the protonated group is supposed to disturb the interaction of the compound with 
R365 in hG6PD, while it enables an ionic interaction with D750 in PfG6PD and thereby a 
selective inhibition of the plasmodial enzyme. To test this hypothesis, the authors designed 
and tested a series of G6P analogs (Alencar et al., 2018). The hypothesis that the replacement 
of R365 (H. sapiens) with D750 (P. falciparum) alone is responsible for the selective inhibition 
has two weaknesses: (I) According to Alencar et al., 2018, adding a short side chain containing 
a basic, protonatable end to G6P should lead to a specific interaction with D750 in PfG6PD. 
Furthermore, they suggest that amino derivatives have a higher selectivity for the plasmodial 
enzyme than guanidino derivatives. Four of their nine tested compounds contained a terminal 
amino group; two of them in fact had a higher affinity for the plasmodial enzyme, while one 
unexpectedly had a higher affinity for hG6PD. The fourth compound containing an amino 
group had approximately the same affinity for the two enzymes. (II) The authors stated that 
in H. sapiens, binding the negative charge of G6P is assisted by positively charged residues like 
R365 which is replaced in P. falciparum with the negatively charged D750. One consequence 
of this would be that binding G6P should be easier in H. sapiens than in P. falciparum. In 
contrast, however, the KM value for G6P of P. falciparum is lower than the KM value of 
H. sapiens (PfG6PD: 11-27 µM (Alencar et al., 2018; Jortzik et al., 2011); hG6PD: 52-72 µM 
(Alencar et al., 2018), 116 µM (Jortzik et al., 2011)). This indicates that there are most likely 
other amino acid residues that also play a role in selectively binding the compounds and that 
the important R365 → D750 replacement alone might not be suitable for the development of 
a selective inhibitor. Site-directed mutagenesis creating the mutants hG6PDR365D and 
PfGluPhoD750R could be used to further investigate the role of the amino acid replacement for 
selective binding of compounds. 
5.5.1.2 Inhibitors of PfGluPho and PvG6PD 
Ellagic acid 
EA is a polyphenol that can be found in different fruits and vegetables; it was identified to be 
an active component in plants used in traditional West African medicine for the treatment of 
malaria (Soh et al., 2009; Verotta et al., 2001). The growth inhibition of Plasmodium parasites 
in vitro ranges between 105 nM and 1.3 µM dependent on the strain. Interestingly, EA also 
inhibits chloroquine-resistant Plasmodium strains (Soh et al., 2009; Sturm et al., 2009; Verotta 
et al., 2001). In combination with commonly used antimalarial drugs, EA is able to potentiate 
the in vitro antiplasmodial activity of the commonly used drugs chloroquine, atovaquone, 
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mefloquine, and artesunate; however, it acts slightly antagonistically with artemisinin. In 
addition to the growth inhibition in vitro, EA was shown to be active in vivo in mice infected 
with P. vinckei petteri; intraperitoneal application of 1 mg∙kg-1 per day had curative 
antiplasmodial activity, 10 mg∙kg-1 per day prophylactic activity. Simultaneously, there was no 
toxicity observed in the mice. The main targets of EA seem to be the most metabolically active 
stages: trophozoites and early schizonts (Soh et al., 2009). 
The actual mechanism of action of EA has been discussed in several studies. EA, as well as its 
derivatives CEA and FEA, are known to inhibit various enzymes. Examples are plasmodial GR, 
GST, and TrxR; however, the IC50 values for these enzymes, 7-74 µM, were moderate (Sturm 
et al., 2009). In accordance with the inhibition of GR, EA is supposed to decrease the 
glutathione content inside the parasites. In the murine model P. yoelii, a strain overproducing 
GSH, the effect of EA is five times lower than the effect on wt parasites (Njomnang Soh et al., 
2012). As stated above, EA is supposed to mainly affect the trophozoites and early schizonts, 
stages with maximal hemoglobin digestion (Soh et al., 2009; Sturm et al., 2009). As described 
in 1.2.3, this digestion leads to the release of high amounts of free heme, which needs to be 
detoxified into hemozoin (Egan et al., 2002; Francis et al., 1997). It has been shown that GSH 
is able to degrade heme (Atamna and Ginsburg, 1995); however, since EA reduces the GSH 
pool (Njomnang Soh et al., 2012), this detoxification path is limited under EA. Moreover, EA 
and its derivatives form soluble complexes with free heme, thereby blocking the hemozoin 
formation (Sturm et al., 2009). Treatment with EA therefore results in increased oxidative 
stress due to insufficient detoxification of heme. 
In summary, the observations have so far indicated that EA exerts its antiplasmodial effect via 
a rather broad mechanism of action, thereby affecting the antioxidant balance of the 
parasites. Interestingly, it was recently shown that EA inhibits PfGluPho with an IC50 of 77 ± 
22 nM (Allen et al., 2015); e.g., compared to the IC50 values on GR, GST, and TrxR stated above 
(Sturm et al., 2009), the inhibition of PfGluPho is three orders of magnitude higher. This 
PfGluPho inhibition is likely associated with the GSH depletion due to a lack of NADPH and less 
efficient glutathione reduction (Allen et al., 2015). Similarly, EA and its derivatives were shown 
to inhibit PvG6PD in the low nanomolar range; the mixed-type inhibition with respect to both 
G6P and NADP+, observed for PfGluPho (Allen et al., 2015), was confirmed for PvG6PD. This 
supports the assumption that PfGluPho and PvGluPho/PvG6PD may structurally be very 
similar. The inhibition of EA is not selective for plasmodial enzymes; with an IC50 of 102 ± 
39 nM, it inhibits hG6PD in the same range. Using in silico modelling it has been proposed that 
the region where EA presumably binds is highly conserved between hG6PD and PfGluPho and 
does not overlap with the substrate/cofactor binding sites. This explains the mixed-type 
inhibition with similar IC50 values in human and plasmodial enzymes (Allen et al., 2015). 
However, since the overall toxicity in mice is still low and there are no observable hemolytic 
effects (Soh et al., 2009), the rapidly growing and multiplying parasites might be more 
susceptible to disturbance of the redox metabolism than human cells. 
Novel series of G6PD inhibitors 
Based on a compound library screening and subsequent analysis of the structure-activity 
relationship, a set of new potential G6PD inhibitors has been designed (Figure 51). Although 
the solubility and stability of several compounds were limited, the approach resulted in two 
novel compounds with activity against both PfGluPho and PvG6PD in the very low micromolar 
range. In contrast to the other inhibitors reported in this thesis, compound 4 (vz1732) was 
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shown to act as a non-competitive inhibitor against both G6P and NADP+. The most promising 
compounds will be further characterized, e.g., by determining their activity in P. falciparum 
cell culture. 
ML304 
To identify inhibitors of PfGluPho, a high-throughput screening of various compound libraries, 
including LOPAC, Spectrum, DIVERSet, and the Molecular Libraries Small Molecule Repository 
(MLSMR) collection of the NIH, was performed (Preuss et al., 2012a). Within this screening, 
two compounds of the MLSMR collection could be identified as potent inhibitors of the G6PD 
reaction of PfGluPho, namely ML276 and ML304. With an IC50 of 0.89 µM against PfGluPho 
and no observable inhibition of hG6PD at 80 µM, ML276 is highly specific for the plasmodial 
enzyme (Preuss et al., 2012c). As described above (chapter 5.5.1.1), Alencar et al., 2018 
hypothesized that selective binding of a compound to the plasmodial enzyme might be 
feasible through the replacement of the negatively charged D750 in PfGluPho with the 
positively charged R365 in hG6PD. To confirm this hypothesis, they simulated the binding of 
ML276 to their PfG6PD model. As shown in Figure 58, this simulation in fact showed that the 
carboxylate group of D750 forms stable hydrogen bonds with the protonated amine and the 
amide NH groups of ML276. The ﬂuorobenzene ring of ML276 was bound in a hydrophobic 
pocket that is shaped by V585 and L778 (Alencar et al., 2018). V585 is conserved 
(corresponding V208 in hG6PD), while the plasmodial leucine L778 is replaced by the similar 
but shorter amino acid valine V394 in hG6PD. This replacement of a compound binding amino 
acid supports the hypothesis that D750 alone might not be responsible for the selectivity; 
most likely, additional amino acid residues of the substrate binding cavity involved in binding 
ML276 differ between H. sapiens and P. falciparum, leading to a selective inhibition of the 
plasmodial enzyme. 
 
Figure 58. Putative binding mode of ML276 to PfG6PD 
Shown is a superposition of the PfG6PD/ML276 complex from Alencar et al., 2018 and the X-ray structure of 
hG6PD in complex with G6P (2BHL (Kotaka et al., 2005)). The protein backbone is colored in light blue, selected 
amino acid residues are shown as blue sticks. ML276 and G6P are shown as sticks with the carbon atoms in green 
and gray, respectively. Asp: aspartic acid; Gln: glutamine; Lys: lysine; Leu: leucine; Val: valine. The figure was 
taken and modified from Alencar et al., 2018. 
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ML304 as the second hit of the high-throughput screening had an IC50 for PfGluPho of 190 nM, 
which was even more potent and was also highly selective for the plasmodial enzyme, with no 
observable inhibition of hG6PD at 80 µM. The pharmacokinetic characteristics of this 
promising compound are described in an NIH probe report. ML304 acts on P. falciparum 3D7, 
a chloroquine sensitive strain, at concentrations below 1 µM; on the chloroquine resistant 
strain Dd2, it is still active at concentrations lower than 5 µM. Interestingly, there was no 
cytotoxicity against human hepatocytic cells observable; the lethal dose killing 50% of the cells 
was above 50 µM. To further evaluate the suitability of the compound as a potential 
antimalarial drug component, an in vitro pharmacology screen was used. ML304 was found to 
have a high passive, transcellular permeability and to be able to cross the blood-brain-barrier. 
Since Plasmodium belongs to the blood-borne parasites, high plasma concentrations of a 
compound increase the exposure of newly arising parasites. ML304 has been shown to bind 
efficiently to plasma proteins; therefore, it remains in the plasma and is hardly distributed to 
other organs or tissues. Even exposure to proteinases and esterases does not significantly 
change the plasma concentration. In summary, ML304 seems to be stable in the plasma, 
resulting in a high exposure of the parasites. However, a microsomal stability assay showed 
that ML304 is completely metabolized in human and mouse liver homogenates within one 
hour (Maloney et al., 2012). 
Within this thesis, ML304 was shown to inhibit PvG6PD in addition to PfGluPho with an IC50 in 
the low micromolar range. Mechanistic studies indicated that it acts as a competitive inhibitor 
towards G6P in both PfGluPho and PvG6PD; this supports the hypothesis – as discussed above 
for EA – that the P. falciparum and P. vivax enzymes are structurally similar. Dr. Mahsa Rahbari 
investigated within her dissertation the effects of ML304 on the cytosolic glutathione 
metabolism of Plasmodium parasites. There, she used the genetically encoded glutathione 
redox sensor “human glutaredoxin 1-reduction-oxidation sensitive green fluorescent protein 
2” (hGrx1-roGFP2), episomally transfected in P. falciparum 3D7 parasites, and stably 
transfected in NF54-attB parasites (Rahbari, 2017). In this sensor, hGrx1 catalyzes the thiol-
disulfide exchange between glutathione and roGFP; therewith it is possible to detect 
alterations in the glutathione redox potential, corresponding to changes in GSSG in the 
nanomolar range (Gutscher et al., 2008). ML304 was shown to significantly disturb the 
cytosolic glutathione redox potential of the parasites in a time and concentration-dependent 
manner (Rahbari, 2017). Moreover, the effects of ML304 on hydrogen peroxide dynamics 
were determined using the H2O2 redox probe roGFP2-Orp1, stably integrated in NF54-attB 
parasites (Rahbari et al., 2017). This sensor is able to detect micromolar H2O2 concentrations 
(Gutscher et al., 2009). It turned out that ML304 significantly increases the cytosolic H2O2 
levels of the parasites (Rahbari et al., 2017). In addition to the effect on asexual blood stage 
parasites, ML304 has been shown to have tremendous synergistic effects with methylene blue 
(MB) on late stage gametocytes, while it was not active alone on gametocytes at a 
concentration of 20 µM. Interestingly, ML304 was also not able to potentiate the effect of MB 
when it was only added prior to the addition of MB; simultaneous application of the drugs was 
necessary (Siciliano et al., 2017). Amongst other effects, MB has been shown to inhibit 
plasmodial GR, leading to a depletion of GSH (Buchholz et al., 2008; Schirmer et al., 2003). 
Importantly, MB acts not only as an inhibitor, but also as a so-called redox-cycling substrate 
of P. falciparum reductases; disulfide reductases such as GR and TrxR reduce MB under the 
consumption of NADPH. The resulting leucoMB is re-oxidized by O2, followed by another 
reduction. Each reaction cycle leads to the consumption of NADPH and O2, accompanied by 
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the generation of reactive oxygen species (Buchholz et al., 2008). The depletion of NADPH due 
to MB and the simultaneous prevention of the generation of new NADPH due to inhibition of 
PfGluPho by ML304 have deleterious effects on the gametocytes (Siciliano et al., 2017). 
Therefore, this drug combination has a transmission-blocking potential. 
In summary, ML304 is able to significantly disturb the overall redox homeostasis of 
Plasmodium parasites via depletion of the important electron donor NADPH. This promising 
compound is currently followed up as described in the chapter below. 
The ML304 derivative SBI-0797750 
ML304 had IC50 values of 190 nM and 2.6 µM on PfGluPho and PvG6PD, respectively. To 
further increase the efficiency of the compound, analyses of the structure-activity relationship 
were performed at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA, 
USA, followed by synthesis of various derivatives. The most promising compound was 
SBI-0797750, which was besides the work performed within this thesis characterized by the 
working group of Prof. Becker and several cooperation partners in yet unpublished 
experiments. The compound inhibits PfGluPho and PvG6PD with IC50 values of 6.7 ± 1.8 and 
31.0 ± 3.1 nM, respectively. At the highest tested concentration of 99 µM, inhibition of hG6PD 
was below 50% (chapter 4.5.3.2); SBI-0797750 is therefore at least 3,200-14,800-fold more 
effective on the plasmodial enzymes than on the human homolog. Good selectivity of a 
compound is described as a minimal difference in effect of 10-100, depending on the biological 
system (Roy, 2018). Therefore, SBI-0797750 is highly selective for the plasmodial enzyme, 
reducing the risk of adverse side effects when used as an antimalarial drug. Similar to ML304, 
SBI-0797750 was found to act as a competitive inhibitor with respect to G6P (chapters 4.5.2 
and 4.5.3.3), meaning that the compound competes with G6P for the binding site (Bisswanger, 
2017). The inhibition of PfGluPho by SBI-0797750 is completely reversible (chapter 4.5.3.4); 
this competitive, reversible inhibition means that high accumulation of G6P – caused by the 
inhibition of the G6PD reaction – can potentially displace the inhibitor from the binding site 
and stop the inhibition. This might be a pitfall when the compound is used in living organisms. 
It has been shown that oxidative and nitrosative stress situations can lead to the 
downregulation of the activity of glycolytic enzymes, redirecting the glucose flux towards the 
PPP to ensure a sufficient production of NADPH (Mullarky and Cantley, 2015; Ralser et al., 
2007; Wang et al., 2014). In this case, an inhibition of PfGluPho might lead to an accumulation 
of high G6P concentrations. However, this seems at least in cell culture not to be problematic 
since besides inhibition of recombinantly produced PfGluPho and PvG6PD, SBI-0797750 has a 
growth inhibitory effect on P. falciparum parasites; on chloroquine-sensitive P. falciparum 
3D7 parasites, the compound showed an IC50 of 22.5 ± 2.2 nM, and growth of P. falciparum 
NF54-attB parasites was inhibited with an IC50 of 83.8 ± 17.3 nM (chapter 4.5.3.5). In addition 
to the effect on asexual blood stage parasites, SBI-0797750 inhibits the gametocyte formation 
of P. falciparum NF54 parasites with an IC50 of 74 ± 22 nM, indicating that it might also be able 
to act as a transmission-blocking agent (personal communication, Dr. Kathrin Buchholz). 
ML304 has been shown to act synergistically with MB; the redox-cycling activity of MB leads 
to the consumption of NADPH, while the inhibition of PfGluPho prevents new synthesis (see 
discussion above; Buchholz et al., 2008; Siciliano et al., 2017). Unexpectedly however, SBI-
0797750 tended to act antagonistically towards MB, chloroquine, and artemisinin. One 
potential explanation for this discrepancy might be found in the different plasmodial stages 
used; the synergistic effect of ML304 and MB was detected in late stage gametocytes (Siciliano 
et al., 2017), whereas the antagonistic effect of SBI-0797750 and MB was detected in asexual 
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blood stage parasites. Stage-dependent differences in metabolism (MacRae et al., 2013) might 
explain the different results of synergy tests. Further investigations ought to be conducted. 
Similar to ML304, SBI-0797750 has been shown to significantly disturb the glutathione 
homeostasis in P. falciparum 3D7 and P. falciparum NF54-attB parasites at the very low 
concentration of 65 nM and after only 4 h of incubation. Moreover, short term-exposure for 
4 h of NF54-attB parasites to 65 nM of SBI-0797750 resulted in a significant increase in 
cytosolic H2O2 concentration; long-term exposure for 24 h significantly increased the H2O2 
concentration in both cytosol and mitochondria. This clearly demonstrates that SBI-0797750 
disturbs the maintenance of the cellular redox balance in Plasmodium parasites (Rahbari, 
2017, SBI-0797750 referred to as "Compound S"). 
In addition to the effect of a compound on its target organism, one important quality factor 
of a potential drug component is its effect on the human patient. As summarized in chapter 
1.2.1.1, hG6PD deficiency is the most common enzymopathy worldwide (Gomez-Manzo et al., 
2016). Since it leads to partial resistance against malaria, G6PD deficiency is mainly distributed 
in areas where malaria is (or was) endemic (Cappellini and Fiorelli, 2008). Most patients stay 
asymptomatic during their entire life; however, drug intake can trigger oxidative stress that 
can manifest as acute hemolysis (Cappellini and Fiorelli, 2008; Luzzatto et al., 2016). To 
prevent this critical situation for the patient, the effect of SBI-0797750 was tested on healthy 
and G6PD deficient RBCs. In comparison to untreated cells, exposure to 2 µM SBI-0797750 for 
24 h did not change the GSH levels in the cells. Cell lysis was determined by measuring the 
hemoglobin release in the supernatant; application of up to 2 µM compound did not change 
the cell lysis in comparison to untreated cells. Moreover, phagocytosis of SBI-0797750-treated 
RBCs by human phagocytes and monocytes did not increase. In summary, both healthy and 
G6PD deficient RBCs tolerated treatment with SBI-0797750 well, indicating that using the 
compound as an antimalarial drug might be nonhazardous (personal communication, Prof. Dr. 
Paolo Arese). Further characterization of its toxicity on human cells, as well as its behavior in 
absorption, distribution, metabolism, and excretion needs to be performed. 
5.5.2 Pf6PGD as a drug target 
Pf6PGD as the second NADPH-producing enzyme of the PPP contributes to the supply of this 
important electron donor in the same amounts as PfGluPho (Stincone et al., 2015). For 
T. brucei, 6PGD is already considered a promising target for the treatment of human African 
trypanosomiasis (Hanau et al., 2004). Therefore, 6PGD is likely to be a promising antimalarial 
drug target (Haeussler et al., 2018). Currently, there is an ongoing effort in Prof. Becker’s group 
to investigate the role of Pf6PGD in parasitic survival using the CRISPR-Cas9 system. 
Within this thesis, the MMV Malaria Box was screened to find an initial set of Pf6PGD 
inhibitors. This Box is a collection of 200 drug-like and 200 probe-like compounds with known 
antimalarial effects and high structural diversity in the compounds. It could be ordered free 
of charge from MMV until December 2015 (Spangenberg et al., 2013). The MMV Malaria Box 
was replaced by ‘The Pathogen Box’, also containing 400 compounds; however, the 
compounds were not specifically selected based on their known antimalarial effect but should 
act against a broader range of pathogens causing neglected diseases (malaria (125), 
tuberculosis (116), kinetoplastids (70), helminths (32), cryptosporidiosis (11), toxoplasmosis 
(15), dengue (5), reference compounds (26), the number of compounds included against each 
disease is given in parenthesis) (https://www.pathogenbox.org/). Compounds of the MMV 
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Malaria Box with promising effect on Pf6PGD were tested on h6PGD in parallel in order to 
study selectivity of the inhibition. Ten compounds were identified to inhibit Pf6PGD with IC50 
values below 5 µM. The best two were MMV011895 and MMV007228, with IC50 values of 1.6 
± 0.6 and 1.8 ± 0.1 µM, respectively. Unfortunately, all compounds inhibited h6PGD in the 
same range. MMV666125 showed a slightly higher preference for the plasmodial enzyme; 
however, the difference, less than 2-fold, was rather small (2.6 µM on Pf6PGD vs. 4.9 µM on 
h6PGD, Table 19). This similar inhibition is likely due to the highly conserved three-
dimensional structure of the 6PGD family. There are some differences between the plasmodial 
and the human structure: (I) an interaction between the strictly conserved W265 and the 
Plasmodium-specific W104, in H. sapiens replaced by a glutamic acid; (II) a disulfide bridge 
between the Plasmodium-specific C281 linking the two subunits of the dimer; (III) the C-
terminal end of h6PGD that has twelve additional amino acids covering the active site as soon 
as the active site loop adopts a closed conformation (Haeussler et al., 2018). However, 
whether these rather small differences are sufficient for developing a highly selective 
compound needs to be investigated. 
Difficulties in developing selective inhibitors might not exclude Pf6PGD as a potential drug 
target. Currently, h6PGD is considered a promising target for anticancer therapy (Cho et al., 
2018; Elf et al., 2017; Guo et al., 2018; Lin et al., 2015). Due to their high metabolic rate, cancer 
cells have a high demand on nucleic acid biosynthesis and NADPH (Cho et al., 2018; De Santis 
et al., 2018; Patra and Hay, 2014; Stincone et al., 2015). Inhibition of h6PGD therefore affects 
cancer cells significantly more than healthy cells. The same effect might be true for 
Plasmodium. During their life cycles, the parasites are continuously exposed to oxidative stress 
of different sources (see chapter 1.2.3) and are highly susceptible to changes in the cellular 
redox equilibrium (Becker et al., 2004). This is supported by experimenta naturae such as the 
G6PD deficiency which leads to a tremendously reduced viability of the parasites, while 
humans can tolerate the deficiency quite well (see chapter 1.2.1.1, Cappellini and Fiorelli, 
2008; Luzzatto et al., 2016). One example of a non-selective compound is EA inhibiting 
PfGluPho and hG6PD in the same range (Allen et al., 2015) but not showing toxic effects on 
mammalian cells (Soh et al., 2009). Therefore, targeting Pf6PGD and simultaneous short-term 
inhibition of h6PGD might be devastating for the parasites, but not for the humans. Together 
with knowledge of the three-dimensional structure of Pf6PGD, the identified inhibitors are 
promising starting points for structure-based compound optimizations. In addition, 
compounds of the MMV Malaria Box found to inhibit h6PGD (Table 19) might be used as a 
starting point for the development of new anticancer drugs. 
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Appendix 
PfGluPho       1 MDYENFVKSAEEINNLHNVNYLETKDLNDFNWKAAYYICKEIYDKQQINK     50 
                 ||.:...||.|::|:||||.|||.|||.|||.|:|||||.:|.:||...: 
PvGluPho       1 MDCQALAKSLEQMNHLHNVKYLEAKDLTDFNQKSAYYICHQIAEKQLSKE     50 
 
PfGluPho      51 DGYVVIGLSGGRTPIDVYKNMCLIKDIKIDKSKLIFFIIDERYKSDDHKF    100 
                 .|:||||||||:||||||||:.|:||||||.|||||||||||||.||||| 
PvGluPho      51 GGHVVIGLSGGKTPIDVYKNIALVKDIKIDTSKLIFFIIDERYKRDDHKF    100 
 
PfGluPho     101 SNYNNIKFLFHNLNINEKEQLYKPDTTKSIVDCILDYNDKIKIMIEKYKK    150 
                 ||||||||||.:|.||||||||:|||:|:||:|:.|||:|||.|::||.| 
PvGluPho     101 SNYNNIKFLFESLKINEKEQLYRPDTSKNIVECVRDYNEKIKNMVKKYTK    150 
 
PfGluPho     151 VDIAILGMGSDFHIASLFPNIFYNIYMNNYQNNYIYNEKTLDFINNDQ--    198 
                 ||||||||||||||||||||||:|||||||||:|||:|.::...|::.   
PvGluPho     151 VDIAILGMGSDFHIASLFPNIFFNIYMNNYQNSYIYDESSIKVANSNDTS    200 
 
PfGluPho     199 DNDNLKYLKEYVYFTTTNQFDVRKRITVSLNLLANASSKIFLLNSKDKLD    248 
                 |||||..|||||||||||.|||||||||||:||.|||||||||||.|||| 
PvGluPho     201 DNDNLDLLKEYVYFTTTNNFDVRKRITVSLDLLGNASSKIFLLNSTDKLD    250 
 
PfGluPho     249 LWKNMLIKSYIEVNYNLYPATYLIDTSCTNENVNINNNNNNNNKNKNNYC    298 
                 ||||||:|||::|||.||||.||||:.                        
PvGluPho     251 LWKNMLLKSYVDVNYCLYPAVYLIDSM-----------------------    277 
 
PfGluPho     299 YSNTTVISCGYENYTKSIEEIYDSKYALSLYSNSLNKEELLTIIIFGCSG    348 
                   ||||::|||.||.:.:|:||.|..:||::|.|||:.|.||||:||||| 
PvGluPho     278 --NTTVVTCGYTNYPQMLEDIYVSNSSLSVHSPSLNRRECLTIIVFGCSG    325 
 
PfGluPho     349 DLAKKKIYPALFKLFCNNSLPKDLLIIGFARTVQDFDTFFDKIVIYLKRC    398 
                 ||||||||||:||||||..|||||||:|||||.|.||:||||||.||||| 
PvGluPho     326 DLAKKKIYPAIFKLFCNKRLPKDLLIVGFARTAQSFDSFFDKIVGYLKRC    375 
 
PfGluPho     399 LLCYEDWSISKKKDLLNGFKNRCRYFVGNYSSSESFENFNKYLTTIEEEE    448 
                 |..|||.|:::||||||.|||:|||::|:||||||||.||||||.:|.|. 
PvGluPho     376 LHSYEDLSLTQKKDLLNCFKNKCRYYIGDYSSSESFERFNKYLTQLEREN    425 
 
PfGluPho     449 ----AKKKYYATCYKMN--------------------------GSDYNIS    468 
                     |...:.|.....:                          |.....: 
PvGluPho     426 LIGTAPTSWAAAAGNASFANDTDKVEHHPDEAILAKGTGAATPGEAPGGA    475 
 
PfGluPho     469 NNVAEDNISIDDENKTNEYFQ-MCTPKNCPDNVFSSNYNFPYVINRMLYL    517 
                 |..|....:....|..:...| ...|.:...:...|..|.|:.|||:||| 
PvGluPho     476 NGPATHGEAHGGANGLSTPMQGKAVPTDDTSDEGHSGANHPFAINRILYL    525 
 
PfGluPho     518 ALPPHIFVSTLKNYKKNCLNSKGTDKILLEKPFGNDLDSFKMLSKQILEN    567 
                 ||||||||||||||||||.|..||||||||||||.||.:||:|||||||| 
PvGluPho     526 ALPPHIFVSTLKNYKKNCQNGNGTDKILLEKPFGKDLQTFKVLSKQILEN    575 
 
PfGluPho     568 FNEQQIYRIDHYLGKDMVSGLLKLKFTNTFLLSLMNRHFIKCIKITLKET    617 
                 |||:.||||||||||||||||||||||||||||||||||||||||||||| 
PvGluPho     576 FNEEHIYRIDHYLGKDMVSGLLKLKFTNTFLLSLMNRHFIKCIKITLKET    625 
 
PfGluPho     618 KGVYGRGQYFDPYGIIRDVMQNHMLQLLTLITMEDPIDLNDESVKNEKIK    667 
                 ||||||||||||||||||||||||||||.||||||||||||||||||||| 
PvGluPho     626 KGVYGRGQYFDPYGIIRDVMQNHMLQLLALITMEDPIDLNDESVKNEKIK    675 
 
PfGluPho     668 ILKSIPSIKLEDTIIGQYEKAENFKEDEN-----NDD----ESKKNHSYH    708 
                 |||.|.||||::||||||.|:||::|::|     :||    |||:||||| 
PvGluPho     676 ILKCIQSIKLDNTIIGQYVKSENYQEEKNLSAPPSDDHPVDESKRNHSYH    725 
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PfGluPho     709 DDPHIDKNSITPTFCTCILYINSINWYGVPIIFKSGKGLNKDICEIRIQF    758 
                 ||||||.|||||||||||||||||||||||||||:||||||||||||:|| 
PvGluPho     726 DDPHIDSNSITPTFCTCILYINSINWYGVPIIFKAGKGLNKDICEIRLQF    775 
 
PfGluPho     759 HNIMGSSDENMNNNEFVIILQPVEAIYLKMMIKKTGCEEMEEVQLNLTVN    808 
                 |||||||||:|.||||||||||||.||||||||||||||||||||||||| 
PvGluPho     776 HNIMGSSDESMYNNEFVIILQPVEVIYLKMMIKKTGCEEMEEVQLNLTVN    825 
 
PfGluPho     809 EKNKKINVPEAYETLLLECFKGHKKKFISDEELYESWRIFTPLLKELQEK    858 
                 .||||..|||||||||||||:|.|||||||||||||||||||||.||||| 
PvGluPho     826 HKNKKNYVPEAYETLLLECFRGFKKKFISDEELYESWRIFTPLLNELQEK    875 
 
PfGluPho     859 QVKPLKYSFGSSGPKEVFGLVKKYYNYGKNYTHRPEFVRKSSFYEDDLLD    908 
                   :|:||||.|||||||||:.||||||||||||.:.|.|||||||||||||| 
PvGluPho     876 KVQPLKYPFGSSGPKEVYDLVKKYYNYGKNYANTPAFVRKSSFYEDDLLD    925 
 
PfGluPho     909 IN    910 
                 || 
PvGluPho     926 IN    927 
Appendix 1 Amino acid sequence alignment of PfGluPho (PF3D7_1453800) and PvGluPho (PVX_117790) 
| Identical residues, : very similar residues, . similar residues. 
 
Pv    MTGTCDIGLIGLAVMGQNLSLNIASNGFTIGVYNRTYERTEDTLKKAKEGNLPIQGYETL 60 
Pk    MAGTCDIGLIGLAVMGQNLSLNIASNGFTIGVYNRTYERTEDTIKKAKESNLPIYGYETL 60 
Pm    MAGVCDIGLVGLAVMGQNLSLNIASKGFKIGVYNRTYARTEVTLKRAKEENLVIYGYKTL 60 
Pf    M---CDIGLIGLAVMGQNLSLNISSKGFKIGVYNRTYERTEETMKRAKEENLVVYGYKTV 57 
Po    MAEVCDVGLVGLAVMGQNLSLNISSKGFKIGVYNRTYERTEETVKRAKEEKLCIYGYKTL 60 
      *   **:**:*************:*:**.******** *** *:*:*** :* : **:*: 
 
Pv    EQLINNLKKPRKIILLIKAGPAVDETIKNILKHFEEGDIIIDGGNEWYLNTERRITLCEE 120 
Pk    EQLIKNLKKPRKIILLIKAGPAVDETIKNILKHFEEGDIIIDGGNEWYLNTERRISICEE 120 
Pm    EELVNSLKKPKKIILLIKAGPAVDENIKNILNFFEKGDIIIDGGNEWYLNSERRIKLCTE 120 
Pf    EELINNLKKPRKVILLIKAGPAVDENISNILKHFEKGDIIIDGGNEWYINSERRIKLCKE 117 
Po    EELIQNLKKPKKIILLIKAGPAVDENINNILKYFEKGDIIIDGGNEWYLNSERRIKLCGE 120 
      *:*::.****:*:************.*.***:.**:************:*:****.:* * 
 
Pv    HKVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDTIKDILEKCSAKVGTSPCVTYIGPRSS 180 
Pk    HKVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDQIKDILEKCSAKVGTSPCVTYIGPRSS 180 
Pm    KQVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDCVQDILEKCSAKVGTSPCVTYIGPGSS 180 
Pf    KDVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDCVKEILEKCSAQVGNSPCVTYIGPGSS 177 
Po    KNVEYLAMGVSGGEAGARYGCSFMPGGSKYAYDCIKDILEKCSAKVGTSPCVTYIGPGSS 180 
      :.******************************* :::*******:**.********* ** 
 
Pv    GNYVKMVHNGIEYGDMQLISESYLLMKNILNYNNEKLSEVFKKWNEGILNSYLIEITYKI 240 
Pk    GNYVKMVHNGIEYGDMQLISESYLLMKHILNYSNEKMSDVFKKWNEGILNSYLIEITYKI 240 
Pm    GNYVKMIHNGIEYGDMQLISESYYLMKHILKYDNKKASDVFKKWNEGILNSYLIEITSKI 240 
Pf    GNYVKMVHNGIEYGDMQLISESYVIMKHILKYDNQKLSEVFNKWNEGILNSYLIEITANI 237 
Po    GNYVKMVHNGIEYGDMQLISESYFIMKHILKYDNKKLSQVFKKWNEGILNSYLIEITANI 240 
      ******:**************** :**:**:*.*:* *:**:*************** :* 
 
Pv    LGKKDELT--DNHLVDMILDIAGAKGTGKWTMLEAIERGIPCPTMCAALDARNISAYKQL 298 
Pk    LGKKDDLT--DKHLVDMILDIAGAKGTGKWTMLEAIERGIPCPTMCAALDARNISAYKNL 298 
Pm    LNKKDNLT--DNYLVDVILDIAGAKGTGKWTMLESIERGIPCPTICAALDSRNISAFKEL 298 
Pf    LAKKDDLT--NNYLVDMILDIAGAKGTGKWTMLEATERGIPCPTMCAALDARNISVFKEL 295 
Po    LGKTDELTGDNNYLVDMILDIAGAKGTGKWTMMEAIERGIPCPTICAALDARNISTFKQL 300 
      * *.*:**  :::***:***************:*: ********:*****:****.:*:* 
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Pv    RVKADSHFSNDMKVNKVEGEN-------LINFEDDLLNALYCCKIISYTQGLFLLKQVSE 351 
Pk    RIKADSHFCNEMKVRKVEGED-------LSHYEDDLLNALYCCKIISYTQGLFLLKQVSG 351 
Pm    RTKADTYFSTVSKVNNLNGDNNLNSNDLMNNFENDLLNALYCCKIISYTQGLFLLRQVSH 358 
Pf    RTKAESNFNKDNILI--------DPNEDLNDFENDLLNALYCCKIISYTQGLFLLKQVSE 347 
Po    RTKADEHFVTTMKMN--------CTTEKLENLENDLLNALYCCKIISYTQGLFLLKQVSQ 352 
      * **:  * .   :              : . *:*********************:***  
 
Pv    EMKWNLNLGEISRIWRGGCIIRAVFLDRITNAYKKNEKLDLLFLDEDFAQEMKNKLPSLR 411 
Pk    EMKWNLNLGEISRIWRGGCIIRAVFLDRITNAYKKNENLDLLFLDEDFAKEMKNKLPSLR 411 
Pm    EMKWNLDLGEISRIWRGGCIIRAVFLDRITKAYKNNNSLELLFLDDEFAEEMKNKLPSLK 418 
Pf    EMNWKLNLGEIARIWRGGCIIRAVFLDRIANAYKNNEKLELLFLDNEFSDDIKNKLPSLR 407 
Po    EMKWNLNLGEISRIWRGGCIIRAVFLDRITNAYKNNEKLELLFMANEFSDEMKNKLPSLR 412 
      **:*:*:****:*****************::***:*:.*:***: ::*:.::*******: 
 
Pv    KVVQVATKSSIPIPAFSASLAYFQMVTSQNLPLNLVQAQRDYFGSHTYKRVDRDGDFHTI 471 
Pk    KVVEVATKSSIPIPAFSASLAYFQMVTSKNLPLNLVQAQRDYFGSHTYKRVDRDGDFHTI 471 
Pm    KVVHISTMCSIPIPAISASLAYFQMITSKDLPLNLVQAQRDYFGSHTYKRIDREGDYHTV 478 
Pf    KIVLMATKYSIPIPAFSASLAYFQMVTSQNLPLNLVQAQRDYFGSHTYRRTDREGNYHTL 467 
Po    KIVNLATQCDIPIPAFSASLAYFQMVTSKNLPLNLVQAQRDYFGSHTYQRTDREGSFHTL 472 
      *:* ::*  .*****:*********:**::******************:* **:*.:**: 
 
Pv    WE 473 
Pk    WE 473 
Pm    WD 480 
Pf    W- 468 
Po    WD 474 
      *  
Appendix 2 Amino acid alignment of 6PGDs from different Plasmodium species 
R36, W104, C281, as well as the flexible loop close to the active site (255-262) are conversed amongst the 
different human-pathogenic species (yellow). Pv: Plasmodium vivax; Pk: Plasmodium knowlesi; Pm: Plasmodium 
malariae; Pf: Plasmodium falciparum; Po: Plasmodium ovale. * Identical residues, : very similar residues, . similar 
residues. 
 
                   899/900 
PfG6PD  LKELQEK-QVKPLKYSFGSSGPKEVFGLVKKYY-NY--GKNYTHRPEFVRKSSFYEDDLL 907 
PvG6PD  LNELQEK-KVQPLKYPFGSSGPKEVYDLVKKYY-NY--GKNYANTPAFVRKSSFYEDDLL 924 
ScG6PD  LKHIERPDGPTPEIYPYGSRGPKGLKEYMQKHKYVMPEKHPYAWPVTKP----EDTKDN- 505 
hG6PD   LHQIELE-KPKPIPYIYGSRGPTEADELMKRVGFQY--EGTYKWVNPHK----L------ 515 
AtG6PD  LHRIDKG-EVKSIPYKPGSRGPKEADQLLEKAGYLQ--THGYIWIPPTL----------- 515 
        *:.::         *  ** **.     :::          *                   
Appendix 3 Alignment of G6PDs from different species 
The serines on positions 899 and 900 were found to be phosphorylated in P. falciparum and are specific for 
malaria parasites. Pf: Plasmodium falciparum (PlasmoDB PF3D7_1453800); Pv: Plasmodium vivax, (PlasmoDB 
PVX_117790); Sc: Saccharomyces cerevisiae (NCBI CAA93357); h: human (NCBI CAA39089.1); At: Arabidopsis 
thaliana (NCBI BAE99888). * Identical residues, : very similar residues, . similar residues. 
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